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ABSTRACT 
 
Chlamydophila abortus is a globally prevalent, highly infectious zoonotic microorganism 
responsible for a number of reproductive disorders in ruminants, characterised by 
spontaneous abortion and foetal loss in sheep, goats and cattle in many countries.  
It has the potential to infect entire flocks in a breeding system; and possibly spread throughout 
an entire local geographical region, due to the latent nature of its infectious cycle. Even though 
there has been no record of the seroprevalence of this organism in South Africa, it has drawn 
much attention in this country in the last few decades, due to its negative impact on the 
economy and agricultural industry. First-generation vaccines are commercially available for 
the prevention and control of this infectious microorganism; and although they provide 
adequate protection, the difficulty encountered during bulk chlamydial growth persists as a 
hindrance to the production process.  
In recent years, considerable attention has been directed towards the major outer-membrane 
protein (MOMP) of C. abortus, as it is an immunodominant antigen that covers 60% of the 
bacterial surface. It has been elucidated to play a key role during infection by facilitating entry 
of the organism into the host via cytoadhesion. Previous attempts at expressing MOMP in E. 
coli have been disappointing due to its toxicity towards the host and when expression is 
achieved, the protein levels generated are too low to scale-up the process. This study 
postulated that if the MOMP protein of C. abortus can be heterologously expressed at a high 
concentration in the yeast expression system Yarrowia lipolytica Po1f, it will expedite the 
evaluation of the immunogenic potential of this antigen as a candidate subunit vaccine against 
C. abortus. 
To investigate this hypothesis, the MOMP gene was codon-optimized for expression in Y. 
lipolytica and designed such that it was subcloned downstream and in-frame with the Lip2 
signal peptide (SP) of pKOV410, which facilitates the secretion of the protein to the 
extracellular. The protein was expressed in this system and used to formulate three 
concentrations of the candidate MOMP subunit vaccine using the Seppic Montanide™ ISA 70 
adjuvant. These candidate MOMP subunit vaccine formulations were then evaluated in terms 
of the level of safety, efficacy and immunogenicity elicited by the antigenic agent in pregnant 
Swiss albino CD-1 mice models. Following immunization with the candidate MOMP subunit 
vaccine, the subjects were challenged with whole, virulent C. abortus B577 and EBA strains. 
Serological analysis was then performed using the ID Screen® Chlamydophila abortus 
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Indirect Multi-Species ELISA kit in order to assess the anti-MOMP antibody titre induced by 
the candidate vaccine.  
Heterologous expression of the MOMP protein was achieved in Y. lipolytica Po1f. This was 
validated by the presence of a 43 kDa protein in the test expression supernatant, which was 
not present in the control. All three formulations of the candidate vaccine produced positive 
results using the ID Screen® Chlamydophila abortus Indirect Multi-Species ELISA kit. The 
anti-MOMP antibody titres for the 30%, 40% and 50% candidate MOMP subunit vaccine 
formulations were 192%, 104% and 191%, respectively. The positive control used as a 
reference for the clinical trial was the commercial whole-cell inactivated vaccine Chlamysure; 
this vaccine produced an anti-MOMP antibody titre of 134%. Therefore, in relation to the 
antibody titre generated by the positive control, the 30% and 50% candidate MOMP subunit 
vaccine formulations produced anti-MOMP antibody tires 58% and 57% greater than that of 
the positive control. The safety thereof was confirmed by the absence of mortality and adverse 
events. In terms of immunogenicity, the unvaccinated control group produced the null result 
which is the lack of anti-MOMP antibody generation; this confirms the validity of the 
immunogenicity screen. However, in terms of efficacy, the outcome is inconclusive, in order 
for the results to be considered accurate, the unvaccinated controls are expected to exhibit 
signs of infection following the introduction of the challenge load. The most significant of which 
in this case, is the occurrence of a spontaneous abortion of the foetus. Conversely, this group 
did not demonstrate the null result and therefore the efficacy of the vaccine cannot be 
confirmed. Based on the current study, the CD-1 mice are not an optimal model for C. abortus 
infection and manifestation. Nevertheless, the candidate MOMP subunit vaccine has 
displayed an enhanced immunogenic potential with a pronounced level of immunogenicity and 
this exhibits great prospect for the development of a highly immunogenic subunit vaccine 
established using the MOMP protein of C. abortus.  
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Chapter 1: Literature review 
 
1.1. General introduction 
 
This study is based on the heterologous expression of the major outer-membrane protein 
(MOMP) of Chlamydophila abortus. The purpose of which is for the development of a 
candidate subunit vaccine for prevention of the occurrence of spontaneous abortions in 
ruminants. C. abortus is an obligate, intracellular Gram-negative bacterium that has a high 
affinity for the reproductive tract and placental tissue of ruminants (Garcia-Seco et al., 2016). 
Its affinity for placental tissue has major implications on the breeding and agricultural industries 
since it hinders the breeding of livestock. Common targets for infection by this bacterium 
include sheep, ewes, cattle, goats, horses and pigs (Li et al., 2015). Once the infection 
colonises within the placental tissue, it can lead to the following occurrences: spontaneous 
abortion, stillbirth, or the birth of a weak offspring which inevitably dies due to the infection 
(Barati et al., 2017; Borel et al., 2018). This disease is often termed the enzootic abortion of 
ewes (EAE) or ovine enzootic abortion (OEA). The prevalence of this bacterium is global, with 
numerous cases of infection reported worldwide, with the exception of Australia, New Zealand 
and some parts of the Scottish Highlands (Selim, 2016). This is a serious concern that has 
negative implications on the economy and sustainability of the breeding and agricultural 
industries. Live attenuated and inactivated whole-cell vaccines are available for the prevention 
and control of the disease. However, the manufacturing process of these vaccines is laborious, 
since it is based on cell tissue culture, with yields that are not always predictable. Furthermore, 
whole-cell vaccines have the disadvantage of possible reversion to virulence. Hence, it is 
important that cost-effective, accessible measures of control are put into place for the 
prevention of this disease and based on current research, the prospective way forward 
involves the development of a subunit vaccine through recombinant DNA technology to 
increase the productivity, efficiency and safety of the vaccine (Longbottom, 2003). 
 
1.2. Chlamydophila abortus 
 
1.2.1. Classification of Chlamydophila abortus 
 
Chlamydophila abortus belongs to the kingdom eubacteria, phylum Chlamydiae, order 
Chlamydiales, family Chlamydiaceae and genus Chlamydophila. The order Chlamydiales 
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consists only of the family Chlamydiaceae, which originally contained only one genus 
Chlamydia and two species trachomatis and psittaci. The distinction between the two species 
was due to the characteristic accumulation of glycogen; and sensitivity to the antibiotic 
sulfadiazine in C. trachomatis, whilst these characteristics are absent in C. psittaci (Everett et 
al., 1999). The classification as it stands today exemplifies two genera in Chlamydiales, these 
are Chlamydia and Chlamydophila. Chlamydia consists of strains C. trachomatis, C. suis and 
C. muridarum; and Chlamydophila consists of strains C. abortus, C. psittaci, C. pneumoniae, 
C. pecorum, C. felis and C. caviae (Joseph et al., 2015)  
There were developments that aided in the distinction of C. abortus from C. psittaci which 
were based on the differences in pathogenicity and the mechanisms used by the respective 
bacteria to carry out DNA-DNA hybridization (Everett et al., 1999). This distinction between C. 
abortus and C. psittaci was made possible by 16S and 23S rRNA gene similarity evaluation. 
This characteristic was used because the family Chlamydiaceae shares 90% homology within 
these genes. Therefore, the differences in the 16S and 23S rRNA gene sequences among all 
the species were used to group the species, such that species sharing the same or very similar 
regions of homology were grouped under the same genera (Karaulov et al., 2010). Differences 
in the phenotypic and ecological traits of the bacteria also aided in the reclassification of 
originally one genus containing two species into two genera containing a total of nine species 
as it stands currently (Everett et al., 1999).  
 
1.2.2. Chlamydophila strains at a molecular level 
 
Chlamydophila abortus is an obligate, intracellular, Gram-negative bacterium (Essig and 
Longbottom, 2015; Garcia-Seco et al., 2016; Livingstone et al., 2017). Gram-negative 
indicates that there’s a reduced peptidoglycan layer between the inner and outer bacterial 
membrane and a layer of lipopolysaccharide (LPS) on the outermost part of the bacterial 
membrane. However, in Chlamydophila, there is no peptidoglycan layer present which puts 
this bacterium at a disadvantage as peptidoglycan provides strength to the bacterial cell wall 
and opposes osmotic pressure caused by the cytoplasm (Rosenfeld and Shai, 2006). It is 
thought to be a possibility that the cysteine-rich proteins OmcB (60 kDa) and OmcA (12 kDa), 
as well as the surface protein MOMP, may form a supramolecular structure with the bacterial 
membrane, therefore providing rigidity to the bacterial wall (Sun et al., 2007). The entire 
genome of Chlamydophila abortus has been sequenced and it contains a total of 1,144,377 
base pairs and a high level of conservation in the coding sequences. A total of 842 of the 961 
coding sequences are found in two other species of Chlamydophila, C. cavaiae and C. 
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pneumonia. The mechanisms used by C. abortus to adapt to reduced structural integrity and 
achieve structural rigidity differs widely from that of other Chlamydial species due to large 
differences in their genetic characteristics. (Thomson et al., 2005).  
 
1.2.3. Characteristics of C. abortus 
 
1.2.3.1. The major outer-membrane protein (MOMP) 
 
Chlamydophila abortus contains a dominant antigen on its surface, termed the major outer-
membrane protein (MOMP), which makes up 60% of the total membrane proteins and is 40 
kDa in size (Wang et al., 2006 and He’chard et al., 2003). It is present in all species of the 
genera Chlamydia and Chlamydophila, with a slight variation at the genus and species level. 
In C. abortus this protein has electrophoretic and sedimentation properties that match that of 
a trimer. It also has four variable domains (VDI-VDIV) on its surface, which are flanked by five 
conserved regions (Vretou et al., 2001; He´chard et al., 2002). It is a multifunctional protein 
that plays a role in the maintenance of structural rigidity; it is present in both developmental 
stages of the bacterium, participates in the infection process and its main function is as a porin 
(Hagemann et al., 2016; Wyllie et al., 1998).  
Porins are proteins that form a channel through the cell membrane of an organism to form a 
pore through which diffusion of large or charged molecules can occur. They are mostly found 
on the surface of Gram-negative bacteria such as C. abortus, but also on a few Gram-positive 
bacterial surfaces (Pages et al., 2008). It is essential for cytoadhesion during the infection 
process, in which the bacterium adheres via the MOMP protein to the surface of a susceptible 
mucosal epithelial host cell, subsequently enabling the entry of the bacterium into the host cell 
(Costa et al., 2015). In terms of structural rigidity, the trimers of the protein are cross-linked 
through disulphide bridges, which maintain the strength of the interaction between the three 
subunits. It is also postulated that the cysteine-rich proteins (CRPs) of the outer-membrane 
complex B (OmcB) and A (OmcA) may be involved in disulphide bond interactions with MOMP, 
which also contributes towards the structural rigidity (Sun et al., 2007).  
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1.2.3.2. Pathogenesis 
 
The infection process of C. abortus is characterised by two developmental stages; an 
infectious, metabolically inactive form called an elementary body (EB); and a non-infectious, 
metabolically active form called a reticulate body (RB). Therefore, their life cycle is termed 
biphasic, meaning that the bacterium transitions through two different developmental stages. 
This developmental cycle is unique to the Chlamydiaceae family, but the outcome of the 
infection by the different members of the family varies widely (Wyllie et al., 1998). The EB is 
0.25–0.3 µm in diameter and is enclosed by a rigid cell wall. This form also contains a gene-
specific for DNA replication accompanied by an open reading frame as well as an RNA 
polymerase and ribosomes that will carry out transcription and translation after transformation 
into the RB form. The RB is 0.6 µm in diameter, which is slightly larger than the EB. It is not 
surrounded by a cell wall and it serves as the structure in which the DNA genome from the EB 
form is replicated, transcribed to RNA and translated into proteins. This is the form in which 
replication and growth take places, while the EB is the form in which transmission and infection 
take place (Baron, 1996; Marques et al., 2010).  
As previously mentioned, C. abortus is an obligate intracellular pathogen, meaning that it 
cannot survive outside of a host cell, as it relies entirely on host cell resources for replication. 
As a result, it binds to the surface of a susceptible mucosal epithelial cell, a process facilitated 
by MOMP and possibly by hemagglutinin which is a glycoprotein that binds to sialic acid 
groups on the surface of membranes (Chen et al., 2014). It then induces endocytosis, in which 
the host cell engulfs the bacterium allowing it into the cytoplasm. In the cell, the EB interacts 
with glycogen which acts as an inducer for its transformation into the RB form. The RB then 
enters an intracellular inclusion, which is a vacuole that stores nutrients, secretory products 
and pigments as well as multiplies by binary fission to produce more RBs. After multiplication, 
the RBs then differentiate back into EBs still within the inclusion, which is capable of evading 
the host endocytic pathway through by-passing the acidic lysosomes that are responsible for 
degradation (Marques et al., 2010).  
They enter the exocytic pathway instead, as they appear as secretory vacuoles to the host 
cell. In the exocytic pathway, materials are transported out of the cell in secretory vesicles, 
this is why exocytosis is the mechanism used for the spread of the EBs to other susceptible 
cells to initiate the infection process again (Wang et al., 2006). The EBs can also be spread 
by cell lysis, in which the integrity of the membrane of the host cell becomes compromised 
and consequently bursts, releasing the infectious EBs into the body for further infection 
(Thomson et al., 2005). 
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1.2.3.4. Mode of transmission 
 
Chlamydial infections can be spread through various modes; this has been elucidated by the 
presence of chlamydial species in all secretions and excretions of infected ruminants (Essig 
and Longbottom, 2015). The mode of transmission of infection between humans or between 
humans and ruminants follow four possible routes depending on the circumstance. 
Transmission is accomplished by inhalation of aerosols produced by infected individuals 
during coughing or sneezing; by ingestion of meat from animals that have been infected by C. 
abortus; by direct physical contact with the bacterium in human fluid; and from mother to child 
during vaginal birth (Baron, 1996). The initial transmission of the infection between ruminants 
may be carried by vectors (domestic or wildlife) from farm to farm. The disease then spreads 
within the farm in a number of ways, with initial infection occurring during grazing in infected 
areas. An area may be infected due to the presence of afterbirth, uterine fluid or vaginal 
discharge. All of these retain the infectious organism in a viable form for a duration of several 
days, and this period may increase if the temperature drops (Mohale, 2013; Mearns, 2007).    
Due to the affinity of C. abortus for placental tissue, it is often found in the placenta and in 
aborted material (Kauffold et al., 2014). Besides the afterbirth, an infected female continues 
to shed C. abortus organisms 2–3 weeks post-birth, therefore unless the infected animals are 
quarantined from the uninfected livestock, the infection can spread very rapidly (Stubbings, 
2017). Infection can also be transmitted from mother to child during birth. In cases where the 
offspring survives it carries the infection latently leading up to its first pregnancy, at which point 
the foetus will spontaneously be aborted. In cases where the offspring is aborted, it carries the 
infection in the same way as the afterbirth does and will thus need to be incinerated to prevent 
the spreading of the infection to other animals in the area (Stubbings, 2017). If a female 
becomes infected during pregnancy, abortion will not occur unless the infection colonized 
within the placenta more than 6 weeks before the due date; the infection will rather remain 
latent until the subsequent pregnancy (NADIS Ltd., 2017).  
An interesting characteristic of the infection is that these ruminants do not often abort more 
than once in a lifetime, therefore for most infected ruminants all subsequent lambing’s will be 
normal, giving rise to healthy offspring (Mearns, 2007; Stubbings, 2017). However, the 
infected ruminant will remain a carrier of the infection, since they retain a persistent infection 
of the reproductive tract. This infection becomes reactivated periodically during each 
subsequent breeding season, resulting in the shedding of the infectious organism in afterbirth, 
uterine fluid and vaginal discharge. In cases where the female is not pregnant during the 
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breeding season, C. abortus is still shed from the reproductive tract 2–3 days before and after 
ovulation (Tibary, 2016).  
The infection may also be sexually transmitted, and in the case of rams and bucks, it may 
cause orchitis and seminal vesiculitis, which leads to the shedding of the infectious organism 
in semen. Due to the vast array of modes through which C. abortus can be transmitted, the 
infection can very easily and rapidly colonize an entire flock leading to a devastating outcome. 
This is why it is considered as one of the most important causes of reproductive failure in 
sheep and goats, and the most frequently diagnosed cause of abortion in many countries in 
Europe, North America and Africa (Selim, 2016). The reason why the infection can be spread 
so easily is due to the latency of the organism, which is a major issue associated with C. 
abortus infection. There are no symptoms present in newly infected animals, since the 
infectious organism remains dormant until the subsequent breeding season, at which point it 
is too late for prevention, therefore it is essential that an entire flock be vaccinated against C. 
abortus infection four to six weeks before the breeding season commences (Mohale, 2013). 
 
1.2.4. Symptoms caused by C. abortus infection and targets of infection 
 
1.2.4.1. Target hosts for C. abortus 
 
Chlamydophila abortus is capable of infection of a wide range of ruminants which includes all 
mammals that use microbes for fermentation of their food prior to digestion; their food source 
is plant matter, and this process occurs in a specialised stomach termed the rumen. These 
ruminants include sheep, goats, cattle, horses and pigs which are economically important and 
pose zoonotic risk to humans (Li et al., 2015 and Buendia et al., 2001). The zoonotic cases 
are rare, but those that have been recorded frequently resulted in life-threatening diseases 
and loss of the foetus (Tibary, 2016).  
Chlamydophila abortus has a high affinity for placental tissue, once it has entered the body of 
its host, it moves to the endometrium where it causes damage in the form of a disrupted 
endometrial lining which lines the uterus (Borel et al., 2018). The continuity of this lining is 
essential for the maintenance of a healthy pregnancy, as it is composed of a network of blood 
vessels and glandular tissue that eventually gives rise to a placenta, which provides oxygen 
and nutrients to the growing foetus, and removes metabolic wastes from the foetal area 
(Garnica and Chan, 1996). Damage to the placenta is therefore detrimental to the growing 
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foetus, and as a result of placental infection, the pregnancy may result in miscarriage, stillbirth, 
premature birth or spontaneous or infrequent abortion (Qin et al., 2014).  
 
1.2.4.2. Mechanism of reproductive failure caused by C. abortus 
 
Chlamydophila abortus colonization within the placenta has negative implications on the 
gestational process, and the entire reproductive system in both ruminants and in humans. This 
is because once the infectious bacteria colonize the placenta, at the 90-day point in the 
gestational period, where the foetus is undergoing rapid growth, it causes suppurative 
necrotising placentitis (Mearns, 2007). This condition is characterised by an inflammation of 
the placenta, and its main cause is due to the entry of bacteria into the vagina, which then 
travels up the cervix enabling penetration of the cervical barrier. This penetration may 
essentially lead to the separation of the placenta from the uterine lining, or it can cause a 
reduction in the amount of oxygen and nutrients that the foetus receives (Barati et al., 2017; 
Borel et al., 2018). Either way, both routes result in the following outcomes: the death of the 
foetus in utero, abortion of the foetus or birth of a compromised foetus (LeBlanc et al., 2004).  
Foetal loss is a common consequence of C. abortus infection in ruminants. Abortion can occur 
as early as three months into the gestational period, but it often occurs two to three weeks 
prior to normal gestational delivery, regardless of when the infection colonized within the host 
(Longbottom et al., 2013). A day or two before the abortion commences, a vaginal discharge 
containing high numbers of C. abortus elementary bodies is released. Following the abortion, 
an examination of the foetus sometimes shows lesions in the brain and liver, and a high 
chlamydial count within the aborted foetus, and in the spleen, liver and placenta of the mother. 
Chlamydophila abortus infection may result in the birth of extremely weak offspring which 
cannot survive longer than a few days (Selim, 2016).  
In humans, abortions caused by C. abortus have been reported to occur in weeks 14–36 of 
the pregnancy (Pospischila et al., 2002), and it is accompanied by several serious 
complications. These include renal failure, in which the body is unable to filter waste for 
removal, and as a result, the waste accumulates to toxic levels if dialysis is not initiated 
(Zaccaria and Claudio, 2012). Hepatic dysfunction in which the liver does not function 
optimally; pelvic inflammatory disease (PIC), which results in damage to the ovaries, uterus 
and fallopian tubes and can often lead to infertility or reproductive failure, chronic pelvic pain, 
ectopic pregnancy and cancer (Walder et al., 2003). As well as disseminated intravascular 
coagulation (DIC), which results in the formation of blood clots in small blood vessels. This 
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can lead to death, as is prevents normal blood flow to tissues, and as a result, organs begin 
to fail and the body shuts down (Levi, 2007). When abortion does not occur during infection, 
according to Longbottom and Livingstone (2006), no congenital defects are found in the baby. 
 
1.2.4.3. Other symptoms caused by C. abortus 
 
Abortion is the focal consequence of C. abortus infection, but it also causes other medical 
conditions, either associated with placental infection or occurring independently of the 
placenta. Epididymitis is an inflammation of the epididymis, which is a narrow tube within the 
testis that is responsible for transporting semen. This condition is caused by C. abortus, as 
the bacterium is often found in the semen of infected males (Kauffold et al., 2014). The 
bacterium also causes conjunctivitis, an inflammation of the conjunctiva of the eye, it results 
in increased sensitivity to light, as well as itchy and burning sensations within the eye caused 
by infection with air-borne bacteria (Azari and Barney, 2013). Moreover, C. abortus can cause 
pneumonia, an inflammation in the alveoli of the lungs. It results in difficulty in breathing and 
puts an infected individual at risk for other respiratory complications (Qin et al., 2014). Arthritis 
which is characterised by an inflammation in the joints – when caused by infectious pathogens 
as such, it does not directly infect the joints, instead it results in symptoms in the joints while 
the infection is housed elsewhere in the body and often leads to irreversible joint damage if 
not detected soon enough (Wollenhaupt and Zeidler, 1998).  
Others include encephalitis and meningitis which is the inflammation of the brain, spinal cord 
and the meninges, which is a protective layer found in the brain and spinal cord respectively 
(Sáez-Llorens and McCraken, 2003 and Allan et al., 2008). Inflammation of the vagina termed 
vaginitis, this is characterised by a discharge that contains C. abortus, and chronic mastitis, 
which is an inflammation of the breasts resulting in the formation of abscesses and flu-like 
symptoms (Kauffold et al., 2014). A symptom specific to bovine animals is possible life-long 
infertility, the basis of which was proved in an experiment conducted by Appino and Co-
workers (2007). During this investigation, bovine oviduct cells (the cells that make up the 
oviducts or fallopian tubes) were infected with C. abortus and allowed to colonize. After the 
infection colonized, the cells showed that the formation of inclusion bodies and vacuoles within 
the microvilli were congregated and stuck together, and overall the cells appeared to be 
damaged–the presence of these three characteristics is essentially what causes infertility in 
animals.      
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1.2.5. Treatment and prevention of infection by C. abortus 
 
1.2.5.1. Treatment with antibiotics 
 
Chlamydophila abortus infection can be treated with a wide range of antibiotics. Antibiotics 
that are effective are tetracyclines, quinolones and erythromycin. Tetracyclines are taken for 
bacterial clearance of the intestines, urinary and reproductive tracts. The mode of action is by 
the inhibition of bacterial protein synthesis, it binds to the 30S ribosomal subunit during 
translation and prevents aminoacyl translocation to the mRNA chain (Chopra and Roberts, 
2001). There is a tetracycline derivative called whole flock long-lasting oxytetracycline 
injection that can also be used as a form of treatment, but it is only an emergency measure. It 
is capable of reducing the number of abortions within a flock, by allowing the foetus to be 
carried closer to term, but the offspring are often weak at birth with a high mortality rate, and 
it cannot reverse any damage endured by the placenta (NADIS Ltd., 2017).   
Quinolones are administered for treatment of genital infections caused by C. abortus, and the 
mode of action is by the inhibition of bacterial DNA replication. They are ideal for the treatment 
of intracellular bacteria, as they are able to enter the cell through porins, where they then bind 
to the topoisomerase ligase domains to inhibit DNA unwinding, therefore, making the DNA 
inaccessible for replication (Andersson and MacGown, 2003). Erythromycin is bacteriostatic, 
it belongs to the macrolide antibiotic family, and is used for the treatment of respiratory 
chlamydial infections. It inhibits bacterial protein synthesis as well, but rather than binding to 
the 30S ribosomal subunit, it binds to the 50S ribosomal subunit, where it allows a tRNA 
charged with an amino acid to enter the rRNA complex, however subsequent movement to 
allow the incorporation of more amino acids is inhibited (Ashley et al., 2006). 
 
1.2.5.2. Prevention by clinical measures 
 
Prevention includes clinical mechanisms in the form of a vaccine, and avoidance of infection 
by taking precautionary measures when in an environment that is prone to infection. When 
working with ruminants in areas prone to C. abortus infection, disinfectants or heat sterilisation 
techniques should be used to ensure that clothes, shoes and the housing spaces of the 
animals and humans are not contaminated with the bacterium. If there is a possibility that the 
ruminants may be infected, dairy products and meat should not be sold for consumption 
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(Pritchard, 2011). Pregnant women are at risk of infection, and therefore should not come into 
contact with: the dairy products produced by an infected animal; any materials, or people that 
have been exposed to the infection; the offspring of ruminants, whether or not infection has 
been confirmed; and vaccines that need to be administered to ruminants that have not yet 
been infected, especially if it is of the live attenuated type. Following infection and subsequent 
abortion in infected animals, the infected animals should be isolated for at least 3 weeks to 
avoid an outbreak. The foetus, placental tissue and all materials used for the birth should be 
incinerated to destroy the bacterial populations (Struen and Longbottom, 2016).  
Clinical prevention in form of a vaccine is the superior option, as it may be possible to 
completely inhibit infection in an area altogether, as the vectors will be immune to the infection; 
and therefore it cannot be transferred between individuals. A vaccine is a preparation of live 
attenuated pathogen, a completely inactivated pathogen or a pathogenic antigen, that is 
capable of triggering an immune response against the pathogen for which the vaccine was 
developed. This immune response then prepares the immune system for future infection, in 
the form of antibodies that are specific for the pathogen (Tahamtan et al., 2017). There are a 
few existing vaccines for prevention against C. abortus infection, all of which are classified as 
first-generation vaccines. First-generation vaccines consist of two classes, these are live 
attenuated, and dead or inactivated whole organisms. Enzovax is an example of a live 
attenuated form and Chlamysure is an example of an inactivated vaccine for C. abortus 
prevention. Class 1: Enzovax is a vaccine developed in the United Kingdom, composed of live 
attenuated 1B strain of C. abortus, in a unisolve solvent. This vaccine targets breeding sheep 
and provides immunity for up to 4 years (MSD animal health, 2011). Class 2: Chlamysure is a 
vaccine developed in South Africa, it is composed of formalin-inactivated whole bacterium in 
an oil adjuvant emulsion and targets cattle, sheep and goats, but it only provides immunity for 
up to 1 year (Onderstepoort Biological products, n.d).  
In terms of the existing vaccines, both the live attenuated and inactivated types offer a 
sufficient amount of protection, and they have been shown to significantly reduce the number 
of infective organisms being shed–essentially leading to a reduction in the spread of infection 
(Longbottom and Livingstone, 2006). There is however still room for improvement in terms of 
safety and efficacy since live organisms have the potential to revert to their virulent state and 
due to the limited duration of protection that the existing vaccines can offer.  
These concerns lead researchers working on C. abortus infection to search for alternatives; 
the structurally and immunologically dominant MOMP was considered as an antigen for a 
subunit vaccine since it covers 60% of the bacterial surface and facilitates cytoadhesion. The 
chlamydial outer membrane complex (COMC) has also been considered since 90% of it is 
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made up of MOMP (Caldwell et al., 1981). Both of these alternatives have proven to be 
immunogenic in small animal models, producing a strong anti-MOMP antibody titre, 
demonstrating the potential of a subunit vaccine consisting of a surface-exposed component 
of the bacterium (Longbottom and Livingstone, 2006). MOMP is therefore the superior option 
for a novel second-generation vaccine design because it is capable of eliciting a strong 
antibody response in which all antibody paratopes generated are against the surface exposed 
conformational epitopes of MOMP. This should, in theory, facilitate easy recognition of the 
whole bacterium since its surface is covered with the target epitopes (Longbotttom, 2003).  
There has been a significant amount of research performed on the expression of the MOMP 
protein from multiple chlamydial species, and the evaluation of these recombinant proteins as 
subunit vaccine candidates (Pal et al., 2005; Pal et al., 2015; Philips et al., 2019; Tifrea, 2013; 
Wen et al., 2016;). Much of the research has focussed on determining the infection cycles and 
the particulars of pathology; to elucidate the immunologic pathways that are activated by the 
MOMP protein to determine not only the type of response elicited; but also the efficacy and 
efficiency of the responses–both primary and secondary (Philips et al., 2019). Table 1 
exemplifies the knowledge gained and contributions made towards chlamydial vaccine 
development in the last 70 years. For all chlamydial species, protein antigens have been the 
antigenic targets in 122 clinical trials, of which MOMP, COMCs and polymorphic outer-
membrane proteins (POMPs) have been evaluated as candidate subunit vaccine antigens. 
Although there is a great amount of data available in this regard for reference; there are no 
MOMP-based subunit vaccines that have been approved and licensed.  
 
Table 1: The number of clinical trials that have been performed; the clinical subjects used; the type of vaccine 
antigens and targets for the past 70 years. Adapted from Philips et al., (2019).  
Chlamydial 
species  
Type of antigen (number of 
studies ) 
Trial subjects  Vaccine 
targets  
Total number 
of trails  
C. abortus  Plasmid (2), protein (2), 
virus (1), whole-cell (7) 
Sheep, pig, 
cattle 
Sheep, 
cattle, pig 
12 
C. caviae Protein (1) Guinea pigs Humans  1 
C. felis Whole-cell (1) Cats  Cat 1 
C. muridarum DNA (1) nanoparticle (1), 
plasmid (5), protein (63), 
virus (1), whole cell (14) 
Mice/rats, 
non-human 
primates  
Human s 85 
C. pecorum Protein (12), whole-cell (1) Koalas, 
sheep 
Koalas, 
sheep  
13 
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C. pneumoniae DNA (1), plasmid (6), protein 
(6), virus (1), whole-cell (1) 
Mice/rats  Human s 15 
C. psittaci Plasmid (3), protein (7), 
virus (1), whole-cell (15) 
Mice/rats, 
sheep, 
guinea pigs, 
birds, cats  
Humans 
sheep, 
birds, cats  
26 
C. trachomatis  Nanoparticle (2), plasmid 
(16), protein (43), virus (7), 
whole-cell (15) 
Mice/rats, 
non-human 
primates, 
guinea pigs, 
pigs, rabbits, 
humans  
Humans, 
pigs  
83 
 
 
1.3. Immunity 
 
1.3.1. The basics of immunity  
 
Immunity is a state brought about by the ability of an organism to confer resistance or 
protection against diseases caused by infectious pathogens, by means of an immunological 
response during both natural and induced infection (Yatim and Lakkis, 2015). There are many 
factors that play a role in the mediation of an immune response, the most important being the 
different types of immune cells along with their main functions in an immune response, their 
primary locations and targets of infection (Figure 1). In terms of immune cells, there are three 
broad categories that play essential roles, these are professional phagocytes, granulocytes 
and lymphocytes (Janeway et al., 2001). These cells, their functions, targets and location have 
been summarized in Table 2.  
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1.3.1.1. The role of professional phagocytes in an immune response 
 
The professional phagocytes include monocytes, macrophages, dendritic cells, neutrophils 
and mast cells, all of which specialize in phagocytosis (Yatim and Lakkis, 2015). Phagocytosis 
is a process used by certain cells in the immune system for engulfment of foreign bodies. 
Once engulfed, the particle is trapped in a phagosome, and this phagosome then fuses with 
a lysosome to form a phagolysosome, in which the particle is digested by degrading enzymes, 
antimicrobial peptides and toxic peroxides (Rosales and Uribe-Querol, 2017). Monocytes 
themselves are not phagocytic, but rather a precursor of the mononuclear phagocytes: 
macrophages and dendritic cells. Monocytes circulate in the bloodstream and upon infection, 
they migrate into the infected tissue where it then differentiates to give rise to a macrophage 
or dendritic cell. This choice depends on the type of tissue that it has migrated into, and the 
type of threat causing infection (Swirki et al., 2009). Mononuclear phagocytes need to satisfy 
three purposes in an immune response: they need to first phagocytose foreign bodies in 
infected tissue; they then need to present the antigens to T cells located nearby; and the third 
purpose is to produce and secrete cytokines which play a major role in cell signalling (Janeway 
et al., 2001). Neutrophils and mast cells are classified as granulocytes but can also be 
considered as professional phagocytes, due to the ease with which they carry out phagocytic 
processes. Basophils, although phagocytic, are not considered to be professional phagocytes 
because they are less efficient at carrying out phagocytosis than the other phagocytes 
mentioned here. These professional phagocytes, therefore, aim to eliminate invading 
pathogens, cell debris and cells that are dead or in the process of dying, using phagocytic 
processes. 
 
1.3.1.2. The role of granulocytes in an immune response 
 
Granulocytes are a type of white blood cell that contains granules within its cytoplasm; these 
granules function as secretory vesicles that assist the granulocytes in combating an invading 
body when encountered. The substances in the granules include toxic materials, antimicrobial 
agents, enzymes and proteins like lysozyme and acid hydrolases, toxic oxygen derivatives, 
and nitrogen oxides (Soehnlein et al., 2008). The three types of granulocytes are neutrophils, 
basophils and eosinophils. As previously mentioned, neutrophils and basophils are also 
capable of phagocytosis, while eosinophils are not. A feature common to all three is 
degranulation, which is the discharge of the granule contents, including antimicrobial agents 
and cytotoxic compounds which aid in the destruction of extracellular pathogens. However, 
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the compounds housed by the granules are not limited to those mentioned, they may also 
include histamines, cytokines, growth factors and platelet-activating factors (Faurschou and 
Borregaard, 2003).  
Neutrophils are the most abundant granulocyte found in most mammals, and the most 
abundant phagocytic cell found in the bloodstream. They are also the first responders, in cases 
where infection by bacteria or certain cancers cause significant inflammation. In terms of 
degranulation, they possess three types of granules, two of which secrete compounds that aid 
in the destruction and elimination of a pathogen. The neutrophilic primary or azurophilic 
granules contain defensins and cationic proteins, which kill bacteria; lysozyme for degradation 
of the bacterial cell wall; proteolytic enzymes and cathepsin G for degradation of bacterial 
proteins and myeloperoxidases which give rise to toxic, bactericidal substances. The 
neutrophilic secondary granules contain lactoferrin whose sole purpose is the removal of iron 
from bacteria, lysozyme, and compounds used for the formation of toxic oxygen-derived 
species (Faurschou and Borregaard, 2003).  
The neutrophilic gelatinase granules help the neutrophils to migrate out of the bloodstream 
and into the tissues, and to navigate through the tissues in order to reach the site of infection. 
Besides its high levels in blood, another distinguishing feature of neutrophils is its ability to 
carry out a phenomenon called Neutrophil Extracellular Traps (NETs). NETs are web-like 
structures of DNA, which are released by neutrophils upon activation by infection markers. 
NETs are made up of chromatin and serine proteases; and contain a high concentration of 
antimicrobial agents, all of which facilitate the entrapment and destruction of bacteria and 
fungi, as well as a reduction in the spread of the infection. Therefore, it is said that neutrophils 
sacrifice themselves by ejecting their DNA in order to save the cell from infection (He et al., 
2018).  
Although basophils can perform phagocytosis, their primary function is the mediation of an 
inflammatory reaction in cases of acute and chronic allergic reactions. Basophilic granules 
contain histamines, proteolytic enzymes, cytokines and proteoglycans such as heparin. All 
these components are secreted in the presence of markers that indicate allergy; and contribute 
towards an inflammatory reaction (Blank et al., 2013). Eosinophils are also involved in the 
mediation of an inflammatory response to an allergic reaction like basophils. Besides the fact 
that they are not phagocytic, another distinguishing feature of this type of granulocyte is its 
ability to kill parasites. Eosinophilic granules contain four highly destructive proteins: the major 
basic protein (MBP), eosinophil peroxidase (EPX), eosinophil cationic protein (ECP) and 
eosinophil-derived neurotoxin (EDN). The MBP acts as a cytotoxin, which is a defence 
mechanism against parasites, and also plays a role in hypersensitivity reactions. EPX gives 
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rise to reactive oxygen species (ROS), this increases the oxidative stress experienced by the 
target, leading to death by necrosis or apoptosis. ECP causes the target cell membrane to 
become porous, therefore enabling entry of other cytotoxic substances into the cell. The EDN 
has antiviral activity, it’s cytotoxic and it also facilitates activation of other immune cells to the 
site of infection (Ramirez et al., 2018).  
 
Table 2: Immune cell types, their main functions, targets and primary locations. 
Types of 
Immune Cells 
Main Functions Targets Location References 
Monocytes  The precursor of macrophages 
and dendritic cells. 
 Various microbes. 
 Necrotic/ apoptotic 
cells. 
 Cell debris. 
 Bloodstream. 
 Monocyte reserves in the 
spleen. 
 Upon movement into 
tissues, they differentiate 
into macrophages and 
dendritic cells. 
 Swirski et al., 
2009 
Macrophages  Professional phagocytes, 
phagocytosis of pathogens and 
apoptotic cells. 
 Presentation of antigens to T 
cells. 
 Gives rise to cytokines which 
regulate lymphocyte activity. 
 Various microbes. 
 Necrotic/ apoptotic 
cells. 
 Cell debris. 
 Essentially in all tissues.  Warrington et 
al., 2011 
 Ovchinnikov et 
al., 2008 
Dendritic cells  Professional phagocyte, 
phagocytosis of pathogens, cell 
debris, necrotic and intact cells. 
 Presentation of antigens to T 
cells. 
 Messenger between innate and 
adaptive immune responses. 
 Bacteria and 
parasites. 
 Necrotic and intact 
cells. 
 Cell debris. 
 Tissues in contact with 
the external environment, 
eg: lungs, stomach, 
intestines, nose and 
blood. 
 
 Savina and 
Amigorena, 
2007 
 
T lymphocytes  Antigen recognition through T 
cell receptor (TCR). 
 Responsible for adaptive 
immune response. 
 Plays a key role in cell-
mediated immunity. 
 Effector T cells respond to 
stimuli. 
 Helper T cells facilitate 
maturation of B cells and 
activation of professional 
phagocytes and cytotoxic T 
cells. 
 Cytotoxic T cells kill tumour and 
virus-infected cells. 
 Virus-infected cells. 
 Tumour cells. 
 Intracellular bacteria. 
 Bone marrow. 
 Thymus. 
 Blood. 
 Alberts et al., 
2002 
 Camara et al., 
2012 
17 
 
 Regulatory T cells facilitate 
immunological tolerance. 
 
B lymphocytes  Antigen recognition through B 
cell receptor (BCR). 
 Functions as an antigen-
presenting cell. 
 Responsible for adaptive 
immune response. 
 Plays a key role in humoral 
immunity. 
 Responsible for production and 
secretion of antigen-specific 
antibodies. 
 Bacteria and viruses. 
 Foreign proteins, 
polysaccharides and 
glycoproteins. 
 Bone marrow. 
 Spleen, lymph and 
secondary lymphoid 
organs. 
 Blood. 
 LaRosa and 
Orange, 2007 
 Murphy, 2012 
NK cells  Responsible for innate immune 
response. 
 Destruction of virus-infected 
cells by induction of apoptosis. 
 Tumours. 
 Viruses. 
 
 Bone marrow. 
 Lymphoid organs. 
 blood 
 Murphy, 2012 
Neutrophils  Gives rise to 
polymorphonuclear cells, 
basophils and eosinophils. 
 Phagocytosis and 
degranulation. 
 Neutrophils extracellular traps 
(NETs) for killing bacteria. 
 Release enzymes that kill 
microbes. 
 Fungi. 
 Bacteria. 
 Bone marrow. 
 Thymus. 
 Blood. 
 Interstitial tissue. 
 Nathan, 2006 
 Warrington et 
al., 2013 
Basophils  Control of allergies and asthma. 
 Phagocytosis and 
degranulation. 
 Secretion of histamines, 
cytokines and enzymes to aid 
the allergic response. 
 Tissues undergoing 
an allergic response. 
 Bone marrow. 
 Blood. 
 Blank, 2013 
 Warrington et 
al., 2013 
Eosinophils  Degranulation (discharge of 
cell contents). 
 Control of allergies and asthma. 
 Secretion of cytokines, growth 
factors and enzymes. 
 Tissues undergoing 
an allergic reaction. 
 Parasites. 
 Bone marrow. 
 Spleen, lymph nodes, 
ovary, gastrointestinal 
tract. 
 Blood. 
 Warrington et 
al., 2011 
 
1.3.1.3. The role of lymphocytes in an immune response 
 
Lymphocytes are a class of leukocytes and there are three primary types: T lymphocytes, B 
lymphocytes and natural killer (NK) cells (Yatim and Lakkis, 2015). Both T and B lymphocytes 
function in the adaptive immune response and are activated by antigen-presenting cells 
(APCs); while NK cells function in the innate immune response. T cells have a T cell receptor 
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(TCR) on their surface, this is an antigen-binding receptor, and therefore binds the antigen 
fragments when presented by an APC after digestion of the antigen. Upon activation of the T 
cell, it secretes cytokines which mediate the immune response and the T cell differentiates to 
give rise to its subtypes (Warrington et al., 2011), the most important of which will be 
discussed.  
Cytotoxic T cells are responsible for the direct killing of tumour- and virus-infected cells. T 
helper cells are the mediators of the immune response, although they are unable themselves 
to carry out specific actions. Instead, they direct other immune cells to carry out specific tasks. 
Another important function is that they facilitate the maturation of B cells in order to activate 
an antibody response (Alberts et al., 2002). Regulatory T cells facilitate immunological 
tolerance, which is the ability to recognise non-self from self-cells. This characteristic is 
essential in any organism, as it prevents the destruction of self-cells which would result in an 
autoimmune disease (Camara et al., 2012). Collectively, T cells carry out the cell-mediated 
adaptive immune response, which is based on the interactions between antigen fragments 
and T lymphocytes. In the cell-mediated response, antigen fragments displayed on an APC 
are presented to a T lymphocyte, the antigen then binds to a TCR which triggers differentiation 
into the different T cell subtypes, and subsequent secretion of cytokines from the T helper 
cells. These cytokines then function as the driving force for the directed killing of altered self -
cells (Saroj et al., 2012).  
B cells have a B cell receptor (BCR) on their surface, and unlike T cells, they do not require 
APCs for antigen recognition (Warrington et al., 2011). The primary function of B cells is the 
production and secretion of anti-antigen antibodies, which are highly specific and effective. B 
cells carry out the humoral adaptive immune response, which is triggered upon binding of an 
antigen to a BCR. This process is also aided by T helper cells when the cytokines are released 
during the cell-mediated response. These cytokines facilitate the differentiation of B cells into 
plasma cells, which are responsible for antibody production and subsequent secretion. These 
antibodies then flag the antigens for destruction, either by activation of phagocytes, activation 
of the complement system, or pathogen and toxin neutralization (Bonilla and Oettgen, 2010).  
B cells produce five different types of antibodies, each of which has specific targets, properties 
or characteristics and functions, these can be found in Table 3. The antibody response is very 
specific and effective, but in cases of virus infection they are not capable of containing the 
infection, and therefore the cell-mediated response is required. The third type of lymphocyte 
is NK cells, they are capable of inducing apoptosis of tumour- and virus-infected cells during 
the innate immune response and this is facilitated by interferons. Interferons are signalling 
proteins; and in the case of virus infection, interferons are secreted from a virus-infected cell, 
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in order to advise all nearby cells to increase their antiviral defence to prevent further infection 
(Lee and Ashkar, 2018).  
 
Table 3: Classes of immunoglobulins produced by B cells and their main functions. 
Type of 
Immunoglobulin 
(Ig) 
Functions  References  
IgM  First-class of antibody produced by the B cell 
during development. 
 Function as receptors for antigens within the 
plasma membrane. 
 Activates complement. 
 Complement fixation. 
 Opsonisation of antigens for destruction.  
 Murray et al., 
2012 
 Janeway et al., 
2001 
 Wilson and 
Walker, 2010 
IgG  Principle antibody required for an immune 
response during a subsequent encounter with a 
previously encountered pathogen. 
 Activates complement. 
 Complement fixation. 
 Opsonisation of antigens for destruction. 
 Capable of crossing the placenta. 
 Binds to macrophages and neutrophils. 
 Neutralization of viruses and toxins. 
 Murray et al., 
2012 
 Janeway et al., 
2001 
IgD  Functions mainly as cell-surface receptors for 
antigens. 
 Involved in homeostasis. 
 Warrington et 
al., 2011 
IgA  Principle antibody class in secretions. 
 Responsible for the mucosal response by 
preventing pathogens from binding to the 
mucosal surface or by direct neutralization. 
 Murray et al., 
2012 
 Janeway et al., 
2001 
IgE  Binds to mast cells and basophils. 
 Plays a key role in the mediation of an immune 
response. 
 Mediates allergic responses.  
 Murray et al., 
2012 
 Janeway et al., 
2011 
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1.3.2. Types of immunity 
 
1.3.2.2. The innate immune system 
 
There are two types of immunological pathways, called innate and adaptive immunity, both of 
which arise from different means which has been illustrated in Figure 1. The innate immunity 
pathway is always active and functions during primary infection, which is the first encounter 
with a particular pathogen. Since it is the first exposure to the pathogen, there is no 
immunological memory, unless the individual has been vaccinated against this type of 
pathogen. Generally, this initial encounter is mediated by the innate immune response which 
is the first line of defence and is independent of the presence of an antigen (Thompson, 2015).  
The innate immune system is an in-born defence mechanism, it offers non-specific immunity, 
and it prompts an immune response that varies in efficiency depending on the amount and 
type of immune cells available at the time (Getz, 2005). It consists of a variety of defence 
barriers which have three main purposes, these are: to reduce the ease with which a microbe 
can enter a host; to recruit specialized proteins or professional phagocytes to assist in the 
destruction of the invader; or to activate the infected cells intrinsic defence mechanisms to 
either cripple the invader or to induce cell death to prevent further infection (Janeway et al., 
2001; Murray et al., 2012). The types of innate defence barriers have been summarized in 
Table 4. 
Since the pathogen is not presented to this system by APCs, the innate immune system must 
be able to distinguish self from non-self, and this requires recognition of microbe-associated 
immunostimulants (MAIs) and pathogen-associated molecular patterns (PAMPs), by pattern 
recognition receptors (PPRs). MAIs and PAMPs include all conserved features of pathogens 
and distinguishing characteristics that are unique to a certain type of pathogen. There are 
many surface antigens that a wide variety of pathogens share; an obvious pattern is the 
presence of LPS in the bacterial cell wall, or the presence of double-stranded RNA which is 
characteristic of some viruses (Murray et al., 2012). Other immunostimulants include peptides, 
containing formyl-methionine which is indicative of bacterial proteins; an unmethylated CpG 
region in bacterial or viral DNA, flanked by two 5’ purine residues and two 3’ pyrimidine 
residues; peptidoglycans in the bacterial cell wall; and the presence of a flagellum and teichoic 
acids (Saroj et al., 2012). Upon stimulation of the innate immune system by PAMPs, vesicular 
or membrane-bound PPRs, like toll-like receptors (TLRs) and NOD-like receptors, bind the 
foreign body activating a group of blood proteins called complement. This leads to the 
destruction of the foreign body by professional phagocytes; followed by disruption of the 
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membrane and finally activation of an intracellular signalling cascade, which leads to the 
activation of a pro-inflammatory response (Tomar, 2016).  
 
Table 4: Types of innate defence barriers and the role that each barrier plays in protection against invading bodies. 
Physical and chemical barriers: reduce the ease of access of microbes into the host’s body.  
 Skin surface as a mechanical barrier made up of a thick layer of dead 
keratinized cells. 
 Inhibition of bacterial colonization by entrapment of microbes in the 
mucous membrane. 
 The tight junctions between epithelial cells. 
 The acidic environment of the stomach (pH 3–5). 
 Reduction in the occurrence of colonization brought about by competition 
between pathogenic bacteria and normal flora for the same ecological 
niche. 
 Lysosomal degradation of the bacterial cell wall. 
 Induction of antiviral defence in uninfected cells by interferons. 
Warrington et 
al., 2011 
 
Cell-intrinsic responses: recognition of infection by the infected cell followed by inducing 
death or crippling of the pathogen. 
 Phagocytosis of the microbe followed by lysosomal degradation. 
 Degradation of double-stranded RNA and its single-stranded counterparts 
to end viral replication. 
Janeway et 
al., 2001 
 
Specialized proteins and professional phagocytes: recruitment of specialized mechanisms 
for destruction of invading microbes. 
 Phagocytic barrier: neutrophils, macrophages, natural killer cells and the 
complement system phagocytose, kill and digest invaders. 
 Endocytic barrier: cells endocytose and breakdown invading 
macromolecules. 
 Inflammatory barrier: infection and resultant tissue damage induce 
leakage of vascular fluid containing serum proteins with antibacterial 
activity, which causes an influx of phagocytic cells to the infected area for 
phagocytosis.  
Murray et al., 
2012 
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1.3.2.3. The adaptive immune system 
 
All components of the adaptive immune system are present at all times in an individual but 
are only activated when a pathogen is encountered. This system is highly specific, meaning 
that the type of response depends on the type of pathogen or foreign body encountered, and 
it is an acquired response, meaning that the response is only developed and induced when a 
dendritic cell presents the antigen fragments to a T cell (Thompson, 2015). This means that 
the dendritic cell provides the link; therefore bridging the innate and adaptive immune systems, 
leading from a general immune response to one of an elevated degree of specificity (Tomar, 
2016). There are three main functions that the adaptive immune system must carry out, these 
are the distinction of self-antigens from non-self-antigens; the induction of an antigen-specific 
immune response in order to eliminate the pathogen; and the development of immunological 
memory (Bonilla and Oettgen, 2010).  
The adaptive immune system can be naturally or artificially acquired as can be seen in Figure 
1, and for each instance, it can occur actively or passively. For a naturally acquired adaptive 
immune response, active acquisition occurs by contact with a pathogen during infection. In 
this case, the immune system must react to the encounter and mount an adaptive immune 
response. Passive acquisition involves maternal transference of antibodies from the mother 
to the foetus before birth via the placenta, or from the mother to the child after birth via 
breastmilk. Although this type of protection is short-lived, it’s also immediate and essential for 
survival. For an artificially acquired adaptive immune response, active acquisition occurs 
through vaccination. This method intentionally exposes the individual to infection, in order to 
mount an immune response so that the efficiency and strength of the response at a 
subsequent encounter will be greater in terms of protective immunity. Passive acquisition 
occurs by the transfer of immune serum from a healthy individual, into an immune-deficient 
individual, therefore it serves to mount an immune response against infection even when an 
individual lacks essential components required for the immune response (Baxter, 2007; Clem, 
2011). Of all the ways that the adaptive immune response can be derived, the actively 
acquired, artificial adaptive immune response will be the focus for the purpose of this research, 
as it is brought about through vaccination. Vaccination targets the antibody response, with the 
end goal being the development of immunological memory, so that a more efficient immune 
response can be mounted against the pathogen on a subsequent encounter (Ratajczak et al., 
2018).  
For an antibody response to occur, the B cells must be activated, Figure 2 describes the 
process that a B cell undergoes in order to produce and secrete antibodies. A resting naïve B 
cell produces a few antibodies, all with the same antigen-binding site; and embeds them into 
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its plasma membrane where they serve as receptors for antigens. Upon binding of an antigen 
to one of the antibodies, a signal is transduced within the B cell and it acts as a trigger for 
activation of that resting B cell. This process is aided by the cytokines released by the T helper 
cells from the cell-mediated immune response. The B cell then proliferates through clonal 
selection, in order to make more of that same B cell. The proliferated B cells then differentiate 
into plasma cells called effector B cells and memory cells. The effector B cells then produce 
and secrete large amounts of soluble antibodies that have identical paratopes to the plasma 
membrane-bound antibodies (Clem, 2011; Chaplin, 2010; Janeway et al., 2001). These 
antibodies, which are highly specific for a particular pathogen then execute their functions, the 
first of which is to prevent pathogens from entering cells, which they do by binding the antigens 
of the pathogen. The second is to stimulate the elimination of the pathogen, by activating the 
complement system, which together with the antibody leads to opsonisation of the antigen for 
destruction, which is carried out by professional phagocytes. Alternatively, it provides 
assistance to the antibodies in the form of membrane attack complexes to destroy the 
pathogen directly (Rus et al., 2005).  
Immunological memory is the ability of an immune system to remember a pathogen that has 
been encountered previously, and induce a more efficient and robust response upon a 
subsequent encounter with the same pathogen (Farber et al., 2016). Immunological memory 
is one of the most important features of the adaptive immune system, as it offers immunity to 
a particular pathogen, and this level of protection increases each time the immune system is 
exposed to the pathogen Therefore building system so strong, that it can be considered to be 
a form of resistance rather than protection (Ratajczak et al., 2018).  
Immunological memory is stored in the form of antigen-specific B and T memory lymphocytes. 
These cells are very specific and in the presence of infection, these cells are activated and 
the response does not lag, it’s almost immediate since the cells were produced during the last 
encounter and have just been waiting for the pathogen that they are specific for (Farber et al., 
2016). As can be seen in Table 5, one of the differences between the innate and adaptive 
immune systems is the presence of immunological memory in the adaptive immune system 
and its absence in the innate immune system. However, this might not be entirely correct, 
since literature shows that some lower organisms have a memory-like mechanism but do not 
possess an adaptive immune system. Other differences between the innate and adaptive 
immune systems have been exemplified in Table 5.  
In the innate immune system, it is the NK cells which show an enhanced response upon 
subsequent encounters, and these responses have proven to be highly specific, therefore 
memory exists in both types of immunity and this makes for a stronger immune system 
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altogether (Sun et al., 2014). Immunological memory offers an organism many benefits, which 
makes it an important feature, but in terms of significance, it is imperative for the success of a 
vaccine. Vaccines rely entirely on immunological memory for prevention of a disease before 
the infection can cultivate to a high titre within the host. The end goal of vaccination is to induce 
long-term protective immunity against a specific pathogen, and this can only be made possible 
by the state of immunological memory (Pulendran and Ahmed, 2006).  
 
 
Figure 2: The pathway that a resting B cell must take to produce and secrete antigen-specific antibodies when an 
antigen is encountered. Adapted from Janeway et al., (2001).  
 
Table 5: Differences between the innate and adaptive immune systems. 
Innate Immunity Adaptive Immunity References  
Pre-existing, inborn defence 
mechanism activated prior to 
exposure to a foreign body or 
antigen.  
Acquired defence mechanism 
activated only upon exposure 
to a foreign body or antigen. 
Saroj et al., 2012 
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Response to the antigen is 
immediate, within minutes, 
therefore there’s no lag phase.  
Response to antigen has a lag 
phase of a few days. 
Warrington et al., 2011 
A non-specific response that 
targets a wide range of 
pathogens. 
A highly-specific response that 
targets a specific pathogen. 
Clark and Kupper, 2005 
No immunological memory, 
therefore, the response is 
always at the same level of 
immunity. 
Development of immunological 
memory, therefore the 
response to a subsequent 
encounter with a pathogen 
mounts a response with a 
higher level of immunity. 
Clark and Kupper, 2005 
 
2.1.1 1.3.3 Immune response to C. abortus infection 
 
Upon initial infection, it is the infectious, metabolically inactive EB form that enters the host. It 
has been elucidated that C. abortus resides in the tonsils before being distributed throughout 
the organs of the host via the blood and lymph (Kerr et al., 2005). Upon recognition of the 
foreign body by the innate immune system, certain defence mechanisms are deployed. In 
order to evade the initial immune response, instead of transitioning into the non-infectious 
metabolically active RB form, the bacteria remains in the EB state. This state allows it to persist 
in a hidden state for several months, the advantage of this is that for as long as it remains 
inactive it can remain undetected by the hosts’ immune system (Wong et al., 2019).  
At the time of infection, should the host not be within the gestational period, the bacteria 
transitions into a latent state and studies suggest that during this phase they reside within 
lymphoid organs. It is only upon detection of gestational hormones that the bacteria become 
active once again (Kerr et al., 2005). This allows for the passage of the bacteria into the 
placenta where they begin to multiply. Once this proliferation begins it becomes more difficult 
for the immune system to ward off the infection as the infectious bodies exercise multiple 
evasion mechanisms (Wong et al., 2019).  
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2.1.1.1 1.3.3.1 Evasion mechanisms  
 
All significant immune cells and their roles in the response has been discussed at length. C. 
abortus is able to evade many of these mechanisms implemented by the hosts’ immune 
system. Neutrophils which play a substantial role in the immune response is affected by the 
bacterial evasion. The exceptional function of neutrophils is the formation of NETs; it is this 
function that is hindered by the bacteria. These bacterial species are able to paralyse the 
extrusion of the NETs by using the Chlamydial-protease-like activity factor (CPAF) to inhibit 
the chemical activation of neutrophils (Rajeeve et al., 2018; Wong et al., 2019). They are also 
capable of evading phagocytosis as a whole though host-cell energy depletion. The bacteria 
induces the relocation of a regulatory subunit of NADPH oxidase from the host cell into the 
chlamydial inclusion membrane where is then increases the bacterial glycolytic function, 
leaving the host cell in state of energy depletion (Tauber et al., 1989).  
Another mechanism used is the inhibition of apoptosis. When the host cell recognizes the 
situation as dire, it may sacrifice itself in order to reduce the infection via apoptosis. However, 
this function is hindered by the expression of an anti-apoptotic protein produced by the 
bacteria (Sakar et al., 2015). They are also capable of eliminating the possibility of T cell 
detection through suppression of the class I and II MHC molecules. By reducing the 
expression of the MHC molecules, antigen presentation is stalled which eliminates the 
recruitment of T helper cells and the activation of the adaptive immune response (Yu et al., 
2011). Lastly, they can also hinder the immune response through mimicking the illusion of T 
cell exhaustion. The bacteria increases the expression of programmed cell death protein-1 
(PD-1); PD-1 then binds to its ligand resulting in the suppression of T cell activation which in 
essence brings the cell-mediated immune response to a holt (Fankhauser and Starnbach, 
2014; Wong et al., 2019).  
 
1.4. Vaccinology  
 
Vaccinology is a complex field of biological sciences, which deals with the development of 
vaccines. There are three main aspects that need to be considered when developing a 
vaccine, in order to maximize its success rate. These are the selection of the best possible 
immunogenic antigen; the type and degree of immunity that it will induce; and selection of the 
most well-suited delivery mechanism to promote recognition of the antigen by the immune 
system and its uptake by the appropriate immune cells (Barrett, 2016). The considerations 
mentioned, have major implications for the functioning of the vaccines, but there are other 
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aspects that are also significant for the utility of the vaccine. These include regulatory aspects, 
the safety of the vaccine, and ethical and economic considerations; all of which contribute 
towards the approval of the vaccine (Wolfe and Sharp, 2002).  
A vaccine is defined as a biological preparation, containing an agent that resembles an 
infectious microorganism. Its primary function is to prevent and protect against a particular 
disease, by inducing an acquired immune response, in order to facilitate the generation of a 
state of immunological memory against that particular pathogen (Plotkin, 2003). Besides the 
fact that it prevents disease, by prepping the immune system with the essential equipment to 
fight the infection before the pathogen can cause serious damage. An added benefit is that 
the vaccination process exposes the body to the infectious agent, but in a form such that the 
disease symptoms are not exhibited (Walker and Rapley, 2009). There are four main types of 
vaccines which will be discussed: the first-generation live attenuated and dead or inactivated 
vaccines, which are produced using conventional methods; the second-generation subunit 
vaccines and third-generation DNA vaccines whose production is based on genetic 
engineering and recombinant DNA technology. These various classes of vaccines all have the 
same end goal, but they differ substantially in terms of the immune potency that they can 
facilitate and in their developmental process.  
 
1.4.1. Types of vaccines  
 
1.4.1.2. Live attenuated vaccines 
 
The live attenuated class of vaccines are made up of whole pathogens, which are alive but in 
a weakened or attenuated state, brought about by manipulation of its growth conditions. 
Attenuation is achieved by continuous culturing or passaging of the pathogen through 
abnormal growth conditions which gives rise to mutant strains that are still highly immunogenic 
but have lost their virulence. Attenuation through continuous culturing is a time-consuming 
process, therefore as a more rapid alternative attenuation can also be achieved by molecular 
means aimed at deleting the pathogens virulence genes (Walker and Rapley, 2009).  
The most distinguishing feature of this class of vaccines is that the pathogen is still alive, and 
therefore able to multiply intracellularly once inside the host, just at a reduced rate due to its 
attenuation. This means that a lower initial pathogen titre is sufficient to facilitate the 
generation of protective immunity; and therefore a single vaccination is adequate to provide 
long-lasting immunity (Vartak and Sucheck, 2016). Another major advantage of this class is 
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that it is capable of inducing both humoral and cell-mediated immunity that functions both 
locally and systemically; and both of these pathways stimulate the development of a state of 
immunological memory, which is the primary goal of vaccination (Singh et al., 2014).  
Since whole pathogens are used in the formulation of live attenuated vaccines, the immune 
response is raised against all protective antigens in their native conformation. This 
characteristic is very important because it provides a broader spectrum of immunity, which is 
essential for protection against variant strains of the same pathogen (Singh et al., 2014). There 
are also significant limitations of this class of vaccine, the most important being that it has the 
potential to revert to its virulent state, consequently causing the disease that it was meant to 
protect against. There are other limitations that arise due to its potential for reversion, these 
include strict storage and transport conditions to maintain viability and potency, and it cannot 
be administered to an immunosuppressed individual because it is more prone to reversion 
(Innes et al., 2011).  
There are two types of live attenuated vaccines used for prevention of C. abortus infection: 
Cevac Chlamydophila® developed by Ceva Sante Animale (Pty) Ltd, France, and Ovilis® 
Enzovax developed by MSD Animal Health, USA. Both of these vaccines are still in use and 
are effective in providing protective immunity but it only lasts for up to two and four years 
respectively (Ceva Sante Animale, 2015; MSD Animal Health, 2011). In terms of duration, the 
live attenuated class of vaccine, should, in essence, provide longer-lasting immunity than other 
types of vaccines. Many other live-attenuated vaccines directed at various organisms offer 
life-long protection; however, this feature has not yet been achievable for C. abortus using this 
class of vaccines (Singh et al., 2014). This indicates the need for an alternative which is 
immunogenic enough to provide longer-lasting immunity 
 
1.4.1.3. Dead or inactivated vaccines 
 
Dead or inactivated vaccines consist of whole pathogens that have been cultured under 
normal growth conditions and then inactivated in order to reduce their virulence. Inactivation 
results in the destruction of the pathogen, in order to deem them incapable of division, which 
will prevent them from increasing in titre; but at the same time, it is performed such that the 
pathogen will preserve the integrity of its immunogenic features (Walker and Rapley, 2009). 
Inactivation can be achieved using chemicals, radiation, antibiotics or heat. The chemicals 
used for inactivation include formaldehyde and beta-propiolactone. These chemicals cause 
inactivation by alkylating the pathogen proteins and nucleic acids, which disrupts their 
structure and therefore function (Walker and Rapley, 2009). Irradiating a pathogen with 
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gamma rays, x-rays or UV rays results in DNA damage, which leads to cell death. An organism 
cannot survive without their DNA, therefore radiation renders the pathogen inactive (Pitonzo 
et al., 1999). Heat inactivation involves the application of extremely high temperatures to the 
pathogen. This results in the destruction of key components in the cell such as the proteins, 
nucleic acids, lipids and carbohydrates, as well as the cell wall and membrane, without which 
the cell cannot survive (Pothakamury et al., 1995). Antibiotics, depending on the type chosen, 
can cause inactivation of the pathogen by inhibiting protein or nucleic acid synthesis; 
preventing cell wall formation; or by interfering with bacterial enzymes that are essential for 
their functioning (Finberg et al., 2004).  
Since this type of vaccine is also a first-generation vaccine, a major advantage of this class is 
its inability to revert to its virulent state, unlike its live attenuated counterpart. This feature 
made inactivated vaccines the superior choice earlier in the history of vaccination, especially 
because it could be administered to immunosuppressed individuals and pregnant women 
(Vartak and Sucheck, 2016). However, if the inactivation process is incomplete and it allows 
even one virulent pathogen into the emulsion, then it may lead to the development of the 
disease because that pathogen can multiply and colonize within the body (Walker and Rapley, 
2009).  
It is also a more stable formulation due to inactivation; and therefore the storage and transport 
conditions are not as critical as for live attenuated vaccines (Clem, 2011). An added advantage 
of inactivation is that it is cheaper and less time-consuming than attenuation, and this 
contributes towards the end goal which is to develop a quicker and more cost-effective 
mechanism to meet the needs of the disease burden. However, inactivation also has its 
drawbacks: it renders the antigen less immunogenic; therefore, the immunity induced is not 
enduring. Since the pathogen cannot multiply intracellularly, a higher initial pathogen titre is 
required for protective immunity; and it decreases the efficacy, therefore multiple boosters are 
required for an effective immune response (Vartak and Sucheck, 2016). Inactivated vaccines 
are also capable of inducing both types of immunity, although they produce a significantly 
weaker cell-mediated immune response when compared to the humoral response (Walker 
and Rapley, 2009).  
Chlamysure is a vaccine used for prevention of C. abortus infection in South Africa, developed 
by Onderstepoort Biological Products (OBP), South Africa. It uses formalin-inactivated whole 
bacterium as the antigen. Although it is effective in providing immunity against C. abortus 
infection, protection only lasts for up to one year. The duration of protective immunity is 
unfortunate, but an even greater concern and the reason why an alternative is needed is that 
the production of this vaccine is time-consuming and unpredictable. These bacterial cells do 
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not multiply very well in the Vero cell line, therefore bacterial growth takes up to 21 days, with 
a possibility of insufficient bacterial production. Since this vaccine requires the whole 
bacterium as the antigen, production is hindered by the inefficient growth process 
(Onderstepoort Biological Products, n.d).  
 
1.4.1.4. Subunit vaccines 
 
The second-generation subunit vaccines were developed to eliminate the risks associated 
with live vaccines; and the drawbacks associated with vaccines containing whole pathogens. 
There are three aspects that make subunit vaccines superior to the first generation vaccines. 
The first is that they eliminate the possibility of co-purifying contaminating products with the 
pathogen since specific antigens are selected for the development of the vaccine. The second 
is that it eliminates the potential for reversion, therefore there’s no possibility that this type of 
vaccine will cause the disease that it is meant to protect against. The third is that it allows for 
large-scale production of the antigens for vaccine formulation because it does not rely on the 
culturing of the pathogen for growth, but rather the use of recombinant DNA technology and 
genetic engineering for the heterologous expression of the selected antigens (Nasiemento 
and Leite, 2012).  
This type of vaccine requires an understanding of the pathogenesis of the disease-causing 
microorganism, in order to enable selection of the best possible immunogenic antigen(s), as 
well as a good understanding of these immunogenic antigen(s) on a genomics and proteomics 
level. Often, conserved surface proteins are the antigen of choice, because they are most 
likely to be in involved in the initial contact between pathogen and host, which enables 
subsequent entry into the host cells and consequent colonization resulting in infection.  
With C. abortus infection, it was found that MOMP plays a major role in the pathogenesis of 
C. abortus by facilitating cytoadhesion to a susceptible mucosal epithelial cell, therefore 
enabling entry into the host cell (Costa et al., 2015). This is one of the main reasons why 
MOMP was chosen as the immunogenic antigen for this study. Production of this type of 
vaccine can be carried out in one of two ways. The selected antigen can be isolated from the 
pathogen, but this is a less efficient route since a large amount of pathogen is needed for this 
technique. The second technique involves the insertion of the gene encoding the antigen of 
choice into a host, to form a recombinant pathogen which is capable of cloning and expressing 
the protein encoded by the gene.  
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Using the second technique, once heterologously expressed, the protein can then be 
purified—at which point it is ready to be transformed into a vaccine emulsion; and this method 
enables the generation of large amounts of the antigenic agent (Soler and Houdebine, 2007). 
There is a variety of expression systems available for heterologous expression including 
bacterial, yeast, mammalian and insect vectors. The aim is to select the vector that will provide 
an optimal quality of expression. For this, many factors need to be taken into account, the 
most important of which is the presence of post-translational modification mechanisms, ideal 
codon usage, and compatibility in terms of folding mechanisms, in order to conserve the native 
quaternary structure of the protein (Clark and Cassidy-Hanley, 2005).  
The fact that there is no potential for reversion due to the absence of a whole pathogen, offers 
many significant advantages for this class of vaccines. The first of which is that it makes for a 
highly stable vaccine, and therefore storage and transport conditions are not critical. It can 
also be administered to immunosuppressed individuals because it has a higher degree of 
safety, which stems from the fact that only one or a few highly immunogenic antigens are used 
as the protection-inducing source (Nasiemento and Leite, 2012; Singh et al., 2014). This class 
of vaccine also results in a lower degree and amount of adverse reactions, which is owed to 
the fact that the vaccine only contains immunogenic antigens and not whole organisms (Singh 
et al., 2014).  
In terms of the immune response, the design of the vaccine targets immunogenic antigens 
that have the potential to be efficacious; and those that are capable of inducing both cell-
mediated and humoral immunity (Nasiemento and Leite, 2012). Even though the target 
antigens are the most immunogenic in relation to the other possible candidates, on their own 
they may not be immunogenic enough; and this characteristic is also due to the fact that the 
antigens cannot replicate inside the host, therefore multiple boosters are required for 
increased efficacy (Xia et al., 2016). The only other significant downfall of subunit vaccines is 
that there is a possibility that the recombinant antigen may not retain its native conformation 
during heterologous expression. In such a case, the antibodies raised against the recombinant 
antigen may not recognise the protein antigen as an identical match during natural infection, 
and therefore the immunological memory developed by the vaccine will be considered 
redundant (Singh et al., 2014). Subunit vaccines have been the focus for improved prevention 
against C. abortus infection since the 1990s. A subunit vaccine has been the superior choice 
for a number of reasons; the first being that it offers large-scale production at a lower cost; it 
reduces the time constraints involved with producing whole organism vaccines; and most 
importantly, it eliminates the risk of reversion (Longbottom, 2003).  
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Currently, there are no patented subunit vaccines commercially available for prevention of C. 
abortus infection, but there are many ongoing studies that focus on various options, other than 
MOMP as the immunogenic antigen for the development of a candidate subunit vaccine. Other 
immunogenic antigens under study include the entire COMC; POMPs, which show great 
immunogenic properties, even though they only make up a small part of the COMC 
(Longbottom, 2003); and more recently, the POMP 18 D has been investigated as an 
alternative with superior immunodominance (Pan et al., 2015). Although there is no MOMP-
based subunit vaccine that has been approved for C. abortus control, there is a great amount 
of potential that lies in this protein as a subunit vaccine. In 2010 a C. psittaci MOMP-based 
subunit vaccine was certified as a new veterinary drug by the Ministry of Agriculture of the 
People’s Republic of China (Zhu et al., 2015). It was developed by the State Key Laboratory 
of Pathogen and Biosecurity, at the Academy of Military Medical Sciences in China. This 
subunit vaccine consists of three doses of a single antigen (MOMP) isolated from a genetically 
engineered C. psittaci (Li et al., 2010). Thus far it has displayed good safety and immunity, 
confirming the potential of this antigen (Zhou et al., 2018).  
 
1.4.1.5. DNA vaccines 
 
The third-generation DNA vaccines also aim to eliminate the potential for reversion and to 
reduce the lengthy duration of time required for the preparation of first-generation vaccines. 
Another similarity between DNA and subunit vaccines is that they both target a specific 
immunodominant antigen from the pathogen, which will enable antibody generation within a 
host or test model. However, there is a small difference, DNA vaccines limit the antigens to 
protein immunogens only. These vaccines therefore also follow the same developmental 
process as subunit vaccines, the major difference being that the antigen is not expressed 
heterologously for the purpose of a DNA vaccine. Instead, the vaccine formulation is 
administered in the form of a recombinant plasmid carrying the gene sequence encoding the 
chosen antigen. Once the DNA vaccine is administered, the DNA is transcribed into mRNA 
and translated into the protein antigen, within the host cell by the host cell machinery. This 
protein is then instantaneously recognised as foreign and presented to the immune system to 
mount an immunological response against the antigen (Khan, 2013).  
A significant downfall of DNA vaccines is that it is possible for the host cell to produce a protein 
that is not identical to the native protein in sequence, and therefore structure; the reason for 
this is codon usage. Since the genetic code consists of 64 codons and there are only 20 
different amino acids, each amino acid can be coded for by more than one codon. This 
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characteristic is significant because different organisms show bias towards certain codons and 
this is demonstrated by the contents of their tRNA pools. This affects protein production when 
the codon usage of the antigen and host organism do not match, as it indicates that the 
recombinant antigen may not be identical to the native antigen (Plotkin and Kudla, 2011). In a 
case as such, the immune response raised against the recombinant antigen will not be able 
to assist during natural infection, because the paratopes of the antibodies will not match the 
epitopes of the native antigen. However, this occurrence can be minimized and the 
immunogenicity of DNA vaccines can be enhanced, by optimizing the codon usage of the 
recombinant antigen to match that of the host (Wang et al., 2015).  
There are many advantages that DNA vaccines offer, the most important being that it is not 
capable of reversion and it can induce long-lasting cell-mediated and humoral immunity (Khan, 
2013). The fact that whole organisms are not used also contributes towards the befits of DNA 
vaccines: it increases the stability of the vaccine, and it enables the elimination of antigens 
that cause harm and those that do not play a role in the elicitation of protective immunity 
(Saade and Petrovsky, 2012).  
Even though DNA vaccines offer many advantages in comparison to the other types of 
vaccines, there are also some significant limitations that require improvement. It has a 
relatively low level of immunogenicity; and to date has shown minimal efficacy in humans and 
in large animal models, although it is quite well-tolerated in humans (Khan, 2013; Lee et al., 
2018). It is also capable of inducing immunological tolerance by antigens expressed inside the 
host; and it has the potential to cause cancer when the foreign DNA is inserted into the host 
cell genome (Vartak and Sucheck, 2016; Singh et al., 2014). In 2003, an attempt was made 
at developing a DNA vaccine against C. abortus infection. The candidate for this vaccine was 
the gene sequence encoding MOMP. The candidate vaccine proved to be effective in terms 
of the serological response, but it only provided partial protection of the foetuses of the mice 
models used, and it did not at all reduce the splenic or placental bacterial titre (He’chard et al., 
2003). Although progress thus far has been disappointing, there is still the possibility for 
improvement and a wide array of features and systems that are yet to be evaluated (Lee et 
al., 2018).  
 
1.4.2. Components of vaccines 
 
The development and manufacturing of a vaccine involve many constituents, all of which play 
a distinct and equally important role in the functioning and safety of the vaccine. Although 
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there are two vital components that have a great influence on the efficacy of the vaccine, 
without which the vaccine would not be able to carry out its purpose, these are the active 
component which is the immunogenic antigen, and the adjuvants or delivery systems (Pashine 
et al., 2005). Other components which all vaccines contain include diluents, this is provided 
along with the vaccine in order to dilute the vaccine emulsion before administration; trace 
compounds, which are present from the early-stage production process; and preservatives 
and stabilizers, to prevent bacterial and fungal contamination and maintain the stability of the 
vaccine (Eldred et al., 2006). 
 
1.4.2.2. Active components 
 
The active component of the vaccine may contain many antigens in the form of a whole 
pathogen; only one or a few antigens in the case of a protein or peptide subunit, a toxin, a 
polysaccharide or recombinant DNA representing one or a few genes (Strugnell et al., 2011). 
The active component must be exceptionally immunogenic in order to mount an adaptive 
immune response against itself (Pashine et al., 2005); and it must have the specific features 
needed for recognition by the TCR or BCR (Strugnell et al., 2011). Another requirement of the 
active component, in the case of a subunit antigen, is that its structure must appear as identical 
as possible to the native antigen in order for the state of immunological memory to function 
during natural infection.  
 
1.4.2.3. Adjuvants 
 
An adjuvant is an immunological agent that facilitates the stimulation of the immune system in 
order to enhance the immunological reaction, by assisting in antigen presentation (Plotkin et 
al., 2013). It can influence the immune response towards the antigen in one of two ways, by 
depot formation or by modifying the type of immune response elicited. An adjuvant can 
function as a depot for the antigen at the injection site, in order to increase the capacity of the 
immune response. This depot facilitates slow-release of the antigen, prolonging its clearance 
which allows the antigen to persistently stimulate the immune system, leading to the 
production of a higher antibody titre (Awate et al., 2013). This property of adjuvants is 
important because by prolonging the release of the antigen, it reduces the antigen titre 
required to mount a sufficient immune response, and it reduces the number of doses required 
because it increases the duration of protective immunity (Offit and Jew, 2003).  
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The second main function of adjuvants is to modify the type of immune response elicited – 
this is imperative because it can facilitate the generation of an immune response which is not 
generally elicited by the antigen alone; and it can mount a specific type of immune response 
depending on the type of antigen, the most effective type of immunity for that specific pathogen 
and the desired immune pathway (Coffman et al., 2012). Adjuvants are also capable of 
enhancing the speed of the initial immune response, and this property is significant in cases 
of severe outbreaks of infection leading to pandemics (Khurana et al., 2010). Adjuvants can 
also facilitate the immune response by increasing the generation of memory cells, which is the 
end goal of vaccination. An added benefit of including an adjuvant in a vaccine formulation is 
that it has the ability to enhance the seroconversion rates in immunosuppressed and 
immunocompromised individuals (Coffman et al., 2012).  
There are many classes of adjuvants, some of which have been approved for use while others 
are in the development or testing phase. The major classes of adjuvants include mineral salts, 
oil emulsions, tensoactive adjuvants, bacteria derivatives, liposomes, cytokines, and 
carbohydrates. The most important of which for most licensed vaccines is the mineral salts; 
and for the purpose of this study, the oil emulsions. The most well-known mineral salt adjuvant 
is the alum-based adjuvants, which are made up of aluminium hydroxide and aluminium 
phosphate. It is the first adjuvant approved for human use; and is still the most commonly 
incorporated adjuvant in human vaccines (Garcon et al., 2011).  
In 1926 the depot effect of aluminium was discovered, when it was included with a toxoid and 
enhanced the immune response towards the antigen, by extending the duration of antigen 
persistence. Since then, this class of adjuvant has been exploited for its depot effect, in order 
to increase the antibody titre produced during vaccination (Garcon et al., 2011; Glenny et al., 
1926). Alum-based adjuvants also facilitate activation of macrophages, eosinophils and 
complement, as well as activation and enhanced efficiency of APCs. An additional befit of this 
type of adjuvant is that it can efficiently promote the humoral immune response, leading to 
antibody production by stimulating certain immune cells to secrete interleukin-1β, which 
signals the immune system to produce antibodies (Leslie, 2013). A major limitation of this type 
of adjuvant is that it is only capable of stimulating a relatively poor T cell immune response 
and therefore cannot assist well in the activation of the cell-mediated immune response. 
Another is that it is often accompanied by a wide array of side effects, the most unfavourable 
being the formation of granulomas, nodules, erythema, allergenicity and neurotoxicity (Eldred, 
2006; Petrovsky and Aguilar, 2004).  
The oil emulsion-based adjuvants include oil-in-water or water-in-oil emulsions, and although 
they have not been approved for human use like the alum-based adjuvants, they carry out 
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more-or-less the same functions. This class also induces the depot effect and stimulates a 
strong antibody response, but it has also displayed many other effective characteristics. It 
plays a role in antigen protection, preventing enzymatic degradation and in the process 
altering its electric charge, which in turn increases the immunogenicity of the antigen 
(Waksman, 1979). It also creates inflammation at the site on injection, which facilitates in the 
recruitment of APCs, and triggers lymphocyte trapping in draining lymph nodes (Ganne et al., 
1994). This class of adjuvant is also capable of stimulating the generation of T cell-mediated 
immune responses, depending on the type of emulsion used.  
However, it also results in some undesirable side effects, such as the formation of granulomas 
and ulcers at the site of injection, as well as inflammatory reactions (which increases the 
immunogenicity of the antigen) depending on the type of oil used (Aucouturier, 2001). The 
Montanide ISA 70 adjuvant that will be included in the formulation for the testing of the 
candidate vaccine is also an oil emulsion, more specifically a water-in-oil emulsion that has 
been combined with recombinant and synthetic antigens for testing in small animals; and it 
has been incorporated in trial vaccines against malaria, HIV and cancer (Jones, 1990).   
 
1.4.3. The immunisation schedule 
 
The immunisation schedule can be considered as a detailed protocol, which stipulates the 
conditions of vaccination specific for a particular vaccine. Such as the mode of administration; 
the amount and concentration of doses required; the duration of rest between the doses; the 
effects of induced infection after vaccination; the type and severity of adverse reactions; and 
a means for quantification of the safety, efficacy and immunogenicity of the vaccine (World 
Health Organisation, 2003).  
 
1.4.3.2. Mode of administration 
 
The mode of administration refers to the route taken by the vaccine in order to reach its desired 
destination within the body, and it is classified by the location at which it is administered. There 
is a multitude of routes that can be used for administration of a vaccine, all of which vary in 
the level of immunogenicity that they can facilitate; the level of safety that they can ensure; 
the viability in terms of efficacy; and the dosage, metabolism and clearance of the drug 
(Herzog, 2014).  
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There are two main modes used for vaccine intake, these are enteral and parenteral. The 
enteral route involves the administration of drugs through the gastrointestinal (GI) tract, which 
involves the oesophagus, stomach and intestines (Williams, 2008); and the parenteral route 
involves drug administration through all other routes excluding the GI tract (Dorj et al., 2014).  
The enteral route which revolves around the GI tract primarily involves the oesophagus, 
stomach and intestines. There are three types of enteral administration, which depends on the 
point of entry of the drug into the GI tract, these are oral, gastric and rectal (Williams, 2008). 
The oral route is the most well-known and most commonly used enteral route, it involves 
ingestion of the drug in the form of a tablet, capsule or liquid. It can also include sublingual 
administration, which involves dissolving the drug under the tongue for diffusion into the 
bloodstream (Röder et al., 2007); buccal administration, where the drug is dissolved inside the 
cheek; and sublabial administration in which the drug is dissolved under the lip (Kraan et al., 
2014). The gastric route involves direct administration of the drug into the stomach, by means 
of a feeding tube. This tube can either be connected through the nasal passage leading into 
the stomach or directly connected in the abdomen leading into the stomach (Williams, 2008). 
The rectal route involves drug administration by means of a suppository, topical ointment, 
Murphy drip, or an enema. The rectal route is often a superior option compared to the oral 
route since the rectum has highly vascularized tissue; therefore, it can absorb the drugs more 
rapidly, and it offers a greater bioavailability of the drug (van Hoogdalem et al., 1991). 
The parenteral route revolves around all other application points besides the GI tract, with the 
mode of administration being injection. There is a wide array of application points but the most 
commonly used types of injection for the purpose of vaccination is intramuscular (IM), 
subcutaneous (SC), intradermal (ID), intraperitoneal (IP) and intravenous (IV). Although oral 
drugs are the preferred option due to ease of intake, they are often not absorbed effectively, 
and when this occurs, the injection route is selected because it offers optimum bioavailability 
of the drug; and drug delivery to the site of action is extremely rapid (Herzog, 2014).  
IM injections are administered into a specific muscle, most commonly into the deltoid muscle 
of the arm, the anterolateral muscle of the thigh, or into the gluteal muscles of the buttocks. 
Injection of drugs into the gluteal muscles is one of the most effective means of drug 
distribution because there is an abundance of veins; therefore the drug reaches the 
bloodstream more rapidly than any other injection type. Another advantage is that it maximises 
the immunogenicity of the drug, while minimising the occurrence of adverse reactions at the 
site of injection (Zuckermann, 2000).  
SC injections are administered into the fatty subcutaneous layer, which is found above the 
muscle and below the skin; and the point of application is the subcutinis of the thigh or upper 
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outer triceps. The subcutaneous layer has significantly fewer blood vessels than the muscle 
layer and as a result, drug release into the bloodstream is much slower, therefore this type of 
injection is used when a prolonged absorption rate is required, as this often increases the 
strength of the immune response mounted against the antigen (Wahl and Hermodsson, 2009; 
Awate et al., 2013). ID injections are administered to the dermis of the arm, which is situated 
just beneath the epidermis. This type of injection has two benefits: it offers the slowest release 
of the drug into the bloodstream, therefore prolonging its existence within the body; and 
adverse reactions are easy to detect and diagnose since they occur very close to the surface 
of the body (Wahl and Hermodsson, 2009).  
IP injections are administered into the thin membrane that lines the abdomen, called the 
peritoneum. Therefore, the injection point for IP injections is the abdomen. Once administered, 
the drug diffuses into the surrounding tissues, where it is then taken up by capillary blood or 
lymph quite rapidly (Das and North, 2007). IV injections are administered directly into the veins 
of the arm allowing for rapid entry into the bloodstream. This is the least preferred route for 
the purpose of vaccination, because intravenous injection results in rapid clearance of the 
antigen, without allowing the immune system to develop a strong immune response that can 
lead to the generation of immunological memory (Awate et al., 2013).  
 
1.4.3.3. Boost 
 
Some vaccines are protective enough to only require one dose in a lifetime, such as the 
hepatitis and measles-mumps-rubella (MMR) vaccines; in both cases, because the 
progression of the disease is slow, there is sufficient time for the immunological memory 
response to take action time and time again. Whereas for diseases that progress at a faster 
rate, booster vaccinations are required in order for the immunological memory response to be 
sustained, to enable it to fulfil its purpose before the infection progresses to a terminal state 
(Leuridan and van Damme, 2011).  
A booster vaccination is a subsequent administration of the same vaccine, which follows after 
a certain period of time after the primary or prime immunization; and it is administered in order 
to increase the protective immunity against the antigen, in cases where the immunological 
memory response has declined in strength or effectiveness (Lu, 2009). The booster/s may be 
required a few days, months, or years after the primary immunization depending on the type 
of vaccine being administered and the rate of progression of the disease. Although there is 
not a clear-cut distinction as to why certain vaccines need boosters, while others do not. 
However, a possible explanation as to why boosters are required may be because the primary 
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immunization elicits a very rapid immune response, and the immune system does not have 
enough time to generate a sufficient state of immunological memory. Therefore, the memory 
T and/or B cells generated, persist at a more constant level in the body with low to minimal 
cell division, which eventually becomes redundant because the rate of cell division is 
overtaken by the rate of cell death—and at this point a booster is required (Janeway et al., 
2001). 
In the case of the tetanus vaccine, during childhood it is recommended that five doses are 
administered, and during adulthood a booster is required every 10 years because, after 10 
years, the memory cells specific for the tetanus toxin lose their function or die due to apoptosis, 
therefore leaving the individual exposed to infection (Burton and Crane, 2005). There are two 
types of prime-boost strategies that are in use, these are the homologous and heterologous. 
In the homologous prime-boost strategy, the same vaccine formulation is used for the primary 
and all subsequent booster immunizations (Nasimento and Leite, 2012). In the heterologous 
prime-boost strategy, different vaccine formulations containing the same immunogenic 
antigen is used for the primary and subsequent booster immunizations.  
The heterologous prime-boost strategy is often the superior option of the two because it has 
proven to be more effective than its homologous counterpart, especially when dealing with an 
intracellular pathogen (Lu, 2009). What makes this strategy so remarkable is the fact that it 
has evolved a means to induce both cell-mediated and humoral immune responses, in cases 
where only one of the two can be elicited. When vaccinating with a subunit antigen, generally 
only a humoral immune response is elicited; while certain delivery systems like DNA vaccines 
and the recombinant live vector vaccines are only capable of eliciting a cell-mediated immune 
response. Therefore, by combining the subunit antigen with a specific delivery system, it’s 
possible to manipulate the immune system to mount both types of immunity against the 
pathogen, which essentially leads to the development of both B and T cell immunological 
memory (Nasimento and Leite, 2012).  
 
1.4.3.4. Challenge 
 
In a vaccination trial, to challenge means to induce infection in the test models used in the trial 
with a virulent, wildtype form of the pathogen after vaccination. This is done in order to study 
the effectiveness and efficiency of the immune response towards the induced infection, and 
an added benefit is that it provides details of the pathogenesis of the infectious pathogen 
(Miller and Grady, 2001). The challenge test is a common method used for the evaluation of 
a candidate vaccine, as it provides insight into the potential efficacy of the candidate vaccine, 
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by testing the immune response generated by the vaccine antigen, before moving to a large-
scale test in larger animals (Garcia et al., 2008). Challenging the test models plays a very 
important role in determining whether the candidate vaccine can prove to be successful or not, 
but in order for the challenge test to be viable as a measure of the efficacy of the vaccine, 
there are two factors that must be considered. These are the challenge dose and the duration 
of time allowed between subsequent boosts and the challenge (Chavez et al., 2008; Islam et 
al., 2007).  
The challenge dose varies depending on the type of pathogen that is used for the challenge 
test. In terms of dosage, a general observation is that there is a linear relationship between 
the dose concentration and level of protective immunity provided, but there is a limit as to how 
high the concentration of the challenge dose may be, without becoming lethal to the test 
models. Too high a dose can lead to the death of the test models, in cases where the immune 
response elicited is not yet strong enough (Islam et al., 2007). In terms of the duration between 
the primary vaccination or subsequent boosts and the challenge test, the duration of the lag 
period influences the quality and concentration of the necessary immune cells generated 
(Chavez et al., 2008).  
For trials that do not include a challenge test, the efficacy is evaluated based on the 
concentration of antibodies generated against the candidate vaccine antigen, but for those 
that do include a challenge test, a more in-depth analysis is required in order to measure 
efficacy. Often after challenging the test models and allowing the immune system to respond, 
the test models are euthanized and the organs in which the pathogen is known to colonize are 
evaluated to determine the pathogen titre, the extent of infection or clearance and the extent 
of the damage caused by the infection (He’chard et al., 2002; Garcia et al., 2008).  
 
1.4.4. Adverse reactions 
 
An adverse reaction refers to any undesirable or harmful reaction that occurs in the body in 
response to a medication; this differs from side effects as the latter may refer to a reaction to 
a medication that may prove to be favourable (Nebeker et al., 2004). Adverse reactions range 
in severity, depending on the part of the body that is affected and the type of adverse reaction. 
When analysing a vaccine in a clinical trial, the occurrence of severe adverse reactions in the 
test models relates directly to the potential success of the vaccine. Depending on the type of 
reaction, the dosage formulation can be altered in order to reduce the impact of the adverse 
reaction. It may even indicate the necessary modifications that must be made in order to 
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eliminate that particular reaction; and in cases in which the vaccine leads to mortality as an 
adverse reaction, the vaccine cannot be approved for use (Edwards and Aronson, 2000). 
There are two classes of adverse reactions that may occur after administration of a vaccine, 
these are local or systemic.  
Local adverse reactions refer to reactions that occur in a specific location and remains in that 
location, most often this type of reaction occurs at the injection site. Common localized 
reactions include swelling, inflammation, pain, redness or itchy rashes – all of which are not 
life-threatening (Gidudu et al., 2008). Systemic adverse reactions refer to any adverse reaction 
that has moved from the initial location affected, into another location or organ by means of 
the systemic circulatory system. Systemic reactions have the potential to become quite severe 
because they may occur in any organ or any part of the body. Common systemic reactions 
include nausea and vomiting, fever, dizziness and diarrhoea. Rare systemic reactions have 
the potential to become life-threatening, they may lead to anaphylaxis, shock, sepsis, and 
sometimes even death (Rashid et al., 2008).  
The adverse events that occur in response to vaccination, may arise due to the vaccine 
antigen itself; due to the other components included in the vaccine formulation, such as the 
adjuvant, stabilisers and preservatives. In the case where the test model is challenged after 
vaccination, then it may occur due to the challenge pathogen (Rashid et al., 2008). As 
previously mentioned, adverse reactions are an undesirable occurrence, therefore a candidate 
vaccine may have a higher success rate if the adverse reactions are minimal or mild. There is 
a wide array of adverse reactions or events associated with the various types of vaccines that 
are available; but subunit vaccines offer an advantage over the other types of vaccines 
because they are often associated with a lower frequency of both local and systemic adverse 
reactions, therefore making subunit vaccines the superior option with regards to safety (Beyer 
et al., 1998).  
 
1.4.5. Safety and efficacy 
 
Vaccination has been a very controversial topic since the commercialisation of the first 
patented vaccine, and still to date there are many people who do not believe in prevention by 
means of vaccination, due to safety reasons. Despite the concerns of many, vaccinology is an 
ever-evolving field, which continuously searches for novel ways in which to improve the 
ultimate goals of vaccination, which is to reduce the occurrence of vaccine-preventable 
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infectious diseases, while maintaining the highest level of safety and efficacy in the vaccinated 
organism (Dowdle and Orenstein, 1994).  
The most obvious indicator of a vaccine that is unsafe is one that results in many fatalities; 
other than this, vaccine safety is evaluated by the number and severity of rare adverse events 
that occur in the vaccinated individual. There is no existing vaccine that is 100% safe, but 
many have reached a very high level of safety. There have been many claims in the past 
relating to the safety of vaccines, stating that vaccines lead to autism. To back up the claims 
three hypotheses were proposed. The first stated that combination vaccines such as the MMR 
vaccine causes damage to the intestinal lining, therefore allowing entry to encephalopathic 
proteins–consequently leading to autism. The second stated that a preservative used in many 
vaccines called thimerosal caused autism, due to its toxicity to the central nervous system. 
The final hypothesis stated that autism was a result of the administration of many vaccines 
simultaneously, which lead to the weakening of the immune system (Plotkin et al., 2009).  
Due to the severity of these allegations, many researchers in multiple countries performed 
twenty epidemiologic studies using a multitude of epidemiologic and statistical tools, and at 
the end, a consensus showing that vaccines did not cause autism by any of the proposed 
means was the conclusion (Plotkin et al., 2009). Many efforts were put into place to prove that 
vaccines do not cause autism, and are indeed safe for use. The reason why researchers 
invested time and money into disproving the allegations was first because such allegations 
have a negative impact on the market, and secondly because they needed to prove that their 
methods of safety evaluation performed before the introduction of the vaccine into the market 
were accurate. Each vaccine undergoes a rigorous safety evaluation, which takes many years 
before the vaccine reaches the market, and even once it’s in use, safety surveillance is still 
performed in the first few years (Centres for Disease Control, 2015).  
To evaluate the safety aspect, the vaccine undergoes many clinical trials in a laboratory 
setting, then in small animal models and larger animal models and finally in humans. Each 
trial will only progress to the next, provided that there is proof from the previous trial that the 
vaccine is safe and efficacious (Wharton, 2010). As soon as the vaccine is regarded as safe 
by the manufacturer, it is then evaluated by the Food and Drug Administration (FDA). 
Scientists and doctors at the FDA then evaluate the vaccine in terms of safety, purity, 
effectiveness and potency. If the vaccine meets all the requirements, then only is it approved 
and licensed for use (Wharton, 2010).  
In the first few years of a vaccine coming into use, post-market surveillance is carried out on 
a large number of people. This is done because in a clinical setting many of the possible side 
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effects may be detected, but often rare adverse events may not appear due to the size of the 
population being tested. Therefore, once a larger population is evaluated, it is more likely for 
the occurrence of an adverse event to be detected if the vaccine is capable of causing one. 
Another reason why this is done is that it increases the diversity of the population being 
evaluated which may reveal events that were not detected during the trial since some are very 
uncommon and only affect a small percentage of a population (Haber, 2008). Post-market 
surveillance is made possible by means of the Vaccine Adverse Event Reporting System 
[VAERS, managed by the FDA and Centres for Disease Control (CDC)]. Recently, multiple 
healthcare databases have been combined for post-market surveillance; all of which 
encourage people who have been vaccinated to report any side effects or adverse events that 
they experience after vaccination. This allows researchers to carry out specialised studies, 
based on the adverse events presented, in order to draw conclusions relating the potential 
adverse events to the safety of the vaccine (Trifirò et al., 2014; Wharton, 2010; CDC, 2015).     
The other equally important characteristic of a vaccine is efficacy, which is defined as the 
ability of a vaccine to prevent the disease that it was developed to protect against (Weinberg 
and Szilagyi, 2010). Next to safety, efficacy is the other determining factor for the success of 
a candidate vaccine, since it confirms whether or not the vaccine antigen can elicit an immune 
response, leading to the elimination of the pathogen during infection and future protection 
against that particular infectious disease. In essence, vaccine efficacy measures the 
percentage reduction in the occurrence of the disease in vaccinated subjects, in comparison 
to non-vaccinated subjects; and this characteristic is implicated in the investigation of the 
vaccine (Shim and Galvani, 2012).  
Efficacy studies are carried out in a randomised controlled trial, in which the vaccine is tested 
under ideal conditions; in such studies, the goal is to determine if the vaccine works. This type 
of study cannot predict the level of protection that a candidate vaccine is capable of eliciting, 
this parameter is determined through vaccine effectiveness studies. What is meant by this 
statement is that an efficacy study, can reveal whether a candidate vaccine can protect against 
the disease that it was developed to prevent, but it cannot predict how well it can function in 
terms of the immunogenicity and duration of protection (Fedson, 1998). The reason why 
efficacy cannot be related to how well the candidate vaccine can perform its function is 
because the studies are carried out under controlled conditions, which are specifically selected 
since they create an ideal situation. Whereas during natural infection, the conditions cannot 
be controlled and circumstances may differ greatly (Weinberg and Szilagyi, 2010). Either way, 
whether the focus is on the efficacy or effectiveness of the vaccine, both factors are imperative 
for the approval of a vaccine. 
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Safety and efficacy are two very important considerations in relation to a potential vaccine for 
C. abortus infection. The need exists because of the loss of livestock, which has a direct impact 
on the economy and the livelihood of many small-scale farmers. The potential vaccine requires 
a level of safety that cannot be compromised, it cannot have any negative effects on the 
reproductive system of ruminants and it needs to be efficacious in order to minimize the global 
risk associated with this infectious organism.  
 
2.1.1.2 1.4.5.1. Importance of a vaccine for C. abortus 
 
Due to the implication of C. abortus infection, new developments which contribute towards a 
viable solution is warranted. A vaccine is the superior option as it preventative not curative. In 
particular, a vaccine which induces the humoral immune response is the target. An obvious 
reason for this choice is the induction of immunological memory cells; moreover, it is ideal 
because cell-mediated immune responses although potent, may offer some undesirable 
consequences. Multiple studies have shown that it is the inflammation triggered by the cell-
mediated immune response that contributes towards the pathology and consequent abortion 
associated with this infection (Kerr et al., 2005; Longbottom and Coulter, 2003; Entrican, 
2002). Inflammatory cytokines play a major role in chlamydial clearance through activation of 
phagocytic cells and maintenance of host resistance (Buxton et al., 2002). Through research, 
the pathways by which inflammatory cytokines compromise the foetus has been elucidated. 
According to Longbottom and Coulter, (2003), the inflammatory response is directed to the 
point of infection which is the placenta; it is at this maternal-foetal interface that the infiltration 
of inflammatory-activated immune cells occur. Due to the location of infection, destruction of 
the foreign bodies also occurs at this interface compromising the maternal-foetal delivery 
system at the interface. It is this interaction which leads to the irreparable damage to the 
placenta and consequently the integrity of the growing foetus.  
 
In conclusion, the implications of the infection caused by C. abortus have been discussed at 
length in this literature review, and the importance of a preventative solution has been 
highlighted. From an economic standpoint – the two major requirements of the solution to this 
problem are that it must be inexpensive and easily accessible, in order to reach the target 
market. From a scientific standpoint – safety, immunogenicity and efficacy are the most 
important requirements. Therefore, both economically and scientifically a subunit vaccine for 
the prevention of C. abortus infection has the highest potential for reduction in the number of 
infections recorded worldwide. Based on the research conducted, the best candidate for a 
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subunit vaccine is the MOMP protein of C. abortus. MOMP makes up 60% of the total 
membrane proteins on the bacterium, which means that it will serve as a highly recognisable 
antigen, and its presence on the outer surface of the bacterium will aid in recognition of the 
bacterium during any subsequent infection by a whole virulent C. abortus. The concept for this 
candidate subunit vaccine can be implemented with the use of recombinant DNA technology 
to produce a heterologous MOMP, which will then be used as the antigen in a vaccine 
formulation which will be evaluated for the generation of anti-MOMP antibodies in a mouse 
model. The heterologous MOMP will resemble the native MOMP found in C. abortus in both 
sequence and structure. Therefore enabling the recognition of C. abortus by the dormant 
memory anti-MOMP antibodies during any subsequent infections by the organism; this will 
essentially facilitate the prevention and control of C. abortus infection.  
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Chapter 2: Introduction to the study 
 
The genus Chlamydia constitutes a group of obligate intracellular bacterial pathogens 
accountable for a diverse range of diseases in humans and animals, including several 
zoonoses (Pannekoek et al., 2010). Ovine chlamydiosis, also known as EAE or OEA, are 
economically important diseases, caused by C. abortus. This bacterium causes abortion in 
ruminants and poses a zoonotic risk to pregnant women (Longbottom and Coulter, 2003). 
An outbreak of OEA poses many possible consequences with an impact on animals, the 
farms, and the breeders or farmers. Farmers rely on breeding for sale of meat and dairy 
products. Therefore an infection that results in reproductive disorders such as infertility or 
abortion leads to the incurrence of huge financial losses by the breeder. This, in turn, affects 
the livelihood of the farmworkers which includes payments cuts and increasing unemployment 
(Junker et al., 2009). However, it does not end there, it consequently disrupts the entire 
agricultural supply chain. This supply chain begins at the producer of the agricultural goods 
and ends at the consumers of the resultant products prepared from these goods (Kozlenkova 
et al., 2015).  
Since C. abortus infection is categorised as a latent infection leading up to a spontaneous 
abortion it is possible for the infection to go unnoticed while ravaging throughout an entire 
flock. If this occurs, and the products of these infected animals reach the public the effects 
may be detrimental owing to the zoonotic nature of C. abortus. It is stated that this type of 
infection can have a negative effect on the economy and the entire agricultural industry 
because the losses sustained are not restricted to the farmers and breeders. The number of 
people affected depends on the product itself, the processing requirements and the target 
market. Therefore, losses are experienced by the farm workers and caretakers, the 
processors, wholesalers, distributors, retailers as well as the consumers. A further 
consequence of the infection is that all fluids secreted from an infected animal and the aborted 
foetuses house the infectious C. abortus bacterium, meaning that transmission is very likely 
to occur especially if the birthing area and infected animals are not cordoned off (Stubbings, 
2017). Therefore, to prevent transmission to uninfected individuals of a flock, all birthing 
equipment, materials and the deceased housing the infection must be incinerated, and 
infected mothers must be quarantined from the rest of the flock (Junker et al., 2009). 
The impact of this infection as an accumulated consequence on the economy and international 
trade is devastating (Federation of American scientists, 2011). From a local standpoint, loss 
of livestock greatly affects the economy since financial losses are endured. However, an even 
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greater threat to the economy is that the World Trade Organization considers infectious 
diseases as one of the main criteria for blocking the import of agricultural products. This puts 
the exporting country at an even greater disadvantage since the export of uninfected 
agricultural products is also no longer allowed internationally for two subsequent years due to 
the potential risk (Federation of American Scientists, 2011). The loss may seem small but 
when the international trade of a particular product is blocked by a country, very soon after, all 
countries importing these products also pull out, increasing the loss to millions or even billions 
of dollars (Oxford Analytica, 2012). For a developing country such as South Africa, the impact 
on the economy can often be overwhelming since the blocking of international trade hinders 
the country’s advancement in terms of its economic and social position. In essence what may 
start out as a loss incurred by an individual breeder often affects the region and very soon 
after affects the nation leading to a global situation (Tisdell et al., 1999).  
Even though the impact of C. abortus infection on the economy of a developing country is 
much greater in comparison to a first world country the risk is rife worldwide. With the exception 
of Australia, New Zealand and some areas of the Scottish highlands, C. abortus infection has 
been documented globally as the main cause of reproductive losses in sheep and goats 
(Mearns, 2001; Selim, 2016; Tibrary, 2016). The first documentation of the bacterium occurred 
in the UK, the UK strain S26/3 was the first referenced genome (Seth-Smith et al., 2017); and 
to date, C. abortus infection is still common in the UK accounting for 50% of all diagnosed 
cases of abortion (Samkange et al., 2010). Many other countries have carried out 
seroprevalence studies to evaluate the occurrence of C. abortus induced spontaneous 
abortions. For a seroprevalence study, the general basis is that the occurrence of abortion in 
5% of the animals of a flock is considered as normal; but once this value exceeds 5% it is 
considered unnatural and most likely induced by an infectious organism (Samkange et al., 
2010). Using this basis, it was found that the seroprevalence of C. abortus infection in goats 
in the Otavi Vet District in Namibia is 25%. This is one-quarter of all goats present in this area 
and this value is alarmingly high. In Spain, 56% of small ruminant abortions were caused by 
C. abortus infection. C. abortus induced abortion is rife in Jordan, and in Saudi Arabia, it has 
an abortion incidence rate of 9. 07% countrywide (Selim, 2016).  
In South Africa, a seroprevalence study has not been carried out and therefore the incidence 
rate of C. abortus induced abortion cannot be calculated. Even though the occurrence is not 
well-documented in South Africa, it is extensive and one of the leading causes of spontaneous 
abortion in sheep and goats. According to the South African Department of Agriculture, 
Forestry and Fisheries newly infected flocks often show an incidence rate of up to 70% 
(Mohale, 2013). This value is disturbingly high and distressing as it indicates that 70% of a 
flock can abort their young and consequently carry the infection leading to further infection as 
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the flock multiplies. This is why the need for a safe, effective, efficacious vaccine is so 
important. The consequences of C. abortus infection and the impact of the infection on the 
economy demands attention and the best way forward is through vaccination.  
Chlamysure is an existing vaccine developed by Onderstepoort Biological Products (OBP) in 
South Africa for the prevention of chlamydiosis caused by Chlamydophila abortus. It is 
effective in providing immunity against C. abortus infection but protection only lasts for up to 
one year. Production of the Chlamysure vaccine is time-consuming as these bacterial cells do 
not multiply proficiently in the Vero cell line. Therefore, growth takes up to 21 days with a 
possibility of insufficient bacterial production. This vaccine uses formalin-inactivated whole 
bacterium as the antigen, therefore if bacterial growth is not optimal, neither is vaccine 
production or the extent and duration of immunity. There are alternatives to Chlamysure that 
are available in the international market such as live-attenuated vaccines (MSD Animal Health, 
2011; Ceva Sante Animale, 2015); other dead or inactivated vaccines like Chlamysure 
(HIPRA, 2019); DNA vaccines are currently under study as an alternative; and for the purpose 
of this study, subunit vaccines. A possible solution can be achieved through recombinant DNA 
technology provided that the major outer membrane protein (MOMP) from C. abortus can be 
produced in a heterologous host. It may be possible to provide longer-lasting immunity against 
C. abortus infection due to the dominant immunogenic properties of MOMP. The efficiency of 
vaccine production would increase as the expression of the MOMP gene in a suitable host 
can be induced more rapidly than bacterial growth. Therefore resulting in a candidate subunit 
vaccine which is much safer for use and can be formulated in a substantially reduced amount 
of time which also contribute towards affordability.  
Thus, the first aim of this study is to heterologously express the major outer-membrane protein 
(MOMP) of Chlamydophila abortus in the Yarrowia lipolytica Po1f strain, which has been 
extensively used to produce several heterologous proteins (Madzak et al., 2004). The second 
aim is to evaluate the degree of safety and immunogenicity of the recombinant MOMP of C. 
abortus as an antigen for immunisation of pregnant mice models, and the efficacy of MOMP 
after challenge with virulent, whole C. abortus bacterium.  
The objectives of the study are as follows: 
 To design and synthesize Y. lipolytica Po1f codon optimized C. abortus MOMP gene.  
 To clone and express the MOMP in Y. lipolytica Po1f. 
 To evaluate the safety and efficacy of the recombinant MOMP using mice.  
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Chapter 3: Codon optimization and heterologous 
expression of the major outer-membrane protein from 
Chlamydophila abortus 
 
3.1. General introduction 
 
The commencement of any research, based on molecular biology and recombinant DNA 
technology, typically begins with the production of the target gene or expression construct 
(Schwartz et al., 2011). This is customarily accomplished through conventional PCR, which 
results in the amplification of a known gene sequence from the genomic DNA of the host 
organism. However, this method is often limited by the availability of the target gene sequence 
information; accessibility of the host genetic material; and when the native gene is poorly 
expressed in or toxic to an expression host (Green et al., 2015; Kunjapur et al., 2018; Saida 
et al., 2006). In such cases, and depending on the desired downstream application of the 
gene, artificial gene synthesis can be pursued (Sequeira et al., 2016). This is due to the fact 
that with this method, it is possible to artificially construct a gene (novel or otherwise), 
consisting of dsDNA, with no limitations on the number of bases or the constituent bases of 
the gene sequence (Ma et al., 2012). Therefore, if gene synthesis is targeted towards 
heterologous expression, the opportunity to strategically alter the constituent bases becomes 
very useful, when codon optimizing for expression in a given host system.  
Codon usage bias is an essential feature on most genomes (Mauro and Chappell, 2014); and 
has been demonstrated to regulate the translation elongation speed and post-translational 
protein folding (Al-Hawash et al., 2017). This, therefore, makes codon adaptation to an 
expression host a prerequisite for heterologous expression, as it may affect the yield and 
recovery of functional proteins (Menzella, 2011; Zhou et al., 2015).  
In this study, we report on codon optimization/harmonisation of the C. abortus MOMP for 
expression in the Y. lipolytica Po1f yeast expression system. The choice of the expression 
host was based on a few important considerations; the high protein yield that is often 
associated with a yeast expression system (Legastelois et al., 2017); the ability of this system 
to carry out protein post-translational modifications (Kim et al., 2015), which depending on the 
purpose of the protein, may be vital for their functioning; and the fact that the gene sequence 
can be optimized to be amenable to the protein synthesis machinery of the host (Zhou et al., 
2016).  
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There are countless reports on the many advantages of yeast expression hosts for 
recombinant protein production (Bathurst, 2008; Dirvishi, 2012; Goncalves et al., 2014; 
Hofmeyer et al., 2014; Kim et al., 2015), and Y. lipolytica is reported to be the most attractive. 
This is due to the fact that this non-conventional dimorphic yeast (Goncalves et al., 2014), 
regularly performs remarkably in the efficient secretion of various heterologous proteins 
following expression (Guo et al., 2017; Madzak et al., 2004; Madzak, 2015; Trassaert et al., 
2017; Yan et al., 2018). Moreover, this yeast is ideal for heterologous protein expression 
because the system is very versatile; it permits the utilisation of a vast array of promoters, 
selective markers and secretory signals. It also allows for the choice of either site-directed or 
random integration of single- or multi-copy expression cassettes into its genome for 
heterologous expression (Laubuschagne and Albertyn, 2006).  
For the purpose of this study, the retention of the protein conformation of the MOMP protein 
is vital for its biological function. Since the role of the recombinant MOMP is to serve as an 
antigen resembling C. abortus, it was imperative that the conformation resembled that of the 
native MOMP. Conformational retention ensures that the paratopes of the antibodies 
generated against the recombinant MOMP will correspond to the MOMP epitope on a whole 
C. abortus bacterium during subsequent infection (Vretou et al., 2001). In terms of 
vaccinology, the most important part of the immune response is the generation of memory B 
cells, which are the cells responsible for the induction of an enhanced immune response, upon 
subsequent infection by the same microorganism. According to Morrison (2015), the 
conformational preservation of the antigenic epitopes is paramount for the recognition of the 
epitopes on a whole bacterium by the paratopes of the antibodies generated, and 
consequently for the induction of the memory B cell response upon subsequent infection post-
immunization. 
In 2003, Vretou and Co-workers reported on the glycosylated POMPs from C. abortus ATCC 
VR 656(T). These proteins are immunologically relevant, and the likelihood is that the 
glycosylation also contributes to the immunogenic properties of the said protein. This is 
supported by the fact that glycosylation of proteins is a common event that contributes to 
protein antigenic properties. Furthermore, antibodies raised against glycoprotein antigens may 
be specific for their carbohydrate units which are recognized irrespective of the protein carrier 
(Lisowska, 2002).   
There is, however, no information on the glycosylation of the target protein, C. abortus MOMP, 
but if parallels are to be drawn between MOMP and POMPs, the possibility that this protein is 
also glycosylated exists. At this stage it is difficult to establish the significance of the possible 
modification in MOMP, however, this becomes less of a challenge because proteins 
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expressed in the selected host (Y. lipolytica) undergo posttranslational modifications, a feature 
characteristic to expression systems of eukaryotic origin, and this will include glycosylation, if 
necessary.  
To date, there is only one report on the heterologous expression of C. abortus MOMP in E. 
coli, and the challenges associated with the expression and functional characterization 
(Hoelzle et al., 2004). Moreover, a report on chlamydial vaccine development by Longbottom 
in 2003 has also demonstrated that the expression of the full-length MOMP protein in 
prokaryotic systems is challenging, due to toxicity which occurs even at low-level protein 
expression. On the other hand, there are no reports on the expression of C. abortus MOMP 
in yeast, let alone Y. lipolytica. Therefore, there is a great possibility to generate new 
information in this regard and also, that the outcomes of this particular study will constitute a 
report which is the first of its kind, in as far as the heterologous expression of C. abortus MOMP 
in yeast is concerned.  
This chapter contains an in-depth report of the use of the Y. lipolytica Po1f as the expression 
host for the heterologous expression and secretion of the synthetic, codon optimized MOMP 
protein of C. abortus. It further reports on the modifications made to the native MOMP gene 
sequence of C. abortus; along with the cloning of the MOMP gene into the expression vector 
pKOV410, for the generation of an expression cassette. It also includes its integration into the 
genome of Y. lipolytica; and finally the evaluation of the biomass accumulation; and MOMP 
identification succeeding the heterologous expression of MOMP, by the Po1f strain of Y. 
lipolytica.  
 
3.2. Materials and methods 
 
This section covers all the procedures followed to accomplish the research objectives of the 
study. It also includes all reagents and their compositions, materials, equipment, software, and 
databases used for the experimentation and the analysis of the results. Reference is given to 
companies that provided the consumables and services required. The manufacturers and 
country of origin, of all the above-mentioned items, can be found in Appendix A.  
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3.2.1. Bacterial, yeasts strains and plasmids 
 
The design of the MOMP gene was based on the native gene sequence of MOMP from C. 
abortus strain B577, obtained from the National Centre for Biotechnology Information (NCBI) 
GenBank accession number KC879303.1 (Benson et al., 2005). The synthetic MOMP 
construct synthesized by Biomatik was encased within the pUC57 cloning vector. Chemically 
competent E. coli JM109 cells were used as the cloning host in this study, for the replication 
of both the pUC57-MOMP construct and the pKOV410-MOMP construct. The pKOV410 
expression vector [which was kindly donated by the University of the Free State (UFS)], was 
used as a source for the expression cassette, which facilitated the integration of the MOMP 
gene into the genome of the expression host Y. lipolytica Po1f (obtained from OBP), for 
subsequent expression of the MOMP protein. 
 
3.2.2. Buffer and media constituents 
 
Tris-EDTA (TE) buffer (1X), made up of 10 mM Tris-Cl was utilized as a diluent for the 
resuspension of the pUC57-MOMP construct. The heat-shock transformation protocol 
required the inclusion of SOC media (2% tryptone, 0.5% yeast extract, 10 mM sodium chloride, 
2.5 mM potassium chloride, 10 mM magnesium chloride and 20 mM glucose). LB media was 
used for selection following the bacterial transformation steps. This media consists of 10 g/L 
tryptone, 5 g/L sodium chloride, 5 g/L yeast extract, 15 g/L bacteriological agar, in the case of 
LB broth, bacteriological agar is excluded; and depending on the plasmid used, this media is 
either supplemented with 100 mg/mL ampicillin when using pUC57, or 50 mg/mL kanamycin 
when using pKOV410. For the analysis of the restriction digestions and the colony PCR, 
agarose gel electrophoresis was used, and it requires 1X TAE buffer (40 mM Tris, 1 mM EDTA 
and acetic acid to pH 8.3).  
To monitor the growth of the yeast Y. lipolytica, YPD media was used (20 g/L peptone, 20 g/L 
glucose, 10 g/L yeast extract and 15 g/L bacteriological agar); for YPD broth, bacteriological 
agar was excluded. For the screening of positive yeast transformants, YNBCasa media was 
used, this consists of 1.7 g/L yeast nitrogen base, 4 g/L ammonium chloride, 2 g/L casamino 
acids and 15 g/L bacteriological agar. The fully inducing YPD medium (0.2% yeast extract, 
0.1% glucose and 5% proteose peptone in 50 mM sodium phosphate buffer pH 6.8) was 
required for the heterologous expression of MOMP in Y. lipolytica. Phosphate buffered saline 
(PBS) pH 7.4 made up of 8 g/L sodium chloride, 0.2 g/L potassium chloride, 1.44 g/L disodium 
phosphate and 0.24 g/L monopotassium phosphate; Laemmli buffer (125 mM tris pH 6.6, 4% 
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SDS, 20% glycerol, 10% β-mercaptoethanol and 0.0025% bromophenol blue); and 1X tank 
buffer made from a 10X stock (3% Tris, 14.5% glycine and 1% SDS); were all required for 
protein precipitation and SDS-PAGE analysis following the heterologous expression of 
MOMP.  
 
3.2.3. Design and synthesis of the gene 
  
The synthetic gene was designed with a few modifications from the original sequence obtained 
from the NCBI GenBank (accession number KC879303.1) (Benson et al., 2005). The first of 
which was codon optimization of the gene for expression in Y. lipolytica. The gene was also 
altered by incorporating the restriction sites XmnI and AvrII, on the 5’ and 3’ ends respectively, 
in order to aid in the directional cloning of the gene into the expression vector pKOV410.  
Another significant modification entailed the removal of the start codon ATG, in order for the 
gene to be in frame with the Lip2 SP of pKOV410, and to ensure secretion of the protein to 
the extracellular environment. Before the gene was ordered from Biomatik, a DNA to protein 
translation on the ExPASy Bioinformatics Resource Portal, operated by the Swiss Institute of 
Bioinformatics (SIB) was performed (Artimo et al., 2012). A Multiple sequence alignment 
(MSA), using the Clustal Omega 1.2.4 programme from the European Molecular Biology 
Laboratory–European Bioinformatics Institute (EMBL–EBI) database was then performed 
(Sievers et al., 2011). The sequences used for the MSA was the MOMP protein sequence of 
C. abortus obtained from NCBI, and the synthetic MOMP protein sequence translated on the 
ExPASy Bioinformatics Resource Portal. This was implemented into the study, to demonstrate 
the homology between the sequences.  
Then an additional MSA was performed, using the native MOMP gene sequence from NCBI, 
and the synthetic MOMP gene sequence obtained from Biomatik after it was codon-optimized 
for expression in Y. lipolytica. This was done in order to elucidate the differences between the 
gene sequences, so as to highlight the regions of the synthetic gene that had been optimized. 
Next, the synthetic MOMP sequence which had been translated into its respective protein 
sequence was analysed for the prediction of possible glycosylation sites, using the NetNGlyc 
4.0 server (Steenthof et al., 2013). 
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3.2.4. Propagation of the recombinant vectors in Escherichia coli 
 
The recombinant pUC57-MOMP construct (5 µg) was obtained in lyophilized form and 
resuspended in 1 X TE buffer pH 8.0 to a final concentration of 0.1 µg/µL. This construct was 
used in the transformation of chemically competent mix and go E. coli JM109 cells using a 
heat shock protocol (Froger and Hall, 2007). The positive transformants were selected on LB-
ampicillin plates and incubated at 37°C overnight. A few positive transformants were selected 
and used to inoculate LB-ampicillin (100 mg/mL) and LB-Kanamycin (50 mg/mL), for pUC57-
MOMP and the pKOV410 clones, respectively. The plasmids were then isolated using the 
GeneJET plasmid miniprep kit, and the concentration of the DNA determined by the Thermo 
Fisher Scientific Nanodrop ND-1000 programme.  
 
3.2.4.1. Cloning of the MOMP gene into pKOV410 
 
The isolated plasmids (recombinant plasmid pUC57-MOMP and pKOV410) were digested 
with 1 µL of each of the restriction enzymes AvrII and XmnI. The standard digestion protocol 
for the enzymes in Table 6A was used, and the samples were allowed to digest overnight at 
37°C. The amount of DNA required for the digest is 1 µg, therefore the volume of isolated 
plasmids required for the reaction was calculated as follows: 
 
𝑉𝑜𝑙𝑢𝑚𝑒 𝑜𝑓 𝐷𝑁𝐴 𝑓𝑜𝑟 𝑑𝑖𝑔𝑒𝑠𝑡 = (
𝐴𝑚𝑜𝑢𝑛𝑡 𝑜𝑓 𝐷𝑁𝐴 𝑟𝑒𝑞𝑢𝑖𝑟𝑒𝑑 (1000 𝑛𝑔)
𝐶𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 𝑜𝑓 𝐷𝑁𝐴 (𝑛𝑔/µ𝐿)
) 
 
The digested samples were then resolved on a 1% agarose gel (1 g agarose in 100 mL 1 X 
TAE buffer), and the GeneRuler™ 1 kb DNA ladder was used as the molecular weight 
standard. After the DNA was subjected to electrophoresis, an image of the agarose gel was 
captured using the Biorad ChemidocTM MP Imaging System. The gel was then viewed under 
a transilluminator in order to excise the MOMP gene and the pKOV410 expression vector. The 
excised fragments of DNA were then purified using the Promega Wizard® SV Gel and PCR 
Clean-Up System, and the concentrations were determined using the Thermo Fisher Scientific 
Nanodrop ND-1000 programme.  
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Table 6: Standard protocol for a restriction digestion using the NEB Cutsmart buffer (6A); and the standard protocol 
for a ligation using the NEB T4 DNA ligase (6B). 
A B 
Reagent Volume (µL)/ 
amount (ng) 
Reagent  Volume (µL)/ 
amount (ng) 
10 X NEB Cutsmart buffer 5 10 X T4 DNA ligase buffer 2 µL 
AvrII 0.5 Vector DNA (4 kb) 50 ng 
XmnI 0.5 Insert DNA (1 kb) 37.5 ng 
DNA 1 µg T4 DNA ligase  1 µL 
Nuclease-free water To 50 µL Nuclease-free water  To 20 µL 
 
The concentration of the DNA was determined spectrophotometrically, and the MOMP gene 
and pKOV410 vector were then ligated, using the standard NEB T4 DNA ligase protocol (Table 
6B), with incubation at 4°C overnight. The DNA was added at a 1:3 ratio of vector: insert. The 
general rule is that for a 4 kb vector, 50 ng of DNA is required. Based on the size of the vector 
(6352 bp), the amount of vector DNA required was 12 ng/kb; and the insert DNA should be 3 
times this amount. Thus to determine the amount of vector DNA and insert DNA required to 
satisfy the ratio, the following calculations were used: 
 
𝑀𝑎𝑠𝑠 𝑜𝑓 𝑣𝑒𝑐𝑡𝑜𝑟 𝐷𝑁𝐴 = 12.5 𝑛𝑔 𝑘𝑔⁄ 𝑥 𝑆𝑖𝑧𝑒𝑜𝑓 𝑣𝑒𝑐𝑡𝑜𝑟 (𝑘𝑏) 
𝑉𝑜𝑙𝑢𝑚𝑒 𝑜𝑓 𝑣𝑒𝑐𝑡𝑜𝑟 𝐷𝑁𝐴 = (
𝑀𝑎𝑠𝑠 𝑜𝑓 𝑣𝑒𝑐𝑡𝑜𝑟 𝐷𝑁𝐴 (𝑛𝑔)
𝐶𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 𝑜𝑓 𝑣𝑒𝑐𝑡𝑜𝑟 𝐷𝑁𝐴 (𝑛𝑔/µ𝐿)
) 
𝑀𝑎𝑠𝑠 𝑜𝑓 𝑖𝑛𝑒𝑟𝑡 𝐷𝑁𝐴 = 𝑚𝑎𝑠𝑠 𝑜𝑓 𝑣𝑒𝑐𝑡𝑜𝑟 𝐷𝑁𝐴 (𝑛𝑔) 𝑥 (
𝑆𝑖𝑧𝑒 𝑜𝑓 𝑖𝑛𝑠𝑒𝑟𝑡 𝐷𝑁𝐴 (𝑏𝑝)
𝑆𝑖𝑧𝑒 𝑜𝑓 𝑣𝑒𝑐𝑡𝑜𝑟 𝐷𝑁𝐴 (𝑏𝑝)
)  𝑥 3 
𝑉𝑜𝑙𝑢𝑚𝑒 𝑜𝑓 𝑖𝑛𝑒𝑟𝑡 𝐷𝑁𝐴 = (
𝑀𝑎𝑠𝑠 𝑜𝑓 𝑖𝑛𝑠𝑒𝑟𝑡 𝐷𝑁𝐴 (𝑛𝑔)
𝐶𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 𝑜𝑓 𝑖𝑛𝑠𝑒𝑟𝑡 𝐷𝑁𝐴 (𝑛𝑔/µ𝐿)
) 
 
Upon the ligation reaction, the ligation mixture was used to transform chemically competent 
E. coli JM109 cells, and the transformants selected on LB-kanamycin plates. The plates were 
then incubated at 37°C overnight, and following this incubation, a few colonies were selected, 
individually inoculated into 5 mL LB-kanamycin and grown overnight at 37°C. The plasmids 
were then purified as detailed in section 3.2.3, and the ligation of MOMP into pKOV410 verified 
by restriction digestion (Table 6A).  
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3.2.4.2. Preparation of the expression cassette 
 
In order to prepare the expression cassette, the recombinant pKOV410-MOMP construct was 
linearized, by digestion with the restriction enzyme NotI. The standard protocol for this NEB 
enzyme was used, with an overnight incubation at 37°C. The linearized construct was 
analysed on a 1% agarose gel along with the GeneRuler™ 1 kb DNA ladder and viewed with 
the Biorad ChemidocTM MP Imaging System. 
 
3.2.5. Transformation of Yarrowia lipolytica with the expression cassette 
 
Before the commencement of the lithium acetate transformation protocol (Gietz and Woods, 
2002), the Y. lipolytica Po1f cells had to be made competent. On the first day, the Y. lipolytica 
Po1f glycerol stock was streaked onto YPD media, and the plates were incubated at 28°C 
overnight. On the second day, 5 mL of YPD broth was inoculated with the overnight culture. 
This culture was then incubated at 28°C, with constant agitation at 130 rpm for 6 hours. The 
culture was then transferred to 20 mL YPD broth and incubated at 28°C overnight with 
constant agitation at 130 rpm. The cells were then centrifuged at 4000 xg for 5 min and the 
supernatant was decanted. The pellet was gently resuspended in 20 mL of 1 X TE buffer pH 
8 by inversion. The suspension was once again centrifuged at 2500 xg for 5 min and the 
supernatant decanted. The pellet was resuspended in 20 mL of 0.1 M lithium acetate–acetic 
acid pH 6 by inversion. This suspension was then incubated at 28°C for 1 hr with constant 
agitation at 120 rpm. Following the incubation, the cells were centrifuged at 1500 xg for 5 min, 
and the pellet resuspended in 3 mL 0.1 M lithium acetate–acetic acid pH by inversion 
Once the Y. lipolytica Po1f cells were competent, the transformation mixture was prepared. 
The mixture contained 100 µL of lithium acetate competent Y. lipolytica Po1f cells, 2 ng of the 
expression cassette, and 5 µL of salmon sperm carrier DNA. A positive control for the 
transformation was also included, this reaction contained all the components of the 
transformation mixture, except for the expression cassette; this was replaced with linearized 
pKOV410. Once combined, the reagents were gently mixed and the mixture incubated at 28°C 
for 15 min. Thereafter, 700 µL of PEG (40% PEG-4000 in 0.1 M lithium acetate–acetic acid 
pH 6) was added to the mixture and gently combined. Next, the mixture was incubated at 28°C 
for 1 hr, with constant agitation at 180 rpm. A further addition of 80 µL of 100% DMSO was 
then made, and the mixture gently shaken. The cells were then heat shocked at 39°C for 10 
min. After the incubatory period had lapsed, 1.2 mL of 0.1 M lithium acetate–acetic acid pH 6 
was added to the cells, the components were combined and 300 µL of the transformation 
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mixture was spread onto YNBCasa media. These plates were then incubated at 28°C until 
colony formation.  
 
3.2.5.1. Screening for positive transformants–Colony PCR 
 
Once the transformants had grown on the YNBCasa media plates, colonies had to be 
screened for the pKOV410-MOMP expression cassette. For this purpose, gene-specific 
primers were designed and purchased from Inqaba BiotechTM. The forward primer (MOMP-
F), was designed to bind to the 5’ end of the MOMP gene (5’–
GAATCGCTTCAAGAAGCTGCTGAAG–3’); while the reverse primer (MOMP-R), was 
designed based on the 3’ end of the gene (5’–CCTAGGTTAGAATCGGAACTGGGCG–3’). 
Ten clones were selected for screening, these were scraped off of the plate with a sterile 
pipette tip. The tip was then immersed in the PCR tube to add a small amount of the colony to 
the reaction mixture, before being inserted into a 40 mL Falcon tube containing YPD media. 
The test plate was used for the screen, this is the one containing cells transformed with the 
expression cassette. The composition of the PCR mixture was according to the standard 
reaction protocol for GoTaq® DNA polymerase (5 u/µL). The cycling conditions used for the 
reaction can be seen in Table 7. Thereafter, the PCR samples were resolved on a 1% agarose 
gel along with the NEB 1 kb ladder. Once the positive clones had been identified, they were 
grown overnight in 5 mL of YPD media at 28°C with constant agitation at 180 rpm; and then 
used in the MOMP expression studies.  
 
Table 7: Cycling conditions used to perform the colony PCR used to screen for positive clones. 
Number of cycles Cycling step Temperature (°C) Time 
1 X Initial denaturation 94 2 min 
29 X Denaturation 94 30 sec 
Annealing 55 30 sec 
Extension 72 1 min 30 sec 
1 X Final extension 72 10 min 
1 X Hold 20 ∞ 
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3.2.6. Heterologous expression of MOMP 
 
The heterologous expression of MOMP was performed as reported by Nicaud and Co-workers 
(2002), with a few alterations to the protocol. Based on the intensity profiles present in Figure 
10, one positive clone was selected, the glycerol stock of which was streaked onto a YPD 
media plate, and allowed to incubate at 28°C for 72 hours to facilitate the growth of medium-
sized single colonies. A positive control was also included for the heterologous expression; it 
contained Y. lipolytica Po1f transformants, containing linearized pKOV410 as the 
transformation DNA. From this point, the experimentation was run in duplicate, since there 
were two glycerol stocks streaked one for the test expressions and one as a positive control. 
Therefore the expression cultures will be referred to as M1 (MOMP) and C (control), 
respectively.  
Following colony formation, a single colony from M1 and C were used to inoculate 5 mL 
individually, of the fully inducing YPD medium. These pre-inoculums were incubated at 28°C 
overnight, with constant agitation at 140 rpm. Once the cultures had grown, displaying an 
opaque consistency, 1 mL of the M1 and C pre-inoculums was used to inoculate two flasks of 
99 mL of the fully inducing YPD medium. Both cultures were then incubated at 28°C for 7 days 
with constant agitation at 140 rpm.  
For both expression cultures, a 2 mL aliquot was removed from the cultures on days 3 to 7. 
These aliquots were used to read the optical density (OD) at 600 nm, in order to measure 
biomass accumulation. Each reading was performed in triplicate, and the average of each 
reading was used to plot a line graph of biomass vs. time for each of the cultures; for the 
comparison of biomass accumulation between the test and control cultures. Subsequent to 
the measurement of the OD, the aliquots were then stored at -80°C until the end of the 
expression period, for the analysis of the expression profiles.  
 
3.2.6.1. Protein precipitation and SDS-PAGE analysis  
 
An ammonium acetate precipitation protocol (Wingfield, 2016) was used to precipitate the 
proteins from 2 of the aliquots collected during the heterologous expression. One from the test 
expression M1, and the other from the positive control expression, both representing day 7. In 
preparation for the ammonium sulphate precipitation, the aliquots were centrifuged at 
maximum speed, in a benchtop microcentrifuge for 10 minutes to separate the intracellular 
from the extracellular proteins. The supernatant contained the extracellular proteins, where 
MOMP is expected to be located, therefore this portion was used for the ammonium sulphate 
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precipitation. A saturated solution of ammonium sulphate was prepared to a volume of 500 
mL, by heating the water on a magnetic stirrer, and slowly adding ammonium sulphate until 
the solution was completely saturated, which is indicated by the presence of ammonium 
sulphate crystals once the solution has cooled to room temperature.  
This saturated ammonium sulphate solution was then added to each of the cultures in a 1:1 
ratio. The mixtures were allowed to equilibrate while incubating at 25°C with constant agitation 
at 120 rpm for 1 hour. Once fully equilibrated, the mixtures were centrifuged at 10 000 xg for 
15 minutes, to facilitate the pelletizing of the proteins. Following the centrifugation, the 
supernatant was decanted, and the pellets were allowed to air-dry. Once dehydrated, the 
pellets were resuspended in 1X PBS pH 7.4.  
The standard sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) 
protocol was used for the analysis of the extracellular proteins from the expression cultures 
after the proteins had been precipitated with ammonium sulphate. Initially, the samples were 
prepared for the SDS-PAGE analysis by mixing the precipitants in a 1: 1 ratio with Laemmli 
buffer. These mixtures were then boiled at 95°C in a digital dry bath for 10 minutes. Next, a 
10% SDS-PAGE gel was prepared, the composition of which has been simplified in Table 8. 
The gel was loaded in the following orientation: PageRuler Plus™ pre-stained 10–250 kDa 
protein ladder, C (Day 7) and M1 (Day 7).  
The SDS-PAGE gel was resolved at 120 V, in 1 X tank buffer. Once complete, the gels were 
stained with Coomassie staining solution (0.1% Coomassie brilliant blue R–25, 40% methanol, 
10% acetic acid) for 1 hour with constant agitation on a gel rocker. The Coomassie staining 
solution was then decanted; the gels were then submerged in water and allowed to de-stain 
overnight with constant agitation on a gel rocker. 
Table 8: Recipe for a 10% SDS-PAGE gel, displaying the compositions and concentrations of each reagent.  
Reagents  10% Resolving gel  Stacking gel  
1 M Tris pH 8.8 (resolving) pH 6.8 (stacking) 3.75 mL 630 µL 
20% SDS 50 µL 50 µL 
30% Acrylamide/Bisacrylamide 2.50 mL 830 µL 
Water 3.73 mL 3.4 mL 
10% Ammonium Persulphate 100 µL 50 µL 
TEMED 10 µL 5 µL 
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3.3. Results 
 
3.3.1. Design and synthesis of the MOMP gene  
 
The results of the analysis of the synthetic MOMP gene are presented using Clustal Omega 
(MSA) profiles (Figures 3 and 4). Figure 3 is a DNA-DNA alignment, of the native MOMP gene 
and the synthetic MOMP gene after it had been codon optimized. The alignment displays 
multiple positions in which there is a variation in the nucleotide base between the two 
sequences. The importance of this alignment is related to the effects of codon optimization. 
Even though the two sequences in the alignment do not display a good level of homology. 
When evaluating each base as a triplet codon, it is easy to identify that synonymous codons 
have been used to replace certain native codons in the sequence, in order for the gene to be 
codon-optimized for expression in Y. lipolytica.  
Figure 4 is a protein-protein alignment of the native and synthetic MOMP proteins. This 
alignment displays complete homology, the two protein sequences are identical; the only 
difference is the presence of the XmnI and AvrII restriction sites on the synthetic MOMP 
protein. The very same query sequences were used in both of these alignments, the only 
variance being that the native and synthetic MOMP gene sequences were translated into 
protein sequences for the subsequent alignment. As can be deduced from Figures 3 and 4 
the alignments exhibit variations in homology. This is expected, since the codon optimization 
targets the sequence at gene level, without making alterations to the protein sequences; this 
is done through replacement of codons encoding the same amino acids to allow for the Y. 
lipolytica system to utilize synonymous codon conversions of its preference. Also illustrated in 
Figure 4 is the lack of a methionine residue at the 5’ end of the synthetic MOMP protein. The 
alignment instead, shows a phenylalanine residue from the XmnI restriction site that aligns 
with the methionine of the native gene in terms of positioning.  
An additional analysis was performed on the synthetic MOMP protein sequence to predict any 
potential glycosylation sites within this protein sequence. The analysis was performed using 
the NetNGlyc 1.0 server, and the outcome of this analysis has been depicted in the form of a 
graph in Figure 5. Theoretically, N-glycosylated sites are located on asparagine residues at 
positions in which the Asn-Xaa-Ser/Thr stretch is situated. In cases as such, the Xaa can 
represent any amino acid excluding proline. Based on the graph in Figure 5, there are four 
potential glycosylation sites in the MOMP protein of C. abortus B577; this is indicated by the 
presence of four vertical lines at residue number 84, 299, 323 and 328, all of which pass the 
predetermined threshold value (0.5) of the N-glycosylation potential.  
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Figure 3: Clustal Omega MSA of the native versus the codon optimized MOMP gene sequence The MSA uses 
consensus symbols to simplify the alignment. The dash lines represent regions where there is no amino acid 
present in the sequence for alignment. An asterisk represents a fully conserved residue, therefore all pairs 
containing an asterisk indicates homology between the two sequences at that particular point (Sievers et al., 2011). 
 
CLUSTAL O(1.2.4) multiple sequence alignment 
 
 
Native         -------ATGAAAAAACTCTTGAAATCGGCATTATTGTTTGCCGCTACGGGTTCCGCTCT 53 
Synthetic      GAATCGCTTCAAGAAGCTGCTGAAGTCTGCCCTGCTGTTCGCCGCCACCGGCTCTGCCCT 60 
                       * ** ** **  **** ** **  *  **** ***** ** ** ** ** ** 
Native         CTCCTTACAAGCCTTGCCTGTAGGGAACCCAGCTGAACCAAGTTTATTAATCGATGGCAC 113 
Synthetic      GTCTCTGCAGGCCCTGCCTGTGGGCAACCCCGCTGAGCCCTCTCTGCTGATCGACGGCAC 120 
                **  * ** *** ******* ** ***** ***** **   * *  * ***** ***** 
Native         TATGTGGGAAGGTGCTTCAGGTGATCCTTGCGATCCTTGCTCTACTTGGTGTGATGCTAT 173 
Synthetic      CATGTGGGAGGGCGCCTCTGGCGACCCTTGCGACCCCTGCTCTACCTGGTGCGACGCCAT 180 
                ******** ** ** ** ** ** ******** ** ******** ***** ** ** ** 
Native         CAGCATCCGCGCAGGATACTACGGAGATTATGTTTTCGATCGTGTATTAAAAGTTGATGT 233 
Synthetic      CTCTATCCGAGCCGGCTACTACGGCGACTACGTGTTCGACCGAGTGCTGAAGGTGGACGT 240 
               *   ***** ** ** ******** ** ** ** ***** ** **  * ** ** ** ** 
Native         GAATAAAACTATCACCGGCATGGGTGCAGTTCCTACAGGAACCGCAGCAGCTAATTACAA 293 
Synthetic      GAACAAGACCATCACCGGCATGGGCGCTGTGCCCACCGGCACCGCCGCTGCCAACTACAA 300 
               *** ** ** ************** ** ** ** ** ** ***** ** ** ** ***** 
Native         AACTCCTACGGATAGACCCAACATCGCTTACGGCAAACACTTACAAGACGCCGAATGGTT 353 
Synthetic      GACCCCTACCGACCGACCTAACATTGCCTACGGCAAGCACCTCCAGGACGCCGAGTGGTT 360 
                ** ***** **  **** ***** ** ******** *** * ** ******** ***** 
Native         CACCAATGCAGCTTTCCTCGCATTGAATATCTGGGATCGCTTTGATATTTTCTGCACATT 413 
Synthetic      TACCAACGCCGCCTTCCTGGCTCTGAACATCTGGGACCGATTCGACATCTTCTGCACCCT 420 
                ***** ** ** ***** **  **** ******** ** ** ** ** ********  * 
Native         AGGCGCTTCTAATGGGTACTTCAAAGCTAGTTCTGCGGCATTCAACCTCGTTGGTTTGAT 473 
Synthetic      GGGAGCCTCTAACGGCTACTTCAAGGCCTCTTCTGCCGCCTTCAACCTGGTGGGCCTGAT 480 
                ** ** ***** ** ******** **   ****** ** ******** ** **  **** 
Native         TGGTGTTAAAGGATCCTCCATAGCAGCTGATCAGCTTCCCAATGTAGGCATCACTCAAGG 533 
Synthetic      CGGCGTGAAGGGATCTTCTATCGCTGCCGACCAGCTGCCTAACGTGGGCATCACCCAGGG 540 
                ** ** ** ***** ** ** ** ** ** ***** ** ** ** ******** ** ** 
Native         AATCGTTGAATTTTATACAGATACAACATTCTCTTGGAGTGTAGGTGCACGCGGAGCTTT 593 
Synthetic      CATCGTCGAGTTCTACACCGACACCACCTTCTCTTGGTCTGTGGGCGCTCGAGGCGCTCT 600 
                ***** ** ** ** ** ** ** ** *********  *** ** ** ** ** *** * 
Native         ATGGGAGTGTGGTTGTGCGACTTTAGGAGCAGAGTTCCAATACGCTCAGTCTAATCCTAA 653 
Synthetic      GTGGGAGTGCGGCTGCGCTACCCTGGGCGCCGAGTTCCAGTACGCCCAGTCTAACCCCAA 660 
                ******** ** ** ** **  * ** ** ******** ***** ******** ** ** 
Native         AATTGAAATGTTGAATGTAGTCTCCAGCCCAGCACAATTTGTGGTTCACAAGCCTAGAGG 713 
Synthetic      GATCGAGATGCTGAACGTGGTGTCGTCGCCCGCTCAGTTCGTGGTGCACAAGCCCCGAGG 720 
                ** ** *** **** ** ** **    ** ** ** ** ***** ********  **** 
Native         ATACAAGGGAACAGCATTTCCTTTACCTCTAACAGCTGGTACTGATCAGGCAACTGACAC 773 
Synthetic      CTACAAGGGAACCGCTTTTCCCCTGCCTCTGACCGCCGGCACCGACCAGGCCACCGACAC 780 
                *********** ** *****  * ***** ** ** ** ** ** ***** ** ***** 
Native         TAAGTCGGCTACAATTAAATACCACGAATGGCAAGTTGGTTTAGCGCTCTCTTATCGATT 833 
Synthetic      TAAGTCTGCCACCATCAAGTACCACGAGTGGCAGGTCGGACTGGCCCTGTCTTACCGACT 840 
               ****** ** ** ** ** ******** ***** ** **  * ** ** ***** *** * 
Native         GAACATGCTTGTTCCTTACATTAGCGTAAACTGGTCACGAGCAACTTTTGATGCTGACGC 893 
Synthetic      GAACATGCTGGTGCCCTACATCTCTGTGAACTGGTCCCGAGCCACCTTCGACGCCGACGC 900 
               ********* ** ** *****    ** ******** ***** ** ** ** ** ***** 
Native         TATCCGCATCGCTCAACCTAAATTAGCTGCTGCTGTGTTAAACTTGACCACATGGAACCC 953 
Synthetic      CATTCGAATCGCTCAGCCCAAGCTGGCCGCTGCCGTGCTGAACCTGACCACTTGGAACCC 960 
                ** ** ******** ** **  * ** ***** *** * *** ******* ******** 
Native         AACCCTTTTAGGAGAAGCTACAGCTTTAGATACTAGCAACAAATTCGCTGACTTCTTGCA 1013 
Synthetic      CACTCTGCTCGGCGAGGCCACCGCTCTGGACACCTCTAACAAGTTCGCCGACTTCCTGCA 1020 
                ** **  * ** ** ** ** *** * ** **    ***** ***** ****** **** 
Native         AATTGCTTCGATTCAGATCAACAAAATGAAGTCTAGAAAAGCTTGTGGTGTAGCTGTTGG 1073 
Synthetic      GATCGCCTCTATCCAGATCAACAAGATGAAGTCTCGAAAGGCCTGCGGCGTGGCCGTGGG 1080 
                ** ** ** ** *********** ********* **** ** ** ** ** ** ** ** 
Native         TGCAACGTTAATCGACGCTGACAAATGGTCAATCACTGGTGAAGCACGCTTAATCAATGA 1133 
Synthetic      AGCTACCCTGATTGACGCCGACAAGTGGTCTATCACCGGCGAGGCTCGACTGATCAACGA 1140 
                ** **  * ** ***** ***** ***** ***** ** ** ** **  * ***** ** 
Native         AAGAGCCGCTCACATGAATGCTCAATTCAGATTCTAA------ 1170 
Synthetic      GCGAGCCGCTCACATGAACGCCCAGTTCCGATTCTAACCTAGG 1183 
                 **************** ** ** *** ********       
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Figure 4: Clustal Omega MSA of the translated protein sequences of the native and synthetic MOMP gene. This 
alignment shows a great degree of homology; the only variation is the presence of additional amino acids on the 
5' and 3' ends of the synthetic MOMP which represent XmnI and AvrII restriction sites. The colon consensus 
symbol represents a difference in the sequence at that particular position, but one that indicates strong 
conservation in chemistry (Sievers et al., 2011).  
 
 
Figure 5: NetNGlyc 1.0 Server graph of sequence position versus N-glycosylation potential. The graph indicates 
four potential N-glycosylation sites at positions 83, 299, 323 and 329; and this is confirmed by the presence of 
four vertical lines which have exceeded the threshold value of the N-glycosylation potential which is 0.5 
(Steenthoft et al., 2013).  
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3.3.2. Cloning of the pUC57-MOMP vector in E. coli  
 
Following the cloning of the pUC57-MOMP construct in E. coli, a double digestion was 
performed to release the MOMP gene from the pUC57 plasmid, to enable subcloning into the 
pKOV410 plasmid. Figure 6A depicts the outcome of this screen, from the image it can be 
confirmed that a positive clone is present since there are fragments that have migrated into 
the anticipated size regions of the gel, which are indicative of the presence of the pUC57 
plasmid and the MOMP gene. The gel displays three DNA fragments of varying sizes. In an 
ideal scenario, a double restriction digest should fragment the DNA such that there are only 
two bands visible; these bands should correspond in size to that of the plasmid and the insert. 
Conversely, in this case, the plasmid used (pUC57), contained its own XmnI restriction site, 
which gave rise to the generation of an additional fragment: a fragment in the 1000–1500 bp 
region of the gel representing the insert (MOMP gene 1183 bp), and two fragments 
representing the pUC57 plasmid in the 750–1000 and 1500–2000 bp regions of the gel at 
approximately 800 bp and 1900 bp respectively, which when added together, accumulates to 
the overall size of the pUC57 plasmid (2710 bp).  
Figure 6B depicts the outcome of the digestion of the expression vector pKOV410. In this 
figure, linearization of the vector is visible in the form of a single fragment present on the 1% 
agarose gel, in the 6000–8000 bp region of the gel, while the actual size of pKOV410 is 6352 
bp (Figure 7), therefore linearization may be confirmed. The reason why only one fragment is 
expected is that within the MCS of the pKOV410 plasmid which can be seen in the vector map 
in Figure 7, the XmnI restriction site at position 659 and the AvrII restriction site at position 669 
within the vector, are only ten bases apart. Therefore, the size of the second fragment 
generated is negligible and cannot be visualised on a 1% agarose gel.  
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Figure 6: The 1% Agarose gel displaying a double digestion with XmnI and AvrII of A). The pUC57-MOMP 
construct; highlighted in the red boxes are the MOMP gene (1183 bp) in the 1000–1500 bp region; and the pUC57 
vector (2710) in the 800 bp and 1900 bp regions. B). The linearized pKOV410 vector (6352 bp) highlighted in the 
6000–8000 bp region.  
 
 
Figure 7: The recombinant pKOV410-MOMP vector map displaying the two NotI, AvrII and XmnI restriction sites, 
their restriction sequences and positioning within the vector. Displayed in the map is also the 26S rDNA regulatory 
sequences, the ura3d4 gene, hp4d promoter, Lip2 SP and terminator; as well as the position into which the MOMP 
gene was cloned; all of which make up the expression cassette. Adapted from (Bulani et al., 2012). 
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3.3.3. Cloning of pKOV410-MOMP in E. coli JM109 
 
Competent E. coli JM109 cells, were transformed with the pKOV410-MOMP expression vector 
generated by the ligation of the MOMP gene and linearized pKOV410 vector, which were 
excised from the gels in Figures 6A and 6B, and spread onto LB agar plates. Several of the 
colonies that had grown on the LB agar plate, were selected for screening, in order to validate 
whether the MOMP gene had indeed ligated into the pKOV410 vector. Therefore, this 
digestion served as a validation procedure. The purpose of this was to digest the recombinant 
plasmid with AvrII and XmnI, which should cleave the MOMP gene from the pKOV410 plasmid 
if it had successfully been ligated into the plasmid initially. Figure 8A depicts the outcome of 
this screen. There are two DNA fragments visible, one representing linearized pKOV410 (6352 
bp) in the 6000–8000 bp region, and another representing the MOMP gene (1183 bp) in the 
1000–1500 bp region of the gel. Therefore, the ligation of the MOMP gene into the pKOV410 
vector may be validated.  
In preparation for the expression of MOMP in Y. lipolytica Po1f, the expression cassette had 
to be generated from the recombinant pKOV410-MOMP vector. Most importantly, the 
expression cassette had to contain the MOMP gene sequence, since this is the sequence that 
will give rise to the MOMP protein. However, there are other elements that are essential to the 
integration and functioning of the expression cassette. These elements include the hp4d 
promoter, the Lip2 SP and its termination sequence, the 26S rDNA regulatory sequences and 
the ura3d4 allele.  
NotI is the restriction enzyme that was selected to perform this cleavage. The reason being 
that pKOV410 has two NotI restriction sites that are ideally located to serve this purpose 
(Figure 7). The result of which has been illustrated in Figure 8B. The 1% agarose gel in Figure 
8B illustrates the fragments produced by the NotI digestion, the red boxes highlight regions of 
the gel displaying the significant bands; and their respective sizes. There are two fragments 
present, one in the 5000–6000 bp region representing the expression cassette (5322 bp), and 
another in the 2000–2500 bp region of the gel representing the DNA moiety (2210 bp) of the 
expression vector. Therefore, the outcome of the digest was positive, and the generation of 
the expression cassette may be confirmed.  
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Figure 8: The 1% Agarose gel displaying the digestion of the pKOV410-MOMP vector. A). The pKOV410-MOMP 
vector was digested with XmnI and AvrII for validation of the ligation of MOMP into pKOV410; highlighted in the 
red boxes are the MOMP gene (1183 bp) in the 1000–1500 bp region and the pKOV410 vector (6352 bp) in the 
6000–8000 bp region. B). The pKOV410-MOMP vector was digested with NotI to generate the expression cassette; 
highlighted in the red boxes are the expression cassette (5322 bp) in the 5000–6000 bp region of the gel; and the 
DNA moiety (2210 bp) in the 2000–2500 bp region.  
 
3.3.4. Transformation of Y. lipolytica with the expression cassette 
 
Competent Y. lipolytica Po1f yeast cells were transformed with the expression cassette 
generated by the digestion of the pKOV410-MOMP construct with NotI. The transformation 
mixture was then spread onto YNBCasa plates, for the selection of Y. lipolytica Po1f 
transformants containing the expression cassette. This screening mechanism uses the ura3d4 
auxotrophic marker of pKOV410. This auxotrophic marker allows for the production of uracil, 
for which the expression host Y. lipolytica Po1f is auxotrophic. This means that only Y. 
lipolytica cells that have taken up the expression cassette will be able to grow on the uracil 
deficient media since the ura3d4 gene of pkOV410 will aid in the production of uracil.  
Five micrograms of the yeast expression cassette generated 56 transformants. Figure 9 
indicates the growth of the Y. lipolytica Po1f transformants on YNBCasa selection plates. The 
plate in Figure 9A is the transformants containing the control (linearized pKOV410); the plate 
in Figure 9B is the transformants containing the expression cassette. It is clear that both 
transformations produced a positive outcome; the yield of the transformation with the 
expression cassette was equally as high as that of the control. 
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Figure 9: YNBCasa selection plates displaying the growth of Y. lipolytica transformants. A). The control plate 
containing linearized pKOV410 as the transformation DNA. B). The test plate containing the expression cassette 
as the transformation DNA.  
 
3.3.4.1. Screening by colony PCR 
 
The Y. lipolytica Po1f transformants (Figure 9B) were then further screened for the presence 
of the MOMP gene; since its amplification from the clones would indicate a successful 
integration of the expression cassette into the genome of the host. These colonies were 
screened using conventional PCR and gene-specific primers designed for the amplification of 
the synthetic MOMP gene. Therefore, if a particular clone contains the expression cassette, 
the colony PCR should result in the amplification of the MOMP gene, since it forms part of the 
expression cassette. As can be seen in Figure 10, the outcome is such, the 1% agarose gel 
indicates the amplification of the MOMP gene (1183 bp) in 6 of the 10 clones that were 
screened. This is confirmed by the presence of a DNA fragment in the 1000–1500 bp region 
of the gel, varying in intensity throughout the 8 lanes which display a positive result.  
A B 
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Figure 10: A 1% agarose gel displaying the amplification of the MOMP gene from the transformation clones in the 
1000-1500 bp region of the gel highlighted in red. Lane 1 contains the NEB 1 kb DNA ladder and lanes 2–11 
contain 10 different Y. lipolytica Po1f transformation clones. 
 
3.3.5. Evaluation of the heterologous expression of MOMP 
 
3.3.5.1. Biomass Accumulation  
 
Following the selection of Y. lipolytica Po1f transformants positive for the expression cassette 
was the commencement of the heterologous expression of MOMP. Throughout the duration 
of the expression, 2 mL aliquots of the two expression cultures were collected from day 3 to 
day 7. The absorbance of these aliquots was measured at 600 nm in triplicate, and the average 
absorbance reading of each aliquot was determined. This data was then used to plot a line 
graph, of time in days versus absorbance at 600 nm for each expression culture. This was 
performed in order to exhibit a comparison in biomass accumulation over the five days 
between the M1 and C expression cultures.  
Figure 11 displays this comparison, in the form of a line graph; in which the blue line represents 
the biomass accumulation of the control and the orange line represents that of the test 
expression. From the graph, it can be determined that the biomass accumulation of both 
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expression cultures are more or less equal at each time point. However, only the M1 
expression culture increases in biomass until the last day, while C displays a decline in 
biomass between days 6 and 7. Based on the average absorbance readings on day 7, the M1 
culture displayed a 17.4% increase in biomass compared to that of the control culture.  
 
 
Figure 11: Comparison of biomass accumulation between the expression control (C) and the test expression (M1), 
over the expression period, displayed in the form of a line graph of time in days versus absorbance at 600 nm. 
 
3.3.5.2. SDS-PAGE analysis following ammonium sulphate precipitation 
 
The aliquots collected on day 7 of the expression for the C and M1 cultures were subjected to 
ammonium sulphate precipitation; in order to purify the protein content through fractionation, 
using a high salt concentration to modify its solubility properties. The respective C (Day 7) and 
M1 (Day 7) ammonium sulphate precipitated samples, were then resolved on a 10% SDS-
PAGE gel. Since the size of the MOMP gene is 1183 bp, the estimated size of the MOMP 
protein is 43 kDa. Therefore, the 43 kDa region of the gel has been highlighted in a red box to 
draw emphasis on the size region in which the MOMP protein is expected to be identified 
(Figure 12). Based on this gel it is clear that the MOMP protein was expressed. This is 
identifiable by the presence of an intense protein fragment in the 43 kDa region of the gel, 
which is not present in the control.  
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Figure 12: 10% SDS-PAGE gel displaying the PageRuler Plus™ pre-stained 10–250 kDa protein ladder in the first 
lane, the +410 control on day 7 in the second lane, and the M1 test expression on day 7 in the last lane. The 43 
kDa region of the gel has been highlighted to emphasize the expression of MOMP at this size in M1 which is not 
present in sample C.  
 
3.4. Discussion  
 
Chlamydia vaccine development was initiated upon the establishment of the infectious nature 
of C. abortus (Littlejohn, 1950). There is already a number of existing, whole-cell attenuated 
and inactivated vaccines for the prophylactic immunisation of ovine against OEA. These 
vaccines offer adequate protection, but challenges associated with bulk chlamydial growth 
and purification necessitates the search for an alternative approach. Vaccine design using 
recombinant DNA technology continues to attract interest as an alternative approach for 
vaccine development. Chlamydia vaccine research has substantially concentrated on the 
predominant MOMP protein present in the outer cell membrane of Chlamydia (Entrican et al., 
2001; Essig and Longbottom, 2015; He’chard et al., 2003; Longbottom, 2003; 2 ; Marques et 
al., 2010; Philips et al., 2019). Experimental vaccine preparations comprised of MOMP have 
been observed to afford a high degree of protection from C. abortus infection (Tan et al., 1990).   
The efficacy of the various forms of the recombinant MOMP against an experimental challenge 
has generally been discouraging (Entrican et al., 2001). This has been attributed to two major 
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postulations; the native conformation of MOMP as a porin protein (Wyllie et al., 1998) required 
to elicit the correct protective immune responses; and the requirement of additional antigens. 
Yarowia lipolytica is the selected expression host for the heterologous expression of MOMP. 
This yeast is known to be a prolific producer of a number of endogenous proteins by secreting 
them into the extracellular medium. It has also been extensively used to express a plethora of 
heterologous proteins (Madzak et al., 2004), however, the expression of the MOMP protein of 
C. abortus has never been attempted in this host. 
To facilitate the expression of the protein in Y. lipolytica Po1f, the synthetic MOMP gene was 
designed codon optimized for expression in Y. lipolytica. The mechanism and purpose of 
which has been discussed in the introduction to the current chapter. Another modification 
implemented was the addition of restriction sequences on the 5’ and 3’ ends of the gene to 
facilitate downstream cloning processes. XmnI and AvrII were selected because pKOV410 
has one restriction site each for both these enzymes within the MCS (Figure 7), and both these 
enzymes do not cleave within the insert or anywhere else in the plasmid outside of the MCS 
(Bulani et al., 2012).  
The final alteration made was the removal of the genes natural start codon. Under normal 
circumstances, this ATG would have been replaced by an amino acid that is compatible in 
terms of chemistry; however, in this case, it was only removed since an XmnI site was added 
to the 5’ end of the gene. Since the chemistry of each particular residue in the sequence is 
important for the correct folding of the protein (Morrison, 2015), it was vital that the first residue 
where methionine was located, be substituted by one of similar chemistry. The reason why 
the addition of a replacement residue was not necessitated, is because the last codon of the 
XmnI restriction site on the 5’ end of the gene is TTC, which contributes phenylalanine as a 
replacement for methionine (Castro-Chavez, 2011). Since the MOMP protein was destined to 
be expressed as a fusion protein with the Lip2 SP, based on the open reading frame of these 
two genes, the phenylalanine residue served in place of the methionine, this is depicted in the 
alignment in Figure 4. This manipulation of the gene was acceptable because methionine and 
phenylalanine are both classified as small hydrophobic residues, therefore, a phenylalanine 
in place of methionine conserves the chemistry (Rudnicki et al., 2014); thus the effect on the 
conformation will be minimal. The chemistry determines the type of bond between amino acids 
and the bonds in-turn dictate the overall structure of the protein (Chu and Zheng, 2013).  
Primarily, the start codon was removed to allow in-frame orientation of the MOMP gene, with 
the Lip2 SP of the pKOV410 expression vector for expression as a recombinant fusion protein 
and eventual secretion into the medium. A recombinant fusion protein is one consisting of two 
separate domains, encoded by completely different genes, which have been linked in order to 
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facilitate their transcription and translation as a single fused protein (Brenner and Miller, 2001). 
According to the pKOV410 vector map and sequence, in order to join the Lip2 SP to the MOMP 
protein to function as a single unit; the ATG start codon of the MOMP gene had to be removed 
to allow for this incorporation. Otherwise, with the start codon still present, the MOMP protein 
would be expressed as an entirely separate entity from the Lip2 SP.  
The Lip2 SP is a short peptide, consisting of 30 amino acids which would be expressed at the 
N-terminal of the MOMP protein since the synthetic gene was designed such that it would be 
inserted downstream of the Lip2 SP. The significance of this modification relates to the location 
of the protein post-expression because the Lip2 SP, like all other signal peptides, prompts the 
host cell to translocate the protein via a secretory pathway to the extracellular environment of 
the host cell (Celinska et al., 2018; Ghahremani et al., 2016). The Lip2 SP encodes the 
extracellular lipase Lip2p, a triacylglycerol hydrolase which is responsible entirely for 
extracellular lipase activity in Y. lipolytica (Pignede et al., 2000). Majority of yeast lipases 
function extracellularly; however, in Y. lipolytica there are more intracellular and membrane-
bound lipases, as such, Lip2p is the only extracellular lipase and therefore catalyses all 
extracellular lipase activity (Darvishi, 2012). The Lip2p is destined for the extracellular 
environment by exocytosis, because it is here where it encounters and catalyses the 
degradation of all hydrophobic substrates into its constituent free fatty acids for utilization by 
the cell (Darvishi, 2012). A study evaluating the efficiency of protein production in Y. lipolytica 
has indicated that fusion to the lip2p secreted protein, is an effective method for the direction 
of a heterologously expressed protein into the extracellular medium for retrieval (Hofmeyer et 
al., 2014).  
Celinska and co-workers (2018), revealed that the Lip2 SP, whether in its native, hybrid or 
synthetic forms, is still one of the best SPs with regard to the efficiency of protein secretion, 
and the overall secreted yield. It is often advantageous to target the recombinant protein to a 
secretory pathway for two main reasons. The first is that it reduces the time required for the 
harvesting of the recombinant protein. The second is that is by-passes potential complications 
that could arise if the protein remains in the intracellular fraction of the host. Research has 
shown that the most common impediment is the entrapment of recombinant proteins in the 
form of insoluble inclusion bodies. Although this form allows for high protein yields, the 
difficulty encountered during the solubilisation and subsequent refolding process is too great 
of a risk to opt for this pathway (Smith et al., 2014; Ramon et al., 2014).  
Subsequent to the design of the synthetic gene, Clustal Omega MSAs on the proposed design 
were performed, to ensure that the synthesised gene would still generate a protein identical 
to that of the native MOMP of C. abortus, after undergoing codon optimization for expression 
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in Y. lipolytica. The codon-optimized synthetic MOMP gene sequence was aligned with the 
native MOMP gene sequence, in order to highlight the regions of the gene that had undergone 
codon optimization. This alignment can be seen in Figure 3, and codon-optimized regions are 
identifiable by a mismatch between the nucleotide residues in the two query sequences.  
A subsequent alignment was then performed, using the native MOMP protein sequence, with 
that of the synthetic codon-optimized MOMP, in order to draw a comparison between the 
homology of the DNA-DNA and protein-protein alignments. Both of which were based on the 
same sequences, the only difference being that the sequences were translated in the latter 
alignment. The protein-protein alignment in Figure 4 exhibits complete homology between the 
two sequences, this is indicated by a match between each and every amino acid residue in 
the alignment (Sievers et al., 2011; Li et al., 2015). It was however expected that the homology 
of the protein-protein alignment would be much greater than that of its DNA counterpart. This 
is because codon optimization replaces certain codons within the gene sequence, with 
synonymous codons encoding the same amino acids to enable the utilization of synonymous 
codon conversions, based on the preference of the host expression system which enhances 
the overall efficiency of heterologous expression (Mezella, 2011; Zhou et al., 2015).  
The prediction of potential glycosylation sites within the MOMP protein sequence was 
performed in order to elucidate whether the protein contains glycosylation requirements. This 
is an important parameter in relation to antigenicity. According to Lisowska (2002), 
glycosylation plays an underlying role in the antigenic properties of proteins. Glycosylation 
sites have been found to play a role in the adaptive immune response; this is likely due to the 
fact that all the proteins that play a key role in antigen recognition and downstream effects are 
glycosylated (Wolfert and Boons, 2013). Literature states that antigenic glycoproteins enhance 
the immunogenic response due to its recognition by both class -I and -II major 
histocompatibility complexes (MHCs) molecule, which in essence initiates the adaptive 
immune response.  
The importance of glycosylation has been identified, and more frequently it has been 
implemented into studies involving vaccine design, immune functioning, and in studies which 
reveal its effects on diseases (Reily et al., 2019). The significance of this occurrence relates 
to the ability of glycoproteins to induce glycopeptidic-specific T cell-dependent cellular immune 
responses (Lisowska, 2002); however, in this study, the humoral immune response has been 
targeted, and for this reason, the potential glycosylation of MOMP will not be investigated in-
depth. This analysis confirms that the MOMP protein has four potential glycosylation sites; 
and Y. lipolytica is capable of performing post-translational modifications, therefore, this 
expression system may prove beneficial for the immunogenicity of the MOMP antigen. 
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Following the sub-cloning of the MOMP gene into the expression vector, the MOMP gene 
required integration into the host’s genome to express the MOMP protein. For this purpose, 
an expression cassette needed to be generated from the recombinant expression vector 
(Papadakis et al., 2004). An expression cassette is a portion of the recombinant expression 
vector containing the gene of interest, and the necessary regulatory sequences required for 
the control of its expression (Vickers et al., 2013). In this case the expression cassette needed 
to consist of the non-inducible, recombinant hp4d promoter to drive the expression of the 
MOMP gene; the Lip2 signal peptide and terminator to function with the expressed gene as a 
fusion protein; the ura3d4 auxotrophic marker for selection; the 26S rDNA regulatory 
sequences; and of course the MOMP gene itself.  
The promoter is required to drive the transcription of the MOMP gene, from its mRNA codons 
into its respective amino acid residues to form the MOMP peptide sequence. The promoter is 
essential for the initiation of transcription; it initiates the process by providing the initial binding 
site for the enzyme responsible for mRNA synthesis – RNA polymerase, and for the 
transcription factors that regulate gene expression within the host cell (Zehavi et al., 2014). 
The strongest native Y. lipolytica promoter is the XPR2 promoter, which serves well in the 
facilitation of transcription. However, due to the complexities endured during induction and 
regulation, according to Blazeck and Co-workers (2011), the recombinant hp4d promoter of 
pKOV410 has become a commonly utilized promoter for heterologous expression in Y. 
lipolytica.  
The recombinant hp4d promoter is unique because it is not inducible, nor is it constitutive; it 
is essentially unaffected by most conditional parameters and media constituents, meaning that 
it is capable of functioning under almost all possible conditions (Madzak et al., 2000). It is 
classified as a quasi-constitutive, growth-phase dependent promoter, in which transcription is 
initiated upon entry into the stationary phase (Nicaud et al., 2002). Besides the beneficial 
contribution made by the hp4d promoter in terms of the ease of use; another reason for using 
this promoter is that the XPR2 gene encoding the native promoter has been deleted in the 
Po1f strain, therefore necessitating the use of an alternative promoter system (Nicaud et al., 
2002). The hp4d promoter is optimal for heterologous protein expression, due to its ability to 
promote gene expression at a steady rate, irrespective of any environmental parameters such 
as nitrogen and carbon source and pH fluctuations (Madzak et al., 2004; Bulani et al., 2012). 
The 26S rDNA regulatory sequences encode the ribosomal RNA sequences that make up the 
large subunit of the ribosome. This rDNA sequence, in particular, serves a dual role. Foremost, 
it functions as a target for the integration of the plasmid as an expression cassette into the 
genome of the host (Bulani et al., 2012). The mechanism by which this is accomplished will 
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become apparent later. Once integrated into the genome of the expression host, it then 
facilitates the transcription process by forming part of the large subunit of the ribosome, which 
is responsible for the linking of consecutive amino acid residues to form a polypeptide chain 
(Juretzek et al., 2000).  
The other portion of the vector is termed the DNA moiety, which is a fragment of the vector 
DNA consisting of an unspecified unit. In this case, the DNA moiety comprises only the 
kanamycin resistance gene (Bulani et al., 2012). The outcome of the digestion of the 
recombinant pKOV410-MOMP vector with NotI is displayed in Figure 8B. The agarose gel 
shows the migration of two fragments, which is expected due to there being two NotI restriction 
sites within the pKOV410 vector. One fragment is in the 5000–6000 bp region of the gel and 
the other is in the 2000–2500 bp region of the gel. Based on the vector map for pKOV410 
(Figure 7), the expression cassette is expected to be the fragment of larger size, and the DNA 
moiety is expected to be the fragment of smaller size (Bulani et al., 2012).  
Generation of an expression cassette is essential for the integration of the foreign genetic 
material into the host’s genome. Transformation of the expression host with the foreign DNA 
will facilitate its entry into the cell, but thereafter the DNA must be able to enter the host cell’s 
nucleus to trigger gene expression (Kamimura et al., 2011). A study on delivery systems for 
gene therapy has shown that in certain cases, the foreign DNA inserts itself into the host’s 
genome, while in other cases it is capable of autonomous replication (Mali, 2013). The 
expression host Y. lipolytica is a eukaryote, and according to Griffiths and Co-workers (2000), 
autonomous replication of a vector in a eukaryotic host is sporadic, therefore integration is 
necessitated for gene expression.  
The expression host pKOV410 is a yeast integrative plasmid which achieves integration into 
a yeast host genome, through homologous recombination into the ribosomal cluster of the 
yeast host. Homologous recombination in yeast is made possible owing to its highly efficient 
DNA repair system. According to a study done by Bulani and Co-workers (2012), all that is 
required is a linearized yeast integrative plasmid containing the hp4d growth-phase dependent 
promoter; the Lip2 signal peptide; the ura3d4 auxotrophic marker and the 26S rDNA regulatory 
sequences. Once the expression cassette containing the 26S rDNA regulatory sequence is 
taken into the cell; homologous recombination takes place. This is achieved by replacing the 
26S rDNA allele of the host’s ribosomal cluster with the respective allele from the plasmid, 
consequently enabling the integration of the expression cassette into the host genome. The 
significance of which is that the hosts' genome will regulate its replication, and the expression 
of all genes, including the gene of interest that had integrated into the genome as a constituent 
of the expression cassette.  
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The Po1f strain of Y. lipolytica is a derivative of the wild-type, one in which the URA3 and 
LEU2 genes have been disrupted. This is an important aspect because it gives rise to the 
method of selection based on auxotrophy. The disruption of the URA3 gene is of importance 
for the purpose of this study. The URA3 gene encodes the enzyme orotidine 5’-phosphate 
decarboxylase (ODCase), which is responsible for the catalysis of an essential reaction in the 
generation of the component pyrimidine ribonucleotides of RNA. Without this enzyme, it is not 
possible to synthesise pyrimidine ribonucleotides, since it is required for the generation of 
uradylic acid (UMP) by the decarboxylation of orotidine 5’-phosphate (OMP). This resultantly 
hinders the transcription of the mRNA into amino acid residues. Therefore, the disruption of 
the URA3 gene deems the Y. lipolytica cells incapable of thriving on media that is not treated 
with uracil or uridine, unless the ODCase activity is restored within the cell, by transfection of 
the cell with a plasmid carrying a URA3 gene or an allele derived from URA3 (Jones, 1992).  
The selective media used for the maintenance of plasmid selection in Y. lipolytica is YNBCasa. 
This selective media comprises yeast nitrogen base (YNB) without amino acids, ammonium 
chloride, glucose and casamino acids (Labuschagne and Albertyn, 2007). The purpose of a 
selective medium is to provide all necessary nutritional supplements to deter the cells from 
the de novo synthesis pathway, thereby allowing for the ease of synthesis to increase the 
growth rate, but excluding a crucial nutritional supplement upon which the selection is based. 
It is termed a dropout medium since it lacks a particular nutritional substance which the cell 
cannot produce, unless it possesses a vector integrated within its genome that carries this 
nutritional marker gene (MacDonald, 2001). The key component of this dropout medium is 
casamino acids which is the acid hydrolysate of casein, predominantly consisting of 
phosphoproteins. The casamino acids provide all the necessary amino acids, in free- and 
peptide-formats required for Y. lipolytica survival and growth, except tryptophan which is 
degraded by the hydrolysis process (Kaushick et al., 2016).  
The mechanism of selection for positive Y. lipolytica Po1f clones is based on the disruption of 
its URA3 gene (Jones, 1992). Consequently, Y. lipolytica Po1f is auxotrophic for uracil. This 
shortcoming hinders the transcription of mRNA into the amino acid sequence in positions 
where pyrimidine ribonucleotides are required. Uracil is a pyrimidine ribonucleotide which is 
essential for the formation of certain codons that encode particular amino acid residues. 
Tryptophan is an amino acid that is encoded by the codon UGG, it is the only mRNA codon 
that encodes tryptophan. There are no synonymous codons for this amino acid (Berleant et 
al., 2009), therefore the availability of the pyrimidine ribonucleotide uracil within the cell is 
critical for tryptophan generation, which in turn is essential for protein synthesis.  
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As previously mentioned, the casamino acids component of the selective media provides all 
amino acids for the cell, except tryptophan. Therefore, if the cells cannot synthesize uracil to 
formulate the codon that encodes tryptophan, and the media is deficient in tryptophan, the 
cells cannot survive and thrive unless there is an alternative means of tryptophan production. 
The pKOV410 vector which forms part of the expression cassette that was used to transform 
the Y. lipolytica Po1f cells, contains a derivative of the URA3 gene. For research purposes, 
the URA3 gene has been used to derive two complements of itself: the wild–type ura3d1 allele, 
and a mutant of the wild-type, the ura3d4 allele (Nicaud et al., 2002). The pKOV410 vector 
carries the ura3d4 allele, as a multi-copy selection marker, meaning that multiple copies of the 
expression cassette are required for the auxotrophy to be effective. This is due to the 
truncation of the promoter for this allele, resulting in a defective 8 bp promoter. The reason 
why this allele is preferred, even though it requires the integration of multiple copies of the 
expression cassette into the genome, is because it also yields multi-copy transformants in 
succession. Multi-copy transformants are beneficial to the expression phase because they 
prompt high levels of protein expression (Juretzek et al., 2000).  
Fundamentally, the ura3d4 allele of the pKOV410 vector serves as a complement of the 
defective URA3 gene of Y. lipolytica Po1f. This complementation encodes ODCase, which 
restores the biosynthesis of pyrimidine ribonucleotides like uracil, leading to normal 
transcription and translation. Therefore, only Y. lipolytica Po1f cells, that have the expression 
cassette integrated within its genome, should be able to grow on the uracil deficient media, as 
the ura3d4 allele will promote a normal growth rate (Juretzek et al., 2000).  
The integration of the expression cassette into the genome of the expression host enables the 
synthesis of the MOMP protein using the Y. lipolytica Po1f expression system. A clone that 
had tested positive for the presence of the expression cassette, was heterologously expressed 
along with the linearized pKOV410 vector which served as the positive control. According to 
Marini and Co-workers (2014), for the evaluation of recombinant protein expression, it is 
beneficial for the experimental design to include a positive control in order to draw 
comparisons in the protein profiles. The protein profiles for the positive control and the test 
expression should be identical, except that the test expression should contain a protein 
fragment which is not present in the control, in the expected size region of the heterologous 
protein (Torlakovic et al., 2015). Based on the protein profiles of the control and MOMP 
expression cultures on day 7, displayed in the form of a 10% SDS-PAGE gel (Figure 12). It is 
clear that there is a protein fragment present in the MOMP expression cultures, which is not 
present in the control, highlighted in the red box. It is plausible that this fragment is the MOMP 
protein at approximately 43 kDa.  
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A comparison of the level of biomass accumulation between the positive control and test 
expression culture throughout the duration of the expression may be a beneficial inclusion in 
a recombinant protein expression study. Based on a study carried out by Marinii and Co-
workers (2014), when selecting the optimal experimental design considerations for a 
recombinant protein expression study, measurement of biomass accumulation during the trial 
expression is a good indicator of the potential concentration of the desired heterologous 
protein. This is because it has been determined that when a recombinant protein is generated 
intracellularly, using a host expression system, the cell growth is directly proportional to the 
recombinant protein yield. Therefore, the higher the cell growth measured in the form of 
biomass, the greater the heterologous recombinant protein yield (Shahrezaei and Marguerat, 
2015). Biomass accumulation could be utilized as a tool for the analysis of recombinant protein 
production in this study because yeasts are capable of balanced cell growth. This is the ability 
of a cell to maintain its biomass, even under conditions of nutrient depletion (Nordholt et al., 
2017).  
A comparison of the levels of biomass accumulation between the positive control and test 
expression was performed, to determine if the test expression cells displayed a higher 
biomass. Figure 11 depicts the outcome of this analysis. In terms of the biomass accumulation 
throughout the expression duration, both cultures displayed similar biomass levels. However, 
at the end of the expression period, on day 7; the biomass of the M1 test expression culture 
was 17.4% greater than that of the positive control. Since the relationship between biomass 
accumulation and protein yield is one of direct proportionality (Shahrezaei and Marguerat, 
2015; Marini et al., 2014), it can be deduced that the increase in biomass of the M1 test 
expression culture, may likely be due to the presence of a high concentration of the 
recombinant MOMP protein.  
In conclusion to this chapter, the synthetic MOMP gene had been designed baring a few 
necessary modifications to aid in sub-cloning and heterologous expression. Through 
successive restriction digests, the MOMP gene and pKOV410 vector led to the development 
of an expression cassette consisting of the non-inducible hp4d promoter to drive the 
expression of the MOMP gene; the Lip2 signal peptide to function with the expressed gene as 
a fusion protein; the ura3d4 auxotrophic marker; the 26S rDNA allele for homologous 
recombination; and most importantly the synthetic MOMP gene. The screening procedure 
applied subsequent to the transformation of Y. lipolytica Po1f with this expression cassette 
yielded the amplification of the MOMP gene from the Y. lipolytica Po1f clones. This is indicative 
of a successful transformation. This outcome stipulated that the heterologous expression of 
the MOMP protein by the Y. lipolytica Po1f expression system had become a feasible 
undertaking because the MOMP gene had integrated into the genome of the host.  
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Subsequent to the heterologous expression of MOMP; a comparison of the level of biomass 
accumulation between the expression cultures displayed a 17.4% increase in the biomass of 
M1 compared to that of the control culture. This indicates that the recombinant MOMP had 
been expressed since the relationship between cell growth and recombinant protein 
production is directly proportional in cells displaying balanced cell growth. The analysis of the 
protein profiles of the positive control, and the test expression supernatant further confirm the 
expression of the MOMP protein, which is indicated by the presence of a protein fragment at 
approximately 43 kDa in the test expression supernatant, which is not visible in the control 
supernatant. The outcome of the heterologous expression of MOMP by Y. lipolytica Po1f is 
promising based on the results obtained, and the expression of MOMP signifies the viability 
of the development of the candidate MOMP subunit vaccine.  
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Chapter 4: Evaluation of the immunogenic properties of the 
recombinant MOMP  
 
4.1. General introduction 
 
In the field of vaccinology, the greatest concern for the veterinary health sector is the cost of 
production. The greater the expenses involved in the production, the higher the overall cost of 
the vaccine. The major implication of which is a reduction in sales, which is directly related to 
the population of unvaccinated animals (Lubroth et al., 2007). This has a negative impact on 
the agricultural industry, especially in a developing country such as South Africa. For small-
scale breeders it is often unaffordable to vaccinate an entire flock against endemic infectious 
organisms, thus rendering them susceptible to a multitude of infections, many of which have 
detrimental effects. The latency of C. abortus infection, in particular, presents major 
implications. It allows for widespread infection across an entire flock, and recurrently 
throughout many farms within a local geographical region (Tisdell et al., 1999). Unvaccinated 
and infected animals have an unfortunate impact on food security as well. Infected animals 
cannot be sold for consumption, especially if the infection is zoonotic like that of C. abortus; 
as it is unethical and introduces the potential for the infection to manifest within human 
communities (Corry and Hinton, 1997). The economy is then further impacted by infection as 
the international trade of all livestock is also hindered, due to safety restrictions that have been 
put into place by the World Trade Organisation to alleviate potential risks (Federation of 
American Scientists, 2011).  
Due to the prospective implications involved with vaccines that are costly to manufacture, 
research on more cost-effective alternatives is continuously being implemented; and the best 
possible solution to this problem is the second-generation subunit vaccines (Longbottom, 
2003). The reason why subunit vaccines are the superior option to live attenuated or dead 
inactivated vaccines, is of course owed to the elimination of the potential for reversion, but 
also because subunit vaccines can be produced on a large-scale, with greater ease and 
reduced costs due to the use of recombinant DNA technology (Nasiemento and Leite, 2012). 
For prevention of infection caused by C. abortus, there are a number of live attenuated and 
inactivated vaccines that are available commercially, many of which offer sufficient 
preventative protection. However, the large-scale propagation of this bacterium is an on-going 
challenge; and the difficulty encountered during the purification process causes an additional 
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hindrance to the manufacturing procedure, both of which contribute towards the cost of the 
vaccine (Longbottom, 2003).  
For most vaccine development and drug discovery research studies, the ultimate objective is 
to investigate the candidate compound in a clinical setting on living subjects, in order to 
evaluate the candidate compound in relation to the level of safety, efficacy and immunogenicity 
elicited (Dimasi et al., 2016). Clinical trials have two significant functions. The first is that it 
allows for the testing of a novel compound, which has the potential to have a great preventative 
effect – this impacts the quality of life. The second is that it provides a contribution towards 
scientific knowledge and medical research, regardless of the outcome, provided that 
researchers refrain from publication or reporting bias (Brassington, 2017). Approval based on 
ethics is required for a clinical trial as such since it will introduce a foreign antigen (MOMP); 
and an infectious organism (C. abortus) into the Swiss albino CD-1 outbred pregnant mice, 
which will be utilised as living subjects for this trial.  
Safety through a clinical trial evaluation is assessed through observation, and the largest 
indicator of safety is mortality. In a clinical trial that does not involve a challenge component, 
mortality is indicative of an unsafe vaccine (Pasquale et al., 2016; Wormsbecker et al., 2019). 
Adverse reactions are also used as a means to evaluate the safety of a vaccine, these can be 
local or systemic, and range in severity depending on what type of adverse reaction is being 
presented; and in which part of the system (Gidudu et al., 2008). Efficacy relates to the ability 
of the candidate vaccine to produce the intended or desired outcome. It is an important 
characteristic of a vaccine because it corresponds to the effectiveness of the vaccine, and 
how capable it is in providing long-term protection against a particular infectious agent 
(Weinberg and Szilagyi, 2010). Immunogenicity evaluates the ability of the vaccine to provoke 
a humoral or cell-mediated immune response against the antigenic agent. The humoral 
response, which is the pathway targeted in this clinical trial is evaluated by the titre of 
antibodies specific for the antigen, that has been generated by the immune system of the test 
subjects in response to the antigen (Weinberg and Szilagyi, 2010).  
Throughout the clinical trial, the level of safety and efficacy of the candidate subunit vaccine 
was evaluated. Succeeding the completion of the clinical trial, the level of immunogenicity 
elicited by the recombinant MOMP was evaluated serologically by means of an enzyme-linked 
immunosorbent assay (ELISA). This is a significant stage in an immunology and vaccinology 
study, as this test retains clinical relevance. This is the point at which the antigen may be 
classified based on the level of immunogenicity elicited (Mitic et al., 2017). The purpose of a 
vaccine development study is this chapter and everything that it encompasses.  
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This chapter signifies the completion of the study and includes the final research objective, 
which evaluated the safety, efficacy and immunogenicity of the recombinant MOMP as an 
antigen in mice. This chapter exhibits the framework required for a clinical trial and the specific 
immunisation schedule that has been dedicated to this trial. It will also comprise the 
mechanisms used to evaluate the safety and efficacy of the recombinant MOMP as an antigen. 
It encompasses the formulation of the candidate MOMP subunit vaccine, generated using the 
heterologously expressed MOMP protein and the preparation of the infectious C. abortus B577 
and EBA strains generated to challenge the vaccinated mice. This chapter illustrates the level 
of immunogenicity elicited by the candidate MOMP subunit vaccine, by means of a serological 
analysis using the ID Screen® Chlamydophila abortus Indirect Multi-Species ELISA kit, to 
determine the anti-MOMP antibody titre present in the sera, extracted from the immunized and 
challenged Swiss albino CD-1 mice.  
 
4.2. Materials and methods 
 
This section contains all procedures followed to accomplish the final research objective of the 
study. It also includes all reagents and their compositions, materials, equipment, software, and 
databases used for the experimentation and the analysis of the results. Reference is made to 
companies that provided the consumables and services required. The manufacturers and 
country of origin of all the above-mentioned items can be found in Appendix A. 
 
4.2.1. Ethics statement 
 
Female Swiss albino CD-1 IGS mice (Charles River Laboratories International Incorporated, 
2011) were used for all immunization experiments, in strict accordance with the 
recommendations in The Guide for the Care and Use of Laboratory Animals (National 
Academy of Sciences, 2011), and the Society for the Prevention of Cruelty to Animals 
(National Council of Societies for the prevention of Cruelty to Animals, 2018). The animal 
protocols (BP2018/007, 2018-02-15/Lu) have been approved by the Onderstepoort Biological 
Products Ethics Committee and the University of Johannesburg Faculty Ethics Committee. 
Both ethics approval letters, have been included in this dissertation and can be found in 
Appendix C and D, respectively. The section 20 permit for this clinical trial has been granted 
by the Department of Agriculture, Forestry and Fisheries, and this documentation has been 
inserted as Appendix E. The mice were housed with food and water ad libitum and monitored 
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under the care of full-time staff. All animals were acclimated for 1 week before any procedures 
were carried out, and were 9–11 weeks old at the start of the immunization.  
 
4.2.2. Recombinant protein production 
 
After 168 hours of the 100 mL YPD shake flasks incubation at 28°C with shaking for the 
heterologous expression of MOMP in Y. lipolytica Po1f, the expression culture was centrifuged 
at 20 000 xg, for 1 hour at 4°C in a Beckman JA rotor to separate the intracellular from the 
extracellular fraction of the cells. Of the two resultant fractions, the extracellular is the fraction 
of interest since the MOMP protein was directed to the secretory pathway of Y. lipolytica Po1f, 
by the Lip2 signal peptide of pKOV410. The extracellular fractions of the C and M1 cultures, 
following the analysis of biomass accumulation (Chapter 3), were then concentrated by use of 
centricons, as a means of purification to isolate MOMP from most of the other extracellular Y. 
lipolytica Po1f proteins. Following the concentrating process, the concentration of the protein 
solution then needed to be determined and this was done spectrophotometrically.  
The Millipore Centricon® centrifugal filter devices were used as a means of concentrating for 
the isolation of the MOMP protein. The procedure followed is the standard process used for 
the concentration of a protein, using the 10 000 nominal molecular weight limit (NMWL) 
Ultracel® YM (Millipore Corporation, 2005). The standard procedure required the use of a 
fixed angle rotor, therefore the Beckman JA–10 rotor was used. Following the centrifugal 
specifications set out in the user guide, and once isolated; the MOMP protein was eluted with 
1 X PBS pH 7.4. Once concentrated, this antigenic MOMP solution was then used to 
determine the concentration; and the remaining solution was stored at -80°C for use as the 
active agent in the upcoming clinical trial. 
For the determination of the protein concentration, the antigenic MOMP solution was analysed 
in duplicate spectrophotometrically, using the Epoch™ Microplate Spectrophotometer and the 
BioTek Gen5 1.10 software. The protocol followed was that of Layne (1957). The UV lamp of 
the spectrophotometer was allowed to equilibrate for 15 minutes; the wavelength was then 
adjusted to 280 nm. The system was calibrated to zero with the YPD buffer solution, before 
measuring the absorbance of the antigenic MOMP solution at 280 nm. The wavelength was 
then adjusted to 160nm; the system was calibrated to zero with the YPD buffer solution, and 
then the absorbance of the protein solution was measured again. Once all readings had been 
captured, the mean values for the duplicates were calculated to determine the average 
concentration of the antigenic MOMP solution following its isolation with the Millipore 
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Centricon® centrifugal filter device, before the candidate MOMP subunit vaccine could be 
formulated.  
 
4.2.3. The clinical trial 
 
4.2.3.1. The immunisation schedule 
 
Thirty pregnant mice were approved and allocated for this study, divided into six groups 
comprised of five mice per group displayed in Table 9. The clinical trial was conducted on the 
OBP premises, Evaluation Unit of the Experimental Animal Building since the conditions for a 
clinical trial required regulation. The facility maintains a temperature of 20°C to 24°C, with a 
relative humidity of 50% to 70%, and a 12 hour day and night cycle is upheld. Since the 
duration of the clinical trial exceeded seven days, the cages were changed every week. Each 
cage housed five mice, all were kept in their respective groups on Corncob™ bedding , and 
fed JCW petfood mice chow and water ad libitum. On every Friday, Phenaminovit™ was 
added to their water and then replaced on Mondays with clean water.  
The immunisation schedule for this clinical trial has been depicted in Table 9. The duration of 
this clinical trial was 21 days in total. As can be seen in Table 9, day one was allocated for the 
vaccination. Twenty-five of the thirty clinical subjects (excluding the non-vaccinated group), 
were vaccinated with 0.2 mL of their respective formulations, subcutaneously. They were then 
allowed six days to develop an immune reaction to the antigen. On day seven, all thirty 
subjects (including the non-vaccinated group), were then challenged intraperitoneally with 0.2 
mL of the virulent form of C. abortus B577 and EBA strains that had been cultured. The 
succeeding fourteen days were then allocated for the evaluations which included mortality, 
adverse reactions, and abortion.  
Subsequent to the completion of the clinical trial, on the final day, serum was drawn from each 
subject to perform a serological analysis, for the determination of the level of immunogenicity 
elicited in the form of an anti-MOMP antibody titre. Thereafter, all mice were euthanized by 
treatment with isoflurane and carbon dioxide and then disposed of by incineration.  
The complete process has been summarised in the form of a schematic displayed in Figure 
13. The schematic illustrates the major procedures and the days upon which they were 
performed.  
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Table 9: Immunisation schedule for the clinical trial testing the safety, efficacy and immunogenicity of the candidate 
MOMP subunit vaccine. 
Group  Formulation  Vaccination Challenge Evaluations Sera collection 
C1 Non-vaccinated  
 
Day 1 
 
 
Day 7 
 
 
Day 8–21 
 
 
 
Day 21 
 
C2 70% adjuvant 
C3 Chlamysure 
M1 70% adjuvant: 30% MOMP 
M2 60% adjuvant: 40% MOMP 
M3 50% adjuvant: 50% MOMP 
 
 
Figure 13: Schematic representing the major procedures of the clinical trial for the evaluation of safety, efficacy 
and immunogenicity of MOMP as a subunit vaccine for prevention of chlamydiosis; and the days upon which each 
procedure is performed.  
 
4.2.3.2. Vaccine formulation 
 
For the study, three controls were used, of which two were negative controls: one absolute 
control and one placebo. The absolute negative control is the first group of five pregnant mice, 
referred to as C1, which were unvaccinated; and the placebo group is the second group of 
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five pregnant mice, referred to as C2, which were vaccinated with a 70% Seppic Montanide™ 
ISA 70 water-in-oil adjuvant formulation. The positive control is the third group of five pregnant 
mice, referred to as C3 which were vaccinated with the commercial whole inactivated vaccine, 
Chlamysure. 
The fourth group of five pregnant mice, referred to as M1, was the first test group to be 
vaccinated with a formulation consisting of the active agent. This group was vaccinated with 
a 70% adjuvant: 30% MOMP vaccine formulation. This vaccine was formulated by dispersing 
7 mL of the Seppic Montanide™ ISA 70 water-in-oil adjuvant, with 3 mL of the antigenic MOMP 
solution.  
The fifth group of five pregnant mice, referred to as M2, was the second test group to be 
vaccinated with a formulation consisting of the active agent. This group was vaccinated with 
a 60% adjuvant: 40% MOMP vaccine formulation. The vaccine was formulated by dispersing 
6 mL of the Seppic Montanide™ ISA 70 water-in-oil adjuvant, with 4 mL of the antigenic MOMP 
solution. 
The sixth and final group of five pregnant mice, referred to as M3, was the third test group to 
be vaccinated with a formulation consisting of the active agent. This group was vaccinated 
with a 50% adjuvant: 50% MOMP vaccine formulation. The vaccine was formulated by 
dispersing 5 mL of the Seppic Montanide™ ISA 70 water-in-oil adjuvant, with 5 mL of the 
antigenic MOMP solution. 
 
4.2.3.3. Preparation of challenge material 
 
The challenge material had to comprise both available strains of C. abortus, which is the B577 
strain and the EBA strain. Therefore, the following protocol was utilized for the preparation of 
both strains simultaneously, in separate T75 cell culture flasks, as well as a control excluding 
any strain of the C. abortus bacterium.  
To begin the process, 10 mL of the Minimum Essential Medium Eagle (MEM) was decanted 
into 80% confluent McCoy cells contained within a cell culture flask. The McCoy cells were 
then trypsinized within the flask by washing three cycles with 1 X PBS pH 7.4 (calcium and 
magnesium-free). Thereafter, 1 mL of trypsin was added to the cell culture flask, and the flask 
was incubated at 37°C for 30–90 seconds until the cells became round in formation and easily 
detachable from the sides of the flask by tapping on the flask.  
Next, the action of trypsin was blocked with 1 mL fetal bovine serum (FBS); 4 mL of Gibco’s 
Eagle Minimum Essential Medium (EMEM) supplemented with (10% L-glutamine, 2% glucose 
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and 10% FBS) was added to the flask. Then, 5 mL of the inoculum (Infectious C. abortus 
strains), was used to inoculate the McCoy cells, in the respective cell culture flasks for B577 
and EBA. The cell-antigen cultures were then centrifuged at 6000 xg, for 1 hour at 37°C. 
Following the completion of the centrifugation step, the cell-antigen cultures were transferred 
to new T75 cell culture flasks and incubated at 37°C for 2 hours. Thereafter, 30 mL of Gibco’s 
EMEM was added to each of the flasks, and the flasks were incubated at 37°C for 4 days 
while monitoring daily for signs relating to the cytopathic effect (CPE).  
Once the McCoy cells had shown signs of CPE, the cells were then quantified by staining 
them with iodine, and the number of inclusion forming units (IFU) was determined through 
examination of the cultures under a light microscope. Once the IFU was determined, the cells 
were then harvested by vigorously shaking the flasks as it leads to the detachment of cells 
from the surface of the flask. Following the harvest, the cells were then examined for sterility 
by inoculating a sample of the cells into a soybean-casein digest and thioglycollate broth 
media and monitoring the cultures for microbial growth.  
Once the cells had passed the sterility checks, the challenge material was prepared. Figure 
14 displays the three T75 cell culture flasks, with their respective cultures within, prior to the 
formulation of the challenge material. The challenge material was made up of 50% C. abortus 
B577-infected McCoy cells and 50% C. abortus EBA-infected McCoy cells. It was prepared to 
a total volume of 10 mL. 
 
 
Figure 14: T75 cell culture flasks of the C. abortus EBA (left) and B577 (middle) cultures and the control culture 
(right) excluding the C. abortus bacterium.  
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4.2.4. Indirect ELISA 
 
The serological analysis was performed using the ID Screen® Chlamydophila abortus Indirect 
Multi-Species ELISA kit. The sample required for this kit is serum from the infected animal. On 
day 21 of the clinical trial, blood was collected from the thirty mice by cardiac puncture, and 
the blood from each mice of a particular group was pooled together. The six vials of blood 
were then centrifuged at 14 000 xg for 15 minutes, to fractionate the blood to separate the 
blood plasma, which makes up the serum component of the blood from the leukocytes and 
erythrocytes. This serum fraction is what was used as the sample material for each respective 
group of mice.  
The procedure followed was according to the protocol specified for the use of the ID Screen® 
Chlamydophila abortus Indirect Multi-Species ELISA kit. The microtiter plate supplied with the 
kit is coated with the MOMP antigen of C. abortus, to enable the detection of anti-MOMP-
antibodies from the serum samples, and all reagents required for the ELISA was supplied with 
the kit. To begin the protocol, 10 µL of the serum samples of each group was added to their 
respective wells, along with the positive and negative controls supplied with the kit. Table 10 
shows the orientation of the microtiter plate and which sample was allocated for each well.  
 
Table 10: Orientation of the microtiter plate, displaying the wells and the serum samples that were added to each 
well. The wells of rows A–E of columns 1 and 2 contained the positive and negative controls supplied with the kit.  
Wells  1 2 3 4 5 6 7 8 
A Positive 
control 
Negative 
control  
C1 C2 M1 M2 M3 C3 
B 
C 
D 
E 
 
Once the samples had been added to their respective wells, 90 µL of dilution buffer 13 was 
added to each of the 40 wells. The reactions were incubated for 45 minutes at room 
temperature. The wells were then washed three times with a 1 X wash solution, before adding 
100 µL of a 1 X conjugate solution to each well, and incubating for 30 minutes at room 
temperature. Following the incubation, 100 µL of substrate solution was added to each well; 
and incubated for 15 minutes at room temperature, in the dark. The plates were then observed 
for a blue colour change, before adding 100 µL of stop solution to stop the reaction. The OD 
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of the reactions were then detected and recorded at 450 nm using the Epoch™ Microplate 
Spectrophotometer and the BioTek Gen5 1.10 software. 
Subsequent to the retrieval of the OD readings at 450 nm, the validity of the test and the 
interpretation of the results had to be calculated. First, the mean OD values for each group 
was calculated, and the mean values were used in all subsequent calculations. To infer the 
validity of the test, the OD of the positive control must be greater than 0.350, and the ratio of 
the OD of the positive control, to that of the negative control, should be greater than 3. For the 
interpretation, the antibody titre is represented by the percentage of the sample OD/positive 
control OD (S/P%). Therefore, the following formula was used to calculate the antibody titre 
for each of the groups: 
 
𝑆 𝑃⁄ % =
𝑂𝐷 𝑠𝑎𝑚𝑝𝑙𝑒
𝑂𝐷 𝑝𝑜𝑠𝑖𝑡𝑖𝑣𝑒 𝑐𝑜𝑛𝑡𝑟𝑜𝑙 
 × 100% 
 
4.3. Results  
 
4.3.1. Spectrophotometric analysis for protein determination 
 
The concentration of the MOMP protein retained, following the concentration process by use 
of the Millipore Centricon® centrifugal filter devices, was determined through 
spectrophotometric quantification. An A260/A280 ratio of 1.8–2 is indicative of nucleic acid 
contamination. Table 11 displays the results for this analysis, the A260/A280 ratio is 1.222, 
therefore, nucleic acid contamination may be ruled out, and the solution may be classified as 
one of pure protein content. The concentration was determined to be 21.7 mg/mL; however, 
this concentration is not owed only to the MOMP protein, but rather to all proteins both native 
and recombinant, expressed by Y. lipolytica Po1f, in the expected size region of the MOMP 
protein (43 kDa) 
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Table 11: Average concentration of the MOMP protein solution determined spectrophotometrically, following its 
isolation using Millipore Centricon® centrifugal filter devices. The table includes duplicate absorbance readings at 
280 nm and 260 nm, as well as the A260/A280 ratio and the concentration in mg/mL wit the average for each 
parameter.  
Parameter Reading 1 Reading 2 Average Reading 
A260 0.754 0.697 0.726 
A280 0.929 0.845 0.887 
A260/A280 1.232 1.212 1.222 
Concentration (mg/mL) 22.507 20.818 21.663 
 
4.3.2. Serological analysis by indirect ELISA 
 
The clinical trial involved the vaccination of each group of mice with their respective 
formulations (Table 9); subsequent infection of the mice with the B577 and EBA strains of C. 
abortus; and the collection of blood by cardiac puncture for the extraction of sera for 
serological analysis. The serological analysis was performed on the sera collected from each 
group, using the ID Screen® Chlamydophila abortus Indirect Multi-Species ELISA kit. Using 
the microtiter plate supplied with the kit, each sample was analysed in quintuplicate, and the 
mean OD value for each of the samples was used to determine the validity of the test, and for 
the interpretation of the data.  
The principle is the same as for all indirect ELISA techniques. Using the ID Screen® 
Chlamydophila abortus Indirect Multi-Species ELISA kit, the microwells are coated with the 
MOMP antigen of C. abortus. In the presence of anti-MOMP-antibodies or anti-Chlamydophila 
abortus-antibodies, an antigen-antibody complex is formulated. A conjugated secondary 
antibody is then added to the reaction. If there is a primary antibody present, it will bind to it, 
and upon the addition of the substrate, there will be a blue colour formation which increases 
in intensity with an increase in antibody titre as a function of direct proportionality.  
Figure 15 displays the microtiter plate, after the addition of the substrate (Figure 15A), and 
upon completion of the ELISA protocol (Figure 15B). The image presents the colour changes 
observed during the reaction. The blue colouration in the microwells vary, as can be seen from 
the figure, the solution remained clear in column two, which contained the negative control for 
the ELISA. The last four columns of the plate, which tested the sera from the three test groups, 
and the positive control group, vaccinated with the Chlamysure vaccine during the clinical trial, 
all display an intense blue colouration. The intensity of the yellow colouration on the right is 
directly related to the antibody titre present. The higher the antibody titre, the more intensified 
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the blue colouration after the addition of the substrate, and the greater the yellow colouration 
upon addition of the stop solution.  
 
 
Figure 15: ID Screen® Chlamydophila abortus Indirect Multi-Species ELISA kit microtiter plate displaying the colour 
changes experienced in each of the lanes in the plate upon addition of the substrate (left) and the stop solution 
(right).  
 
The antibody titre was quantified by determining the OD of each of the reactions at 450 nm 
using the Epoch™ Microplate Spectrophotometer and the BioTek Gen5 1.10 software. Figure 
17 represents the data retrieved. The data includes the OD readings at 450 nm, for each of 
the reactions performed for each group, and the mean OD reading for each group. In order for 
the test to be valid, the mean OD of the positive control must be greater than 0.350, and the 
mean OD of the positive control in this test was 0.360 (Figure 17). Validity also depends on 
the ratio of the mean OD of the positive control to that of the negative control, which should 
be greater than 3. In this case, 0.360/0.066 equates to 5, therefore the validity of the test can 
be confirmed.  
Once the validity of the test has been confirmed, the data can be interpreted to determine its 
significance. Using this ELISA kit, the S/P% is the value that quantifies the antibody titre. 
Therefore, this value was calculated for each of the groups excluding the positive and negative 
ELISA controls. Table 13 characterises this data, it includes the S/P% values for the clinical 
trial controls (C1–C3), and the clinical trial tests groups (M1–M3), as well as the outcome of 
each group. For this kit, the significance of each read is dependent on the S/P% value, which 
directly relates to the titre of anti-MOMP-antibodies present within the serum. If the S/P% value 
is less than or equal to 50%, the outcome of the screen is considered to be negative. If the 
S/P% value is greater or equal to 60%, the outcome of the screen is considered to be positive. 
If the S/P% value is greater than 50% but less than 60%, then the outcome of the screen is 
considered to be doubtful. There are four clinical trial samples displaying significant outcomes: 
A B 
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the serum extracted from the C3 group, vaccinated with Chlamysure, and the serum extracted 
from the test groups M1, M2 and M3, all of which were vaccinated with varying formulations 
(Table 9) of the candidate subunit vaccine.  
 
 
Figure 16: Scatter plot illustrating the differences in the OD readings between the ELISA controls, the immunization 
controls and the test samples. The red threshold line at OD 0.066 represents the ELISA negative control. 
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Table 12: S/P% values for each of the samples tested using the ID Screen® Chlamydophila abortus Indirect Multi-
Species ELISA kit; and the outcome or each sample. Samples C1–C3 are the controls used for the clinical trial and 
samples M1–M3 are the test formulations used for the clinical trial.  
Sample S/P%  
(𝑆 𝑃⁄ % =
𝑂𝐷 𝑠𝑎𝑚𝑝𝑙𝑒
𝑂𝐷 𝑝𝑜𝑠𝑖𝑡𝑖𝑣𝑒 𝑐𝑜𝑛𝑡𝑟𝑜𝑙 
 × 100%) 
 
Outcome   
C1 45% Negative  
C2 56% Doubtful 
C3 134% Positive 
M1 192% Positive 
M2 104% Positive 
M3 191% Positive  
 
4.4. Discussion  
 
The relevance of C. abortus infection is prominent now, more than ever before. A recent review 
on Chlamydia infection traces the last seventy years of the existence of C. abortus. The review 
article highlights chlamydial vaccine development during this time period, demonstrating prior 
limitations and the proposed guidelines for the future (Philips et al., 2019). Much attention has 
been directed towards the prevention and control of C. abortus due to the economic impact 
that this organism has, especially in developing countries and the consequences of its 
zoonotic potential (Cheong et al., 2019). In the last two years alone, there have been several 
reports of a novel nature, documenting new targets for the infection, in countries where these 
particular animals were not previously the primary targets (Borujeni et al., 2019; Li et al., 2018; 
Origlia et al., 2019; Paolo et al., 2019); a recapitulation into the details of the progress that has 
been made (Borel et al., 2018; Cheong et al., 2019; Zhou et al., 2018); and potential pathways 
for the way forward (Philips et al., 2019).  
A global effort has been made towards the prevention and control of C. abortus infections. 
This is a multinational priority, as the effects of this highly infectious organism have been 
observed and endured throughout the world for many decades (Longbottom, 2003; Philips et 
al., 2019). Vaccine-related research is at the forefront for this organism, with much progress 
that has already been made. Although there are multiple whole-cell based vaccines that are 
available commercially which targets C. abortus infection; there is potential for enhancement 
in the degree of protection that it is capable of eliciting. In recent times the MOMP protein of 
C. abortus has shown promise as an excellent candidate for a second-generation subunit 
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vaccine (Longbottom, 2003). Therefore, this chapter encompasses the evaluation of the 
MOMP protein of C. abortus B577 as a potential antigen for C. abortus prevention and control.  
For the clinical trial in this study, the duration was 21 days, which is greatly reduced compared 
to similar trials evaluating the same infectious organism, with a second-generation candidate 
subunit vaccine or third-generation candidate DNA vaccine (Garcia-Seco et al., 2016; 
He’chard et al., 2003; Longbottom, 2003; Rekiki et al., 2004). The duration was restricted for 
this clinical trial as pregnant mice were used for the evaluation; the gestational period for mice 
is limited to 18–22 days (Murray et al., 2010), meaning that if the trial had commenced at an 
extended duration, the mice would have given birth before the challenge model could have 
been implemented. According to the World Health Organisation (2003), in order to assess the 
effects of a vaccine through the gestational period, the animal must be exposed to the vaccine 
from implantation through to the end of the pregnancy. Therefore, animals baring a relatively 
short gestational period should be pre-mated prior to the commencement of the clinical trial, 
to ensure maximal exposure of the animal and foetus to the immune response, induced by the 
vaccine. This clause was implemented into the study, the mice were pre-mated and the clinical 
trial commenced on the day that gestation was detected to maximise the exposure to the 
vaccine; and to be able to include the challenge model.  
Specifically, for this clinical trial, the albino CD-1 mice (outbred mice of Swiss descent) were 
the selected animals utilized for the evaluation of the candidate MOMP subunit vaccine. They 
are multipurpose mice showcasing great genetic variability (Chia et al., 2005), and are 
commonly utilized as models for pharmacology- and toxicology-based evaluations in a clinical 
setting. This stock is often used to study the safety and efficacy of novel vaccines and drugs 
and has also served as a model for ageing and oncology research (Charles River Laboratories 
International Inc., 2011). There are a few obvious reasons for using mice for the clinical trial: 
they are small, incur low costs, great availability and they have a rapid reproduction rate. 
However, more specifically for this study mice were the selected animals because previous 
studies have shown that they share many similar characteristics with ruminants (Notebaert 
and Meyer, 2006) and that they are useful models for the study of ovine diseases such as 
OEA caused by C. abortus (Caro et al., 2009). 
The administration of the candidate subunit vaccine required a prolonged absorption rate to 
induce a more significant immune response against the MOMP antigen. For this reason, the 
subcutaneous route was chosen, since this layer has a reduced number of blood vessels 
available for absorption (Wahl and Hermodsson, 2009; Awate et al., 2013). In contrast, the 
administration of the challenge material required a large titre of infectious C. abortus B577 and 
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EBA bacteria, to be absorbed rapidly into the bloodstream, and since the intravenous route is 
not feasible for mice the intraperitoneal route was selected (Das and North, 2007).   
The immunisation schedule specifies the number of doses and the concentration of the doses. 
Customarily, subunit vaccines require a subsequent boost vaccination, primarily due to the 
lack of an entire infectious organism and replication mechanisms (Gupta et al., 2018). The 
constituents of a subunit vaccine may not be sufficiently immunogenic to induce a satisfactory 
state of immunological memory. In cases as such, the memory cells generated during the 
initial immunisation become redundant at the point at which the rate of cell death overtakes 
the rate of cell division (Janeway et al., 2001). For the current clinical trial, a booster was not 
feasible due to the gestational duration of the CD-1 mice (Murray et al., 2010); especially 
because a challenge model was implemented into the study. The study focused on the effects 
of C. abortus, the major implication of which is the induction of a spontaneous abortion. 
Therefore the booster vaccination had to be sacrificed, in order to challenge the hosts to 
determine the efficacy of the candidate subunit vaccine. However, the first stage clinical trial 
is executed to determine the efficacy of the vaccine and not necessarily the effectiveness and 
efficiency which is related to the duration of protective immunity (Lipsitch et al., 2016). This 
becomes an important aspect of the phases to follow. 
Implementation of a challenge model is the intentional infection of healthy subjects, with the 
infectious disease being assessed for the purpose of data collection on the efficacy of the 
candidate vaccine under evaluation (Cooper et al., 2019). More and more frequently in recent 
times, the challenge model has become a routine potency assay of vaccine clinical trials 
(World Health Organisation, 2003). According to Cooper and Co-workers (2019), this enables 
an acceleration in the timeline for the development of effective antigens. The challenge model 
is beneficial to the study because it provides insight into the efficiency of the memory immune 
response upon subsequent infection (Rang and Hill, 2013). The experimental challenge 
material must contain a version of the infectious organism which is whole and virulent. For this 
clinical trial, the challenge material consisted of the virulent forms of both the EBA and B577 
strains of C. abortus. According to Wen and Co-workers (2016), the MOMP protein sequence 
is relatively conserved between the C. abortus strains and serovars. Therefore, the antibodies 
generated against the MOMP antigen, which was based on the MOMP gene sequence of C. 
abortus strain B577, should be able to recognise the MOMP epitope on a whole C. abortus 
EBA bacterial strain. It is probable that the conservation between the MOMP protein along all 
strains and serovars of C. abortus is due to the function of MOMP during the infection process. 
Although all strains display variation at the genetic level, the entry of all strains into their target 
hosts is facilitated by the MOMP protein via cytoadhesion (Costa et al., 2015).  
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Serology is the diagnostic evaluation of blood serum, in order to elucidate the immune 
response mounted against the vaccine antigen (Wine et al., 2015). It is related to the 
immunogenicity of the vaccine antigen, which is a measure of its potential to induce an 
immune response in a living subject (Mahanty et al., 2015). In this clinical trial, the blood 
collected for serum extraction was achieved through cardiac puncture. Cardiac puncture was 
the procedure implemented since this mode offers the extraction of large amounts of blood, of 
high quality in a single extraction (Beeton et al., 2007).  
Through the entire duration of the clinical trial, the mice were monitored to draw conclusions 
with regard to the safety and efficacy of the candidate MOMP subunit vaccine. The official 
report of the evaluation of the safety and efficacy of the candidate Chlamydophila abortus 
recombinant MOMP has been included as Appendix F. The criteria used for the evaluation of 
the six groups of mice was the occurrence of adverse events, mortality and abortion.  
Referring to the official report of the evaluation of the safety and efficacy of the candidate 
Chlamydophila abortus recombinant MOMP in Appendix F, it can be deduced that the 
candidate MOMP subunit vaccine displayed a satisfactory level of safety. The report accounts 
for no incidences of mortality or adverse events, throughout the six groups of mice, during the 
entire duration of the clinical trial. Outbred mice were used for the evaluation since it is 
recommended by the World Health Organisation that outbred mice be utilized for safety and 
toxicity investigations; as they broaden the genetic field and eliminate the usage of a single 
genetic line which may be predisposed to certain medical occurrences (World Health 
Organisation, 2003). According to Ellenberg and Co-workers (2005), an appropriate 
population size for phase I clinical trials is 20–80 subjects; the population size for this clinical 
trial falls within this range, therefore the safety outcomes are not insignificant. However, there 
still remains the possibility that an increase in the population size, may lead to the discovery 
of a greater incidence rate.  
According to the European Medicines Agency (2011), the inclusion of a challenge model is 
paramount to the evaluation of efficacy. This is because, in order to determine how well the 
candidate vaccine can provide protection against the infection, the infection must be 
introduced post-vaccination to evaluate its effects. All existing vaccines that provide protection 
against C. abortus infection, involved the usage of a challenge model to determine the degree 
of efficacy conferred in a clinical setting (Garcia-Seco et al., 2016; He’chard et al., 2003; 
Livingstone et al., 2017; Rekiki et al., 2004; Rodolakis and Souriau, 1979). The major 
implication of infection by C. abortus is the occurrence of a spontaneous abortion in pregnant 
ruminants. Therefore the most ideal indicator of the efficacy of the candidate MOMP subunit 
vaccine would be a measure of its ability to prevent the spontaneous abortion of the foetus, in 
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the vaccinated mice, which have been challenged with the virulent B577 and EBA strains of 
C. abortus.  
Referring to the official report of the evaluation of the safety and efficacy of the candidate 
Chlamydophila abortus recombinant MOMP in Appendix F, it is shown that there were no 
occurrences of abortion throughout the six groups of mice post-challenge. This outcome is 
objectionable since the unvaccinated group C1 (absolute negative control) and the group 
vaccinated with the 70% adjuvant formulation C2 (placebo negative control), also did not 
exhibit any signs or symptoms of a spontaneous abortion. Since efficacy is based on 
observation, the inclusion of negative controls eliminates the possibility of confounding and 
biased results. According to Lipsitch and Co-workers (2010), the validity of an efficacy study 
may only be implied, if the study involves the inclusion of a negative control, which is expected 
to produce a null result; and if it does indeed produce the specified outcome. Therefore, for a 
vaccine to be classified as efficacious, the groups that were administered a formulation 
containing the active agent should exhibit signs of protection; simultaneously the negative 
control groups must exhibit a null result, to confer legitimacy of the outcome (Lipsitch et al., 
2016).  
The pre-eminent reason for this finding is that the stock of mice used was not a good challenge 
model for C. abortus infection and manifestation. The fact that the challenge material did not 
produce a null result, in the absolute and placebo negative control groups indicates that the 
infection did not manifest within this stock of mice. Previously this stock has been used 
successfully as a challenge model, for multiple infections in a clinical setting (Felio et al., 2009; 
Leitner et al., 2010; Pastoris et al., 1997; Yanke et al., 2000;). However, there has been a 
study which has suggested that CD-1 mice are resistant to chronic vulvovaginal candidiasis 
caused by Candida albicans (Gabrielli et al., 2017). It has been established, that this 
resistance was due to an insufficient challenge titre, rather than the inability of the infection to 
propagate. The significance of which is that this stock has increased resilience towards 
infection and requires a substantially higher challenge load in order for an infection to manifest 
within the stock (Gabrielli et al., 2017). Therefore, the results obtained with reference to the 
efficacy of the candidate MOMP subunit vaccine, are inconclusive.  
Literature on previous studies, involving the evaluation of candidate vaccines for the 
prevention of chlamydiosis, has revealed an ideal challenge model for C. abortus infection. 
The Swiss OF1 outbred mouse model of abortion has been established as a good model for 
the evaluation of C. abortus virulence and vaccine efficacy and efficiency (He’chard et al., 
2003). The OF1 outbred mouse model of abortion has successfully been utilised for the 
evaluation of the efficiency of the marketed 1B vaccine for chlamydiosis (Rodolakis, 1983) and 
98 
 
for the efficacy of a candidate DNA vaccine (He’chard et al., 2003). Previous studies have 
shown, that this model is ideal for clinical studies relating to C. abortus infection because the 
protective effects exhibited in this murine model has been correlated with that exhibited in an 
ovine model for the analysis of the same candidate vaccine for prevention of OEA and EAE 
(Rodolakis, 1983).  
The importance of the immunogenicity of an antigen lies in its ability to provoke a response 
from the lymphocytic cells of the immune system. In particular, for the purpose of this study, 
the B cell lymphocytic reaction is of interest, since B cells are responsible for the activation of 
the humoral immune response, which leads to the production of anti-antigen antibodies 
(Mahanty et al., 2015). The generation of anti-MOMP antibodies and the abundance thereof 
signifies the potency of the MOMP antigen and how great of an immune response it is capable 
of eliciting. Immunogenicity is a highly significant consideration because it is associated with 
the state of immunological memory. In any vaccine development study, the induction of the 
immunological memory phenomenon is the ultimate objective (Ratajczak et al., 2018). It 
ensures long-term protection against a particular infectious organism, often persisting in a 
dormant state for decades succeeding the initial infection until activated, at which point these 
cells display rapid proliferation to enable immediate elimination of the pathogen (Janeway et 
al., 2001; Vujanic et al., 2011).  
For the evaluation of the level of immunogenicity elicited by the MOMP antigen, a measure of 
the induced humoral immune response has to be detected. The ID Screen® Chlamydophila 
abortus Indirect Multi-Species ELISA kit was used for this purpose; the results and significance 
thereof are depicted in Figure 17 and Table 13 respectively. ID Screen® Chlamydophila 
abortus Indirect Multi-Species ELISA kit has been used for the evaluation of C. abortus 
vaccines (Garcia-Seco et al., 2016); as a diagnostic tool in many countries to screen ewes, 
rams, sheep, goats and roe deer (Jalboush et al., 2017; Mukhtar, 2015; O’Neil et al., 2018; 
Tavernier et al., 2015), and even for case-specific studies on zoonotic infection (Ortega et al., 
2016). The negative control for the assay is porcine serum, negative for C. abortus; the 
positive control is ovine serum, positive for C. abortus infection; both of which are used as an 
internal reference standard for quality control purposes (ID. Vet, 2019). The ID Screen® 
Chlamydophila abortus Indirect Multi-Species ELISA kit expresses the outcome of the analysis 
as a ratio of the percentage of the optical density of the sample, by that of the assay positive 
control (S/P%).  
Table 13 displays the S/P% for each of the six groups and the significance of each outcome. 
C1 (unvaccinated group) presented an S/P% of 45%, the significance of which is negative 
since it is less than 50%. This is expected since this group served as the absolute negative 
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control and therefore had not been exposed to any formulation of the candidate MOMP subunit 
vaccine. C2 (70% adjuvant) displayed an S/P% of 56%; the significance of this outcome is 
doubtful, since it is greater than 50%, but less than 60%. However, these results were 
anticipated since all subjects that do not receive a formulation containing the active compound, 
should not produce a specific immune response.  
The antibody response in the placebo negative group is 11% greater than that of the absolute 
negative control group. The presence of an adjuvant in this group can account for the increase 
in antibody production. According to Plotkin and Co-workers (2013), the presence of an 
adjuvant has a stimulatory effect on the immune system of a living subject, accomplished 
through the facilitation of antigen presentation to the APCs. Adjuvants prolong the clearance 
of the antigen to enable constant stimulation of the immune system by the antigen; this is a 
possible explanation for the higher antibody concentration, exhibited by C2 in comparison to 
C1 (Awate et al., 2013).  
C3 (Chlamysure vaccine) resulted in an S/P% of 134%, the significance of this outcome is 
positive, since samples with S/P% values greater than 60% are considered to be positive for 
anti-MOMP antibodies. This result is expected, as Chlamysure is a marketed inactivated C. 
abortus vaccine, which has proven to be adequately protective against C. abortus infection. 
M1 (70% adjuvant: 30% MOMP), M2 (60% adjuvant: 40% MOMP), and M3 (50% adjuvant: 
50% MOMP) all displayed positive outcomes, the S/P% values were 192%, 104% and 191% 
respectively. Group M1 produced the highest antibody titre, compared to that of groups M2 
and M3. The S/P% of M1, also greatly exceeded that of the positive control group C3.  
The literature used as a point of reference in this chapter, corresponds directly to the 
prevalence of this bacterium and the consequences of the infection imposed. There have been 
many recent studies published on the genetics and pathogenesis of C. abortus, to find targets 
for vaccine development studies (Essig and Longbottom, 2015; Livingstone et al., 2017; Pan 
et al., 2017; Phillips et al., 2019), the seroprevalence of C. abortus infection worldwide 
(Jalboush et al., 2017; Li et al., 2018; Li et al., 2018; Pinheiro et al., 2010; Sankange et al., 
2010), and on the evaluation of novel candidate vaccine antigens for prevention of OEA and 
EAE (Garcia-Seco et al., 2016; He’chard et al., 2003; Zhou et al., 2018). This infectious 
organism was a problem seventy years ago; and based on current literature, is still a problem 
to date, globally. The need for enhanced preventative measures is necessitated, and any 
contribution towards research on C. abortus may prove to be beneficial. 
In conclusion, the current study utilized an animal challenge model that was suboptimal for 
the evaluation of C. abortus infection and manifestation. As a result, the evidence of the 
efficacy of the candidate MOMP subunit vaccine is inconclusive. The safety of this vaccine 
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can, however, be confirmed as it did not result in mortality or provoke the occurrence of any 
adverse reactions. In terms of immunogenicity, the outcome was positive. All three 
formulations of the candidate MOMP subunit vaccine displayed high levels of anti-MOMP 
antibody titres. The findings of the study may not have provided definitive proof of concept, 
however, it did reveal that the Swiss albino CD-1 outbred mice model is not an optimal 
challenge model for C. abortus, due to the inability of C. abortus to achieve clinical 
manifestation within this stock at the endeavoured load. Research has shown, that MOMP is 
a noteworthy antigenic target; and that it has the potential to serve as the antigenic agent in a 
vaccine that is safe and displays boundless efficacy and immunogenicity. Until such time that 
the relevant additions can be implemented, to accurately depict the efficacy of the candidate 
MOMP subunit vaccine, research will continue; and contributions towards the specific 
requirements of this vaccine will shape the way forward, for the prevention and control of the 
highly prevalent C. abortus.  
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Chapter 5: Conclusion and future studies 
 
It is known, that C. abortus is a highly infectious microorganism, which causes major 
reproductive implications for infected ruminants; foremost of which is the occurrence of a 
spontaneous abortion of the foetus. The reproductive failures associated with this type of 
infection is enduring. Animals infected by C. abortus often display reproductive insufficiencies 
and continual shedding of infectious EBs during subsequent gestational periods; and in cases 
where the foetus survives the gestational period, it is often born weak and underdeveloped, 
leading to mortality post-birth after just a few days. The latency of this infection escalates its 
ability for contagion; it is this characteristic which is responsible for the high incidence rates in 
many countries worldwide.  
This is a major issue globally; publications have drawn attention to the elucidation of the 
pathogenesis, immunology and genetics of C. abortus in the UK, Greece, Switzerland, 
Pakistan, Germany, Austria and China (Forsbach-Birk et al., 2013; Kerr et al., 2005; Li et al., 
2018; Livingstone et al., 2017; Selim, 2016). Seroprevalence and risk factor studies have been 
implemented and reported on in Namibia, China, Iraq, Brazil, India, and Palestine (Chahota et 
al., 2015; Jalboush et al., 2017; Majed et al., 2018; Pinheiro et al., 2010; Samkange et al., 
2010; Qin et al., 2014; Zhou et al., 2018). Vaccine research is an on-going study being carried 
out by researchers in Spain, Switzerland, Tunisia, America, Germany, France, China and 
South Africa (Garcia-Seco et al., 2016; He’chard et al., 2003; Longbottom et al., 2018; Rekiki 
et al., 2004; Zhou et al., 2018). The C. abortus-related research being executed in various 
regions of the world relates directly to the cosmopolitan distribution of this infectious 
microorganism and therefore to its prevalence and relevance worldwide.  
A global effort has been initiated in the attempt to eradicate this contagious organism; 
researchers from all over the world are participating, they are elucidating vital information to 
facilitate the design and development of a novel vaccine. One which can bypass the bulk 
chlamydial production process and the limitations that hinder this process. A vaccine that can 
be produced on a large-scale, while incurring minimal costs to aid affordability especially in 
developing countries as South Africa. Most importantly, the need requires a vaccine which 
eliminates the risk for reversion, while providing a great degree of safety, efficacy and 
immunogenicity in order to prevent and control C. abortus.  
The research objectives highlighted in this dissertation were aimed at the development of a 
recombinant candidate MOMP subunit vaccine. This design was dependent on the 
heterologous expression of the MOMP protein of C. abortus in Y. lipolytica Po1f; the efficiency 
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of which was supported by the codon optimization of the gene for expression in Y. lipolytica. 
This heterologously expressed MOMP served as the antigenic agent in the clinical trial, in 
which the immunogenicity of MOMP was evaluated as a potential vaccine antigen in Swiss 
albino CD-1 mice models. During the clinical trial, three parameters were evaluated: safety, 
efficacy and immunogenicity.  
The safety of the candidate vaccine may be confirmed since there was a 0% mortality rate 
and the candidate MOMP subunit vaccine did not provoke the incidence of any adverse 
events. Efficacy is related to the ability of the vaccine to produce an anticipated outcome. In 
this case, it would be expected that the unvaccinated control group would produce a null result, 
which is the spontaneous abortion of their foetuses. However, the null result was not achieved. 
This occurrence is indicative of a suboptimal challenge model. It is probable that the CD-1 
mice were not a good model for C. abortus infection and manifestation. Literature suggests 
that this may be overcome by the use of a higher challenge titre, however, at this stage, the 
outcome of the efficacy of this vaccine remains inconclusive. In terms of immunogenicity, all 
three candidate MOMP subunit vaccine formulations produced extraordinary anti-MOMP 
antibody titres in relation to that of the positive control Chlamysure 
The conclusions revealed through this study have provided insight into the boundless 
immunogenic potential of MOMP as a candidate for the way forward. Definitive proof of 
concept for the efficacy of the MOMP protein of C. abortus was not obtainable at this point. 
The study did, however, disclose information on the effectiveness of the Swiss albino CD-1 
mice as a model of C. abortus infection. The inability to achieve clinical manifestation in this 
stock means that it is not an ideal model for C. abortus challenge. Additionally, the study 
confirmed the safety of the MOMP antigen-Seppic Montanide™ ISA 70 adjuvant formulation 
in its phase I clinical trial.  
Through this study, some important questions have arisen, which may lead to further research 
on this matter. Literature states that in a previous study, the CD-1 mice were thought to be 
resistant to Candida albicans (Gabrielli et al., 2017), however, further investigations have 
revealed that is it not the inability of the infection to propagate within this stock; but rather that 
it requires a substantially higher challenge load in order to proliferate sufficiently (Gabrielli et 
al., 2017). Therefore, for future reference, efficacy may be confirmed in this stock by 
implementing a greater challenge dose. Alternatively, the Swiss OF1 outbred mouse model of 
abortion has been classified as an ideal model for the evaluation of C. abortus virulence and 
the efficacy and efficiency of candidate vaccines. Utilization of this model, for further evaluation 
of the immunogenic properties of the candidate MOMP subunit vaccine, may prove to be 
beneficial for research into the prevention and control of this prevailing, infectious pathogen.   
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Appendix A  
 
Reagents, material and biological specimens 
 
Acetic acid (Associated Chemical Enterprises, Johannesburg, RSA) 
Acetone (Sigma-Aldrich, St. Louis, USA) 
30% Acrylamide/bisacrylamide (Sigma, St. Louis, USA) 
Agarose (Lonza, Rockland, USA) 
Ammonium bicarbonate (Sigma-Aldrich, Darmstadt, GermanyAmmonium chloride (Sigma, 
Tokyo, Japan) 
Ammonium persulphate (Sigma-Aldrich, Darmstadt, Germany) 
Ammonium sulphate (Rochelle Chemicals, Johannesburg, RSA) 
Ampicillin (Sigma-Aldrich, Missouri, USA) 
AvrII (New England Biolabs, Massachusetts, USA) 
Bacteriological agar (Sigma-Aldrich, State of Mexico, Mexico) 
Bromophenol blue (Sigma, Bangalore, India) 
Butanol (Sigma-Aldrich, St. Louis, USA) 
Carbon dioxide (Afrox, Johannesburg, RSA) 
Casamaino acids (VWR Life Science, Ohio, USA) 
Chlamydophila abortus B577 (Onderstepoort Biological Products, Pretoria, RSA) 
Chlamydophila abortus EBA (Onderstepoort Biological Products, Pretoria, RSA) 
Coomassie brilliant blue R (Sigma-Aldrich, St. Louis, USA) 
Corncob™ bedding (Lab Supply, Texas, USA) 
D (+) Glucose anhydrous (Merck, Lethabong, RSA) 
Dimethylsulfoxide (Merck, New Jersey, USA) 
Disodium phosphate (Sigma-Aldrich, Tokyo, Japan) 
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Ethanol (Rochelle Chemicals, Johannesburg, RSA) 
Ethidium bromide (Sigma, St. Louis, USA) 
Ethylenediaminetetra-acetic acid (Sigma-Aldrich, Darmstadt, Germany) 
GeneRuler™ 1kb (Thermo Scientific, Massachusetts, USA) 
Gibco’s eagle minimum essential medium (Thermo Fisher Scientific, Massachusetts, USA) 
Glycerol (Sigma-Aldrich, Missouri, USA) 
Glycine (VWR Life Science, Ohio, USA) 
GoTaq® DNA polymerase (Promega, Wisconsin, USA) 
Hydrochloric acid (Sigma-Aldrich, Sydney, Australia) 
Iodine (Associated Chemical Enterprises, Johannesburg, RSA) 
Isoflurane (Sigma-Aldrich, Darmstadt, Germany) 
JCW Petfoods mice chow (JCW Petfoods, Johannesburg, RSA) 
Kanamycin (Sigma-Aldrich, Missouri, USA) 
L-glutamine (Merck, Madrid, Spain) 
Lithium acetate (Sigma-Aldrich, Missouri, USA) 
Magnesium chloride (Sigma-Aldrich, Missouri, USA) 
β-Mercaptoethanol (Sigma, Darmstadt, Germany) 
Methanol (Sigma-Aldrich, St. Louis, USA) 
McCoy cells (Sigma-Aldrich, St. Louis, USA) 
Millipore Centricon® centrifugal filter devices (Millipore, Corporation, Massachusetts, USA) 
MilliQ water (Millipore Corporation, Massachusetts, USA) 
Minimum essential eagle medium (Thermo Fisher Scientific, Massachusetts, USA) 
Mix and Go JM109 chemically competent cells (Zymo Research, California, USA) 
Monopotassium phosphate (Merck, Madrid, Spain) 
NEB 1 kb ladder (New England Biolabs, Massachusetts, USA) 
NotI (New England Biolabs, Massachusetts, USA) 
132 
 
N,N,N’,N’-tetramethylethylenediamine (Sigma-Aldrich, Overijse, Belgium) 
Oligonucleotide primers (Inqaba Biotec™, Pretoria, RSA) 
PageRuler Plus™ prestained 10-250 (Thermo Scientific, Massachusetts, USA) 
Peptone (VWR Life Science, Ohio, USA) 
Phenaminovit™ (Groenvoer, Johannesburg, RSA) 
pKOV410 (University of the Free State, Free State, RSA) 
Polyethylene glycol-800 (VWR Life Science, Ohio, USA) 
Potassium chloride (Sigma-Aldrich, Missouri, USA) 
Proteose peptone (Conda, Madrid, Spain) 
6X Purple loading dye (New England Biolabs, Massachusetts, USA) 
Salmon sperm carrier DNA (Thermo Fisher Scientific, Massachusetts, USA) 
Seppic Montanide™ ISA 70 water-in-oil adjuvant (Seppic, Paris, France) 
Sodium chloride (Sigma-Aldrich, St. Louis, USA) 
Sodium dodecyl sulphate (Sigma, Tokyo, Japan) 
Sodium phosphate monobasic dihydrate (Sigma, Darmstadt, Germany) 
Soybean casein digest medium (Himedia Laboratories, Mumbai, India) 
Swiss albino CD-1 mice (Onderstepoort Biological Products, Pretoria, RSA) 
Synthetic MOMP construct (Biomatik, Ontario, Canada) 
T4 DNA Ligase (New England Biolabs, Massachusetts, USA) 
Thioglycollate (Sigma-Aldrich, Tokyo, Japan) 
Tris (hydroxymethyl) aminomethane (Merck, Madrid, Spain) 
Tryptone (Sigma-Aldrich, Auckland, New Zealand) 
XmnI (New England Biolabs, Massachusetts, USA) 
Yarrowia lipolytica (Onderstepoort Biological Products, Pretoria, RSA) 
Yeast extract (VWR Life Science, Ohio, USA) 
Yeast nitrogen base (VWR Life Science, Ohio, USA) 
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Kits, equipment and services 
 
Agarose Gel System (Bio-Rad Laboratories, California, USA) 
Beckman fixed-angle centrifuge (Beckman Coulter, California, USA) 
Chemidoc™ MP Imaging System (Bio-Rad Laboratories, California, USA) 
Digital dry bath (Labnet International, New Jersey, USA) 
Epoch™ Microplate Spectrophotometer (BioTek, Vermont, USA) 
ID Screen® Chlamydophila abortus Indirect Multi-Species (IDVet, Grabels, France) 
Incubator (Merck, New Jersey, USA) 
Light microscope (Zeiss, Oberkochen, Germany) 
Mastercycler (Eppendorf, Hamburg, Germany) 
Microcentrifuge (Hettich Zentrifugen, Tuttlingen, Germany) 
Nanodrop ND-1000 spectrophotometer (Thermo Fisher Scientific, Massachusetts, USA) 
GeneJET Plasmid miniprep Kit (Thermo Scientific, Baltics, Lithuania) 
pH meter (HANNA Instruments, Johannesburg, RSA) 
Vortex (Labnet International, New Jersey, USA) 
Wizard® SV Gel and PCR Clean-Up System (Promega, Wisconsin, USA) 
 
Software and databases 
 
BioTek Gen5 1.10 Software (BioTek, Vermont, USA) 
Clustal Omega (European Bioinformatics Institute, Cambridge, UK) 
European Molecular Biology Laboratory (European Bioinformatics Institute, Cambridge, UK) 
Expert Protein Analysis System (Swiss Institute of Bioinformatics, Lausanne, Switzerland) 
Image lab Software 4.1 (Bio-Rad Laboratories, California, USA) 
Nanodrop ND-1000 V3.8.1 Software (Thermo Fisher Scientific, Massachusetts, USA) 
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National Centre for Biotechnology Information (National Institutes of Health, Maryland, USA) 
NetNGlyc 1.0 Server (DTU Bioinformatics, Kemitorvet, Denmark) 
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Appendix B 
 
Abbreviations and acronyms  
 
APC: Antigen Presenting Cell 
BCR: B-Cell Receptor 
CDC: Centres for Disease Control  
COMC: Chlamydial Outer Membrane Complex 
CPAF: Chlamydial-protease-like activity factor 
CPE: Cytopathic Effect  
CRP: Cysteine Rich Protein  
DIC: Disseminated Intravascular Coagulation 
EAE: Enzootic Abortion of Ewes 
EB: Elementary Body 
ECP: Eosinophil Cationic Protein  
EMEM: Eagle Minimum Essential Medium  
EDN: Eosinophil-Derived Toxin  
EDTA: Ethylenediamineetraacetic acid 
ELISA: Enzyme-Linked Immunosorbent Assay  
EMBL-EBI: European Molecular Biology Laboratory- European Bioinformatics Institute  
EPX: Eosinophil Peroxidase 
FBS: Fetal Bovine Serum  
FDA: Food and Drug Administration  
GI: Gastrointestinal  
HBV: Hepatitis B Vaccine 
HPV: Human Papilloma Virus  
ID: Intradermal 
IFU: Inclusion Forming Units  
Ig: Immunoglobulin 
IM: Intramuscular 
IV: Intravenous  
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LPS: Lipopolysaccharide 
MAI: Microbe Associated Immunostimulant  
MBP: Major Basic Protein  
MCS: Multiple Cloning Site  
MEM: Minimum Essential Medium  
MMR: Measles, Mumps and Rubella  
MOMP: Major Outer-Membrane Protein 
mRNA: Messenger Ribonucleic Acid 
MSA: Multiple Sequence Alignment  
NCBI: National Centre for Biotechnology Information 
NET: Neutrophil Extracellular Trap 
NK: Natural Killer 
NMWL: Nominal Molecular Weight Limit 
OBP: Onderstepoort Biological Products 
OEA: Ovine Enzootic Abortion 
OD: Optical Density  
ODCase: Orotidine 5’-Phosphate Dehydrogenase  
OMC: Outer Membrane Complex 
OMP: Orotidine 5’-Phosphate  
ORF: Open Reading Frame  
PAMP: Pathogen Associated Molecular Patterns 
PBS: Phosphate Buffered Saline  
PCR: Polymerase Chain Reaction  
PIC: Pelvic Inflammatory Disease 
POMP: Polymorphic Outer-Membrane Protein  
PRR: Pattern Recognition Receptor 
RB: Reticulate Body 
rDNA: Recombinant Deoxyribonucleic Acid  
RE: Restriction Enzyme  
ROS: Reactive Oxygen Species 
rRNA: Ribosomal Ribonucleic Acid 
SC: Subcutaneous  
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SDS-PAGE: Sodium Dodecyl Sulphate- Polyacrylamide Gel Electrophoresis  
SIB: Swiss Institute of Bioinformatics  
SP: Signal Peptide  
STD: Sexually Transmitted Disease 
TCR: T-Cell Receptor 
TE: Tris-Ethylenediamineetraacetic acid 
TFA: Trifluoroacetic Acid  
TLR: Toll-Like Receptor 
tRNA: Transfer Ribonucleic Acid 
UFS: University of the Free State  
UMP: Uradylic Acid  
VAERS: Vaccine Adverse Event Reporting System  
YNB: Yeast Nitrogen Base  
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Appendix C 
 
Ethics approval from the University of Johannesburg Faculty Ethics Committee  
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Appendix D 
 
Ethics approval from the Onderstepoort Biological Products Ethics Committee  
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Appendix E 
 
Section 20 permit from the Department of Agriculture, Forestry and Fisheries 
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Appendix F 
 
Official report of the evaluation of the safety and efficacy of the candidate 
Chlamydophila abortus recombinant MOMP 
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